Department of Neurology

University of Pittsburgh School of Medicine University of Pittsburgh Physicians

2009 Annual Report

Lawrence R. Wechsler, M.D. Interim Chair

Annual Report for the Period July 1, 2008 through June 30, 2009

TABLE OF CONTENTS

Department Overview/Mission/Activities 5

Department Clinical Activities and Divisions 13

Department Institutes and National Center Affiliations 17

Research and Scholarly Activities

Faculty Summaries by Division

Cognitive and Behavioral Neurology 25

Epilepsy 27

General Neurology 31

Headache Division 33

Movement Disorders 35

Neuroimmunology/MS 42

Neuromuscular Diseases 44

Neuro-Oncology 46

Research Division 47

Vascular Neurology 54

Faculty Service on Study Sections and Advisory Committees 57

Department Grant Activity

Grant and Funding Information 66

Faculty Research Collaborations 72

Faculty Honors, Editorial Service and Professional Affiliations 78

Faculty Mentoring and Teaching Contributions

Post Doctoral and Graduate Students 90

Clinical Education 92

Departing House Officers 93

Graduate and Medical School Teaching 95

Grand Rounds and Special Lectures 102

Faculty and Staff 108

Bibliography 116

Department Budget and Budget Methodology 137

Cover Photo Credits: Upper left: Barb Beatty; lower left: Ruth Perez, PhD; upper right and lower right: Barb Woolcott. Inside Photo Credits: Page 25, Barb Beatty; page 65, Rehanna Leak, PhD; page 89, Barb Woolcott; page 107, Paula Clemens, MD (right photo) and Barb Woolcott (left photo); page 115, Barb Woolcott Editing: Leslie Dunn, MPH and Barbara Woolcott Annual Report Working Group: Patrick Conway, Leslie Dunn, Erin McCloskey, Barbara Beatty, Earl Humes, Barbara Woolcott Cover Design: Barbara Woolcott

2009 Department Overview, Mission and Activities

The Department of Neurology continues to advance its mission, capabilities, and reputation for academic, clinical and research activities. We strive to foster a working environment that supports and encourages the development and growth of our faculty and staff's professional careers. From July 1, 2008 through June 30, 2009, there were 48 faculty members with primary appointments in Neurology and we expect additional faculty to join us next year. The Department welcomed 3 new faculty members with a variety of specialties: Angela Lu, MD, General Neurology and EMG; Asim Roy, MD, General Neurology and Sleep Disorders; and Syed Zaidi, MD, Stroke. Secondary appointments are held by Bing Wang, MD, PhD, Mary Ganguli, MD, William Klunk, MD, PhD, Robert Sweet, MD and Cheryl Bernstein, MD in recognition of their clinical and research interactions with the Department of Neurology. Many faculty members maintain secondary appointments throughout the University providing clinical and research collaborations.

The Department continues to make significant advances in patient care, teaching, and clinical and basic research, consistent with the mission of the Neurology Department, the School of Medicine, and University of Pittsburgh Physicians (UPP). Key areas of excellence include the UPMC Stroke Institute; the UPMC Headache Center; the Alzheimer’s Disease Research Center (ADRC); the Pittsburgh Institute for Neurodegenerative Diseases (PIND); the Morris K. Udall Center for Excellence for Parkinson’s Disease Research; the American Parkinson Disease Association Advanced Center for Parkinson’s Research; and the Commonwealth of Pennsylvania Center for Detection, Diagnosis, and Intervention in Dementia (DDID). The Neuromuscular, Epilepsy, Headache, Cognitive and Behavioral Neurology, Stroke, Movement, Neuro-immunology/Multiple Sclerosis and General Neurology divisions provide key clinical diagnosis and treatment.

We are committed to providing compassionate, comprehensive, timely and high quality service to our patients. We maintain a policy of making an appointment within three days of the request. Our clinical faculty receives a large number of referrals for sub-specialty care from community neurologists, other community specialists, and other clinical department faculty physicians.

Our clinical and research faculty value the role of providing education and support for future physicians and researchers. We provide our residents, medical students, graduate students and postdoctoral student researchers with an enriched and supportive professional environment that creates a high-value educational experience. The Department conducts weekly Neurology Grand Rounds; our program in 2008-2009 featured 33 lectures with 31 speakers--3 from other institutions. In addition, multiple conferences and lectures were overseen by our clinical divisions or research centers. The department also co-sponsors special lectures through PIND, the ADRC and in conjunction with the Department of Medicine.

Clinical research activities benefit our current patients, allow access to cutting-edge therapeutic trials, and provide significant advances in the overall field of clinical neurology and our clinical research programs have grown significantly. We develop, maintain, and promote innovative and integrated research programs that promote fundamental discoveries in basic science areas.

The Department of Neurology faculty and staff are very involved with medically related organizations on the local, national, and international levels. This involvement extends beyond the medical realm to groups providing support to patients and caregivers, organizing and supporting fundraising efforts for voluntary health organizations and raising awareness of neurological diseases. Many of our faculty members and staff have national leadership positions on NIH advisory or research review committees, in voluntary health organizations, and professional societies.

Leadership

Lawrence Wechsler, M.D., Interim Chair of the Department of Neurology is professor of Neurology and Neurological Surgery at the University of Pittsburgh School of Medicine and is director of the University of Pittsburgh Medical Center (UPMC) Stroke Institute. He also serves as Vice President for Telemedicine in the Physician Services Division. Prior to assuming the interim chair position, Dr. Wechsler served as Vice Chair for Clinical Affairs and maintained oversight of all clinical operations within the department. Under his direction the neurology has continued to expand both its clinical operations and research activities. The

5

department was ranked 17th in the US News and World Report rankings of neurology and neurosurgery programs and 8th in NIH funding among all university medical schools.

Dr. Wechsler’s interests include acute stroke therapy, imaging and telemedicine. He has participated in many clinical trials of treatments for stroke as an investigator or member of the steering committee. He was Editor in Chief of the Journal of Neuroimaging from 1999-2007. Dr. Wechsler holds memberships in several organizations, including the American Neurological Association, American Stroke Association, American Society of Neuroimaging and the American Academy of Neurology. He is currently the president of the American Society of Neuroimaging. He chairs the Stroke Systems Work Group at the American Academy of Neurology and co-chairs the telemedicine work group. Dr. Wechsler has authored or co-authored numerous articles related to stroke and stroke therapy.

At UPMC, Dr. Wechsler developed and implemented the telemedicine program for acute stroke assessment. Beginning in 2006, telemedicine has been implemented in all UPMC system hospitals in order to provide access to acute stroke assessment and treatment by faculty of the UPMC Stroke Institute. Additionally, several other non UPMC facilities are now utilizing telemedicine similarly for stroke care.

There are 3 other vice chairs in the Department of Neurology:

• Steven H. Graham, M.D., Ph.D. is Professor of Neurology and Vice Chair for Research. He directs the operations of the Research Division. Chief among his responsibilities is recruiting world-quality researchers to an expanding basic science program. Dr. Graham is an accomplished researcher in neuronal cell death following ischemic injury. He is Associate Chief of Staff for Research for the Pittsburgh VA Healthcare System and is the Director of the Geriatric Research Educational and Clinical Center, the major focus of which is cerebrovascular disease.

• Paula Clemens, M.D. is Associate Professor of Neurology and Vice Chair for Veterans Affairs. She is Chief of the Neurology Service at the Pittsburgh VA Healthcare System, responsible for clinical care and teaching at the VA. She is also an accomplished researcher in clinical and basic studies of treatments for disorders of skeletal muscle, one of an elite group of researchers who utilize gene therapy in the experimental treatment of neuromuscular diseases.

Additional leadership is provided by the Executive Committee: the Department Chair; Vice Chairs; the Division Chiefs; and Patrick Conway, Department Executive Administrator; Leslie Dunn, Academic Administrator; and Erin McCloskey, Clinical Administrator.

Research Activities

The Department of Neurology has a sustained commitment to excellence in the three major components of academic medicine: teaching, clinical care and research that advances medical knowledge and therapy. Research funding for the clinical, basic, and translational studies in the department has increased steadily over the past few years and in FY2009 the department received over $10,000,000 of NIH grant support.

Basic Research

Basic scientists in the Department of Neurology continue to be highly successful in securing extramural funding. Several new extramural basic science grants were awarded to neurology faculty from July 1, 2008 to June 30, 2009. In addition, Neurology faculty received notice that several other awards will be funded in the coming fiscal year.

Basic neuro-science investigators in the Department of Neurology had a number of successes during the previous academic year. Some of the major achievements include:

• J. Timothy Greenamyre received a grant from the Michael J. Fox Foundation to examine the pathological characteristics of alpha-synuclein transgenic rats. He also received a grant from the

6

Parkinson’s Disease Foundation to examine gastrointestinal dysfunction in Parkinson’s Disease. A new NINDS-funded Program Project Grant studying mitochondrial proteins in Parkinson’s disease will be funded in the coming year.

• Jun Chen was awarded a grant from the Department of Defense to study scaffold/neural stem cells-based tissue engineering in a traumatic brain injury model. In addition, his cont laboratory discovered a novel mitochondrial-dependent signaling pathway that mediates the neuroprotective effect of HSP27 against ischemic neuronal injury and discovered that cross-talk between PARP-1 and calpain signaling mediates the AIF-dependent cell death pathway in neuronal apoptosis

• Guodong Cao received an R21 grant to study the therapeutic effects of a novel erythropoietin (EPO) mutant molecule against ischemic brain injury. He also has received a funding notice (VA Rehabilitation Research and Development) from the Department of Veterans Affairs to study the neurorecovery effect of mutant EPO after a clinically-related delayed administration approach.

• Ed Burton was awarded a grant from the Dystonia Medical Research Foundation for the analysis of the dopamine system in the zebrafish dystonia model. He also continued his work on his R21 to examine the zebrafish model of multiple system atrophy as well as several foundation awards examining a zebrafish model of DYT1 dystonia and an exploration of the phenotypic characterization of tauopathy zebrafish.

• David Hinkle received a Parkinson’s Disease Foundation grant to assess the role of GDNF and BDNF in DJ-1 dependent, astrocyte-mediated neuroprotection in an in vitro neuron-astrocyte co-culture model system. He also continued work on his K08 Mentored Clinical Scientist Development Award to study the potential role of DJ-1, an astrocyte-expressed gene that is implicated in Parkinson’s disease.

• Amanda Smith was awarded a VA grant to examine the impact of exercise on the aged parkinsonian rodent nigrostriatal pathway. In addition, she continued work with endogenous neuroprotective agents in Parkinson disease, the focus of her K01 Mentored Research Scientist Development Award, mentored by Dr. Michael Zigmond.

• Sarah Berman continued to work on her K08 Mentored Clinical Scientist Development Award focused on mitochondrial dynamics in neurodegeneration and her project funded by the American Parkinson Disease Association to explore mitochondrial dynamics in models of Parkinson’s disease.

• Milos Ikonomovic & Steven Graham continued to work on their respective projects in the renewed Program Project Grant from the NINDS entitled “Molecular Mechanisms in Traumatic Brain Injury: Bench to Bedside.”

• Paula Clemens continued work on her R01 “Genetic Rescue of Dystrophic Muscle in Utero” and will be starting her VA Administration Merit Review award “Molecular Treatment of Muscle Atrophy” in the coming year.

• J. Timothy Greenamyre received a grant from the Michael J. Fox Foundation to examine the pathological characteristics of alpha-synuclein transgenic rats. He also received a grant from the Parkinson’s Disease Foundation to examine gastrointestinal dysfunction in Parkinson’s Disease. A new NINDS-funded Program Project Grant studying mitochondrial proteins in Parkinson’s disease will be funded in the coming year.

Clinical Research

Clinical research in the Department of Neurology has also expanded in the last several years and significant numbers of patients with neurologic diseases are enrolled in ongoing clinical trials. In some disease categories, the department has developed into a national leader in enrolling patients in such trials. This is an invaluable resource for continued development of research in the department, and also attracts patients to our medical center.

7

• Lawrence Wechsler, Max Hammer, Tudor Jovin and Ken Uchino from the UPMC Stroke Institute continued their participation in federal and industry sponsored clinical trials.

• Oscar Lopez was named the Director of the NIA-funded Alzheimer Disease Research Center and assumed University of Pittsburgh leadership of the ginkgo biloba prevention trial. In addition he continued work on his refunded NIA R01 grant “Predictors of Alzheimer’s Disease in Mild cognitive Impairment.”

• The ADRC continued to be a part of the NIA-funded Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer’s Disease Cooperative Study Program, an NIH-funded multi-center program doing clinical research on medications for Alzheimer’s disease including a DHA study and a RAGE study

• Judith Saxton assumed leadership of the Detection, Diagnosis and Intervention in Dementia state grant and was named Clinical Core leader for both the Alzheimer’s Disease Research Center and the PiB PET imaging Program Project grant. She continued to work on her NIA-funded R01 grant which investigates the utility of cognitive testing in the primary care setting by using computer tests to identify older patients with mild cognitive impairment.

• Drs. Lopez, Moore and Saxton continued exploration of the diagnostic capabilities of the PET Amyloid imaging agent, Pittsburgh Compound B (PiB) in mild cognitive impairment and dementia.

• Samay Jain received funding from the large pilot project program of the Pittsburgh Claude D. Pepper Older Americans Independence Center to explore risk factors and non-motor features of Parkinson’s disease in the Cardiovascular Health study and funding from the Center’s Junior Scholar Small Pilot Funding program to determine the feasibility of an exercise program using an interactive dance game in Parkinson’s disease patients. He also continued to examine the use of non-motor assessments of clinical and physiological measures to improve diagnosis and treatment of Parkinson’s disease, the focus of his award from University of Pittsburgh Multidisciplinary Clinical Research Scholars Program (CTSA K12).

Training Grants • Michael Zigmond is the Director of two T32 training grants, one funded by the NIMH to provide

training in the neurobiology of psychiatry disorders and the second funded by NINDS to provide training in the neurobiology of neurodegenerative diseases. In addition, Dr. Zigmond continues to direct an NIMH R 25 grant that provides support for faculty to teach survival skills and ethics and an NINDS U13 grant to conduct survival skills and ethics workshops for neuroscientists.

Department Research Funding Sources and Growth

Extramural Funding

Industry3% Training

2%State3%

DoD3%

VA/Other Federal4%

K Awards6%

Foundation14%Fellowships

1%

Program Projects20%

Center23%

R Awards21%

8

Department Funding Sources

$-

$2,000,000

$4,000,000

$6,000,000

$8,000,000

$10,000,000

$12,000,000

$14,000,000

$16,000,000

$18,000,000

$20,000,000

FY 02 FY 03 FY 04 FY 05 FY 06 FY 07 FY 08 FY 09

Fiscal Year

Ann

ual F

undi

ng

OTHERSTATEVANIH

Funding by NIH Institute FY09

National Institute of Aging (NIA), 36%

National Institute of Neurological Disorders

& Stroke (NINDS), 28%

National Institute of Arthritis &

Musculoskeletal & Skin Diseases (NIAMS), 2%

National Institute of Mental Health (NIMH),

2%

National Center for Complementary &

Alternative Medicine (NCCAM), 28%

National Institute of Environmental Health

Sciences (NIEHS), 1%

Fogarty International Center (FIC), 2% National Institute of

Child Health & Human Development (NICHD),

1%

9

Educational Activities

The Adult Neurology Residency Training Program

The Neurology Residency Training Program continues to attract outstanding physicians from the United States and around the world for state-of-the-art training in the diagnosis and treatment of diseases of the nervous system. Twenty residents train in the four-year program, which begins with one year of internal medicine residency and then proceeds to three years of fulltime training in neurology. Resident trainees receive detailed instruction and practical daily experience in the art of the neurological examination, localization of abnormalities in the nervous system, differential diagnosis, and neurological therapeutics. For a solid underpinning of basic neuroscience for their clinical training, our residents are taught neuroanatomy, neurophysiology, neurochemistry, neuroradiology, neuropathology, and neuropharmacology as well as retrieval and analysis of current medical information. There has been increased emphasis on the fundamentals and application of evidence-based neurology in the last three years, with special emphasis on the use of online data for decision-making assistance. Under the direction of an outstanding faculty of attending neurologists, residents assume progressive oversight of patient care during the course of their training. During the last two years of training, ample elective time allows each resident to develop skills and expertise tailored to his or her particular interests, while the core curriculum assures a high degree of competency in general neurology. Our graduating residents have been highly successful in obtaining positions of their choice. In the past several years 90% of our graduating senior residents pursue advanced training fellowships and 10% directly enter clinical practice.

Neurology Boot Camp: Incoming residents are greeted by an innovative and unique method of introducing trainees to the rapidly growing field of neurology. This approach, termed “Neurology Boot Camp,” immerses our junior trainees in a month-long fulltime intensive experience fashioned to provide a strong base of knowledge and understanding upon which the remainder of their experience will build. This introductory course makes use of extensive case studies, case simulations, an intensive Basic Neurologic Life Support lecture series, a series of interactive neuroradiology-neuroanatomy correlation sessions, neurological examination rounds, and hands-on rapid medical information retrieval, using the University’s extensive computerized medical databases and Internet resources. This shift in initial training fosters the achievement of a high level of clinical competency earlier in the course of training, and lays an even stronger foundation of skills for ongoing lifelong self-education. The unique intensive introductory program encompassing core clinical neurosciences has been further developed and refined to insure that neurology residents enter their clinical training with a solid grounding in the fundamental principles underlying current diagnosis and treatment. At this point, six classes of junior trainees have completed the course and unanimously agreed that the intensive training gave them a real advantage when they arrived on the floors to start their clinical training in neurology.

The residency program continues to attract outstanding applicants from medical schools across the country. Recent achievements and changes in the residency program include:

• Addition of a “Basic Neurologic Life Support” lecture series to the four week “Intensive Introduction to Clinical Neurology” course held for the junior residents each July.

• Over 495 applications were received for the 2008-2009 match. This marks a continued increase in applications to the program. We continue to fill all 5 slots. Strong recruitment results continue to improve the overall quality of the residency program.

• Graduating residents who completed neurology training in the Department of Neurology continued to pass the American Board of Psychiatry and Neurology (ABPN) Part 1 board examination with very high pass rates.

• Residents from Neurosurgery, Medicine, Psychiatry, and PM&R rotated through the neurology service to receive their required specialty training, enhancing the experience for both them and the Neurology residents.

10

Dr. John Doyle maintains leadership of the Neurology Residency Program as well as serving as Chief of the Division of General Neurology.

Advanced Neurological Fellowships

Advanced training fellowships in Clinical Neurophysiology, Stroke and Endovascular Neurology are offered through the Department of Neurology. In July 2002 the Stroke fellowship here was one of the first in the county to receive ACGME approval. Fellows enter these highly competitive positions after completing a full neurology residency.

Clinical Neurophysiology fellowships emphasize human electroencephalography, peripheral neuromuscular physiology, epilepsy, and neuromuscular disease. Fellows can elect regions of emphasis within these areas, but graduate with a broad skill set in clinical neurophysiology.

Stroke fellowships provide training in the rapidly evolving field of neurovascular disorders and therapeutics. Stroke fellows gain extensive experience with clinical management of complex disorders, advanced neuroimaging techniques, thrombolytic therapy, evidence-based stroke therapy, and investigational approaches to stroke treatment. The Stroke fellowship has been expanded to include exposure to interventional therapies and procedures as well.

Endovascular Neurology fellowships include training in diagnostic angiography, aneurysm coiling and stroke interventions. Fellows are trained by an interventional team including a neurologist and neurosurgeon. A considerable experience is obtained from an extremely active acute stroke service and a busy neurosurgical referral practice.

Neurology Medical Student Curriculum

Neurology is taught in a combined 8 week course with Psychiatry in the third year of medical school. The clinical portion of the rotation is divided into two parts with the students dividing their clinical time between 3 weeks of Neurology and 5 weeks of Psychiatry. This clinical exposure has mixed inpatient, outpatient and consult time slots. Throughout the rotation, all students are provided didactic material primarily from Neurology and Psychiatry. This consists of 8 core lectures each from Neurology and Psychiatry. In addition to the Neurology and Psychiatry material, students are also exposed to additional didactic material from Pediatric Neurology, Neurosurgery, Neuropathology and Neuro-radiology throughout the rotation. Occasionally, students are allowed to monitor neurosurgical cases in the operating room. They also attend two formal neuropathology conferences that include gross sectioning of brains obtained at autopsy with discussion of the noted pathology.

Students are evaluated via evaluation form by the faculty who mentored and oversaw them during the clinical aspect of the course. This form requires more objective criteria for evaluation of the student’s history and physical examination, case presentations, data analysis, factual knowledge, problem solving, patient interaction, cooperation and dependability. This portion of their evaluation comprises 66% of their final neurology grade. The other 33% is determined by the student’s performance on a standardized test from the National Board of Medical Examiners for Neurology. This allows comparison of our students with others across the nation. It is our desire that all students should be able to handle common neurological problems and emergencies in their future practices.

The neurological clerkship is comprised of a well-balanced curriculum including didactic and “hands on” exposure. The students are provided detailed goals and objectives that should direct them in their studies and prepare them for medical practice and on national board-type examinations. Dr. Galen Mitchell continues as Director of Medical Student Education.

Other Departmental Highlights

• Lawrence Wechsler was named Interim Chair of Neurology.

11

• UPMC Stroke Institute received the Stroke Silver Performance Achievement Award from the American Stroke Association.

• Edward A. Burton, MD, DPhil, MRCP, Assistant Professor of Neurology was named a Fellow of the Royal College of Physicians (FRCP), UK in May 2009.

• Gena Ghearing, MD received the 2009 Excellence in Teaching Award from the Neurology residents.

• Robert Y. Moore, MD, PhD was appointed to a second two-year term on the President’s Committee for the National Medal of Science by President George Bush.

• Anne Van Cott, MD was named the 2009 Outstanding Professional Employee (Medical/Scientific) Bronze Award recipient in the Excellence in Government Awards Program, Pittsburgh Federal Executive Board. Additionally Dr. Van Cott was elected a Fellow Member of the American Academy of Neurology (AAN) in recognition of her research and educational contributions to the field of epilepsy and the neurology community.

Future Initiatives

Plans for the Department of Neurology include initiatives in the clinical, research, and teaching areas of our mission. The department continues to expand with resultant improvement in clinical patient diagnosis and treatment activities. In addition to the access provided by the clinic and patient intake coordinators the department will adopt the Healthtrak program which allows patients immediate electronic access to test results, appointment scheduling, and the patient’s physician via e-mail. The department will conclude an intensive clinical process improvement plan, workflow renovations, and hands-on training with its rollout of the Electronic Medial Record system in September 2009. The Electronic Prescribing (E-Rx) application will result in increased patient safety across all sub-specialties in the department and reduce duplication for patients and clinical faculty. Patients and payors will benefit from the increased availability of electronic orders, prescriptions, and office notes as well as increased access to care and follow-up provided by a centralized system that promotes timeliness and accountability.

A major initiative is recruitment of several physicians in General Neurology and several subspecialty areas. The sub-specialty areas of Vascular Neurology, Movement Disorders, Neuroimmunology/Multiple Sclerosis, Neuromuscular Disorders, Cognitive and Behavioral Neurology and Epilepsy will receive particular emphasis to provide the most comprehensive outpatient neurology services and respond to referrals from other physicians.

Neurology’s research program continues to grow. Our researchers have specific plans to increase funding for basic, clinical and translational research. The department has become one of the top nationwide for NIH research funding and will strive to achieve more funding. The firm establishment and expansion of the clinical and translational research programs in neurodegenerative diseases will receive increasing attention and resources.

The education of medical students, residents, and fellows continues to be a high priority. The department will continue to improve and further develop the didactic programs for neurology residents under the direction of residency director John Doyle, M.D. Fellowships will be organized and further developed in Vascular Neurology, Movement Disorders, Neurobehavior, Epilepsy and Neuromuscular Disease.

The administrative functions of the department are continuously reviewed and improvements made whenever appropriate. The roles of our Division Chiefs have been expanded to support department administrative efforts. The Executive Committee consists of the 8 Division Chiefs and the Vice Chairs for Research, Academic Affairs and VA Affairs. The Executive Committee will continue to regularly review Department operations and initiate improvements, modify policy, and advise expansion of clinical, research and teaching programs as appropriate.

12

Clinical Activities

2008-2009 saw continuing growth in the diagnosis and treatment services of the clinical practice in the Department of Neurology (University of Pittsburgh Physicians–Neurology). The Department includes the Divisions of Epilepsy, General Neurology, Headache, Movement Disorders, Neuromuscular Disorders, Neuroimmunology/Multiple Sclerosis, Cognitive and Behavioral Neurology, and Vascular Neurology. The continued growth of the Alzheimer Disease Research Center in Neurology has expanded services in behavioral neurology and memory disorders. Each division maintains a distinct mix of patient care, clinical research, and teaching activities.

Neurology maintains a highly visible presence at several locations throughout Western Pennsylvania. The majority of clinical activity takes place in the Oakland health system facilities but meets clinical needs in other geographical areas. The Department has two headache center locations—Oakland and Wexford—and sees cognitive and behavioral patients in Wexford in addition to the Kaufmann outpatient clinic. An active physician practice continues to operate in Mt. Lebanon. Both the Monroeville-Oxford Drive and UPMC Mercy offices offer general neurology appointments, as well as Electromyograms (EMG) in an outpatient setting. Additionally, the Stroke division opened a center at UPMC Mercy in the fall of 2008. Faculty members continue to be very active in community programs relating to their subspecialties, such as the MS Society, National Parkinson’s Foundation, Pittsburgh Parkinson’s Foundation, the ALS Society, the National Headache Society, Epilepsy Foundation of America, Muscular Dystrophy Association, Myasthenia Gravis Association, Huntington’s Disease Society of America, and the Alzheimer’s Association. The myriad of activities include serving on community or professional advisory boards and national boards of directors.

Financially, the Neurology clinical practice continues to maintain strong controls over expenditures and consistent efforts at revenue enhancement including further expansion of clinical practice locations. Clinic operations and staffing patterns are continuously monitored to ensure optimum return on financial investments. Faculty members are encouraged to optimize their clinic time and to fully and efficiently utilize the time they spend in the clinic. The patient population continues to grow and clinic accessibility has expanded to meet the demand. Neurology clinic accessibility has been significantly enhanced with new faculty, appointment time management, and appropriate utilization of support staff.

Departmental Divisions Division of Cognitive and Behavioral Neurology

Oscar Lopez, MD, Chief of the Cognitive and Behavioral Neurology Division directs the NIA-funded Alzheimer’s Disease Research Center (ADRC) and is Co-Leader of the ADRC Clinical Core and conducts both NIH and industry-sponsored experimental therapeutic studies of Alzheimer’s disease. Dr. Lopez’s main area of concentration is Alzheimer’s disease research, AIDS dementia, and vascular dementia. He leads an NIH-funded study examining predictors of Alzheimer’s disease in mild cognitive impairment (MCI). His recent findings are relevant to the understanding of the symptom profile and nosology of MCI. He assumed University of Pittsburgh leadership of the NIH-funded 3000 person multi-center national trial of Ginkgo biloba in the prevention of dementia in September 2009 when principal investigator Steven DeKosky, MD moved to the University of Virginia to become Dean of the Medical School. In addition, he is a collaborator on the NIA-Icelandic Heart Association Study on Aging and is the organizer of the bi-annual Pittsburgh-Barcelona Dementia Update and provides scientific consultation to the Fundacion ACE in Barcelona. Judith Saxton, PhD focuses her research on the assessment of older patients with cognitive problems. She is Core leader of the ADRC Clinical Core and Co-Leader of the ADRC Training and Information Core. She is the principal investigator of an NIA-funded grant that investigates the utility of cognitive testing in the primary care setting by using computer tests to identify older patients with mild cognitive impairment. In addition she is a co-investigator on the ginkgo biloba trial, Clinical Core leader of the PIB-PET imaging program project grant and assumed overall leadership of the Commonwealth of Pennsylvania Center of Excellence in the Detection, Diagnosis and Intervention in Dementia in September, 2009.

13

Epilepsy Division

During the 2008-2009 academic year, Epilepsy Division staff included: Anto Bagić, MD, MSc, Chief (Assistant Professor of Neurology and Neurological Surgery; Director, University of Pittsburgh Comprehensive Epilepsy Center; Director, UPMC Epilepsy Monitoring Unit; Director, Center for Advanced Brain Magnetic Source Imaging), Richard Brenner, MD (Clinical Professor of Neurology; Chief, EEG Laboratory), Gena Ghearing, MD (Assistant Professor of Neurology), Rick Hendrickson, PhD (Neuropsychologist, Assistant Professor of Neurology) and Anne C. Van Cott, MD (Assistant Professor of Neurology; Neurology Service/ VA Pittsburgh Healthcare System).

In addition to the Department of Neurology, clinical and research activities of the Epilepsy Division take place in the context of University of Pittsburgh Epilepsy Center (UPEC), a level IV Epilepsy Center according to the National Association of Epilepsy Centers (NAEC) designation that provides state-of-the-art diagnostic and treatment services to adults and children with uncontrolled seizures. The center is a joint program combining the resources of the University of Pittsburgh School of Medicine, the University of Pittsburgh Medical Center (UPMC), Presbyterian University Hospital (PUH) and Children's Hospital of Pittsburgh (CHP). Established in 1986, it provides regional referral and consultative services to Pennsylvania, Ohio, West Virginia, and beyond. Staff specializes in the evaluation and treatment of patients with forms of epilepsy that are difficult to diagnose or manage. The center includes clinical and research facilities for adults and children. Research conducted at the Epilepsy Center has contributed to the introduction of seven new antiepileptic drugs over the past decade.

In terms of technology, the epilepsy clinical care facilities of the University of Pittsburgh Epilepsy Center and the University of Pittsburgh Medical Center is second-to-none with pediatric and adult epilepsy closed-circuit television/electroencephalography (CCTV-EEG), adult and pediatric outpatient ambulatory care facilities, EEG labs, ambulatory EEG, state-of-the-art neurosurgical operating rooms, PET, SPECT, MRI, fMRI, and a state-of-the-art magnetoencephalography (MEG) facility featuring a 306 sensors whole head MEG system that also includes 128 channel EEG recording capabilities. The University of Pittsburgh Medical Center belongs to the select group of premier institutions in the world to offer the best available whole head MEG evaluations to intractable epilepsy patients and patients with other brain disorders. UPMC MEG System operates within the Center for Advanced Brain Magnetic Source Imaging (CABMSI) located on the first level of PUH. This was the first MEG System in the region that includes Pennsylvania, Ohio, West Virginia, Virginia and Maryland. On this merit, many distant referrals ended in Pittsburgh and were deemed seizure-free after successful surgery that was planned based on multimodal imaging that includes MEG study.

Facilities at the center and the expertise of the staff allow the staff to establish definitive diagnoses in patients with seizures of uncertain origin and medication regimens for optimal seizure control and minimal side-effects. Patients with medication-resistant seizures can be evaluated for all surgical treatment alternatives including most commonly performed resective surgery and a Vagal Nerve Stimulator (VNS) implantation. Patients also have access to neuropsychological evaluations, medication response monitoring, rehabilitation, psychosocial services, referrals and the possibility of participating in promising clinical drug trials.

Headache Division

The Headache Division continues to operate clinically at 2 different locations: the state-of-the art outpatient facility opened in 2007 in central Oakland, and the satellite office situated in the North Hills along the I-79 corridor. Faculty transitions during the year included the departure of Dr David Watson to develop the headache program at the West Virginia University School of Medicine and the addition of Dr Miguel Estevez. Drs. Robert Kaniecki, Michael Soso, Barbara Vogler and Dr Estevez, as well as physician assistants Kimberly McGonigle and John Lucking, continue to provide outpatient clinical services. Monthly clinical volumes at the Headache Center continued to exceed expectations and approximated 800 patients each month. In addition to outpatient responsibilities in the clinic setting, all headache physicians actively participate on the inpatient service at Presbyterian University Hospital. Lectures on headache and pain are delivered by Dr Kaniecki to the first-year medical students and by Drs Kaniecki and Vogler to the third-year medical students. All physicians supervise residents and medical students on the inpatient service, while Dr Kaniecki supervises resident and student rotations though the Headache Center. Dr Soso serves on the Institutional Review Board

14

for the University of Pittsburgh School of Medicine, while Dr Kaniecki serves as chairman of the Scientific Review Committee for the Department of Neurology. Dr Kaniecki continues to serve on the residency selection committee and the executive committee for the Department of Neurology. Dr Vogler has expanded the clinical research program at the Headache Center, recruiting several important multicenter trials to the department, and Dr Estevez has continued his basic science research in the field of headache. The Headache Center is planning to continue the expansion of clinical and research services as it begins the recruitment process for additional faculty.

The Movement Disorders Division is directed by J. Timothy Greenamyre, M.D., Ph.D. and includes Drs. Sarah Berman, Ed Burton, David Hinkle, Samay Jain, Robert Moore and Valerie Suski. The Movement Disorders Division has three objectives: (i) to provide subspecialty care in Parkinson’s disease and other movement disorders; (ii) provide education in movement disorders for medical students, graduate students, residents and fellows; and (iii) carry out research in basic and clinical aspects of movement disorders. The American Parkinson Disease Association (APDA) has designated the Division as an Advanced Center for Parkinson’s Disease Research, one of only 8 such centers in the nation.

The Division currently provides subspecialty care to patients with movement disorders through the Comprehensive Movement Disorders Clinic, with participation by faculty and staff from the Departments of Physical Medicine and Rehabilitation, Otolaryngology and Neurological Surgery. Many individuals seen in the clinic also volunteer to participate in clinical trials of new treatments and in studies supported by the NIH and the VA Healthcare System. Clinical programs have grown steadily over the last few years and include the continued expansion of deep brain stimulation as a treatment for advanced Parkinson disease (in collaboration with the Department of Neurological Surgery) and a Dystonia/Botulinum Toxin Clinic. The Huntington Disease Clinic continues to grow and is a Huntington Study Group research site.

During the past year, the Movement Disorders faculty continued to provide bedside and didactic teaching to undergraduates, medical students and residents. Twice a month there is a clinical conference for faculty, residents and students at which interesting or difficult-to-diagnose cases are presented. There is a regular lecture series for residents, and the Movement Disorders lecture series for the first year medical students has been revised and has received excellent evaluations. In May 2009, the Division hosted its 3rd CME course on Parkinson’s Disease and other Movement Disorders; it was well attended and received excellent reviews from attendees. A clinical fellowship program is planned.

As it expands, the Division continues to have a vigorous and well-funded research program that investigates both clinical and basic aspects of movement disorders. Each of the faculty has been successful in obtaining extramural funding for their projects. Several new collaborative projects have begun, which cross traditional boundaries of scientific discipline and academic department.

Neuroimmunology/Multiple Sclerosis Division

The Neuroimmunology Division includes physicians Rock Heyman, and Galen Mitchell. This active division has a comprehensive outpatient clinical program that has earned awards for its excellence. The MS program is accredited as a MS Center by the National MS Society, recognizing comprehensive clinical, research, and educational programs. Two of the division's nurses (Margie O’Leary and Marlene Boyd) as well as Speech Pathologist Patricia Bednarik are board certified in MS care. The program includes comprehensive care for all aspects of care with close affiliations with many services at UPMC and throughout the region to meet the needs of people with MS at all levels of disease severity. The infusion center, managed by Susan Duttenhofer, RN, has expanded to meet the needs of patients on intravenous therapies including monoclonal antibodies, corticosteroids and immunoglobulin. Many patients with other immunologic conditions such as Sjogren's syndrome or sarcoidosis involving the central nervous system are seen by this division in support of UPMC's regional physicians.

Division research continues and includes involvement in multi-center studies of novel oral or infusion therapies for MS. Some of the agents used in current protocols are fingolimid (FTY720), alemtuzumab,

15

MBP8298, BG00012, and botulinum toxin (Neurogenic bladder). The research coordinator Kerry Oddis and assistant Darlene Punjack provide organization and support for these trials.

Educational programs by division staff are directed towards people with MS, caregivers, allied health professionals, medical students, residents, and physicians. Division personnel frequently lecture to the numerous support groups throughout the region and often nationally, and Margie O’Leary, CRNP, MS Division was selected as the 2009 “Physician Services Division Award for Staff Excellence in Service to the Community.” The division has trained fellows in clinical MS as has developed a fellowship program designed to allow nurses to obtain a MSCN board certification. Weekly divisional educational conferences occur every Thursday morning.

Neuromuscular Division

The Neuromuscular Division is directed by David Lacomis, MD. Dr. Lacomis and Division members Paula Clemens, MD, and Chitharanjan Rao, MD, and Sasa Zivkovic, MD provide care for neuromuscular patients including those seen in the affiliated Muscular Dystrophy Association Clinic and MDA-ALS Center. Drs. Clemens and Zivkovic also treat patients at the Oakland VA Medical Center.

The division trains fellows in clinical neurophysiology and provides electrodiagnostic services (electromyography and autonomic testing) at UPMC-Presbyterian and Dr. Rao provides EMG services at UPMC Magee. Dr. Lacomis performs needle muscle biopsies and is in charge of the neuromuscular pathology services in the Neuropathology Division. Dr. Clemens also trains pre-doctoral students working in her laboratory.

Active research programs include both basic and clinical studies (Dr. Clemens). Basic research projects include gene replacement and gene editing studies for muscular dystrophy in utero, characterization of the molecular pathology of muscle wasting in cancer cachexia, and several methods of modulation of NF-κB signaling pathways for amelioration of the dystrophic phenotype and modulation of the immunity induced by viral vector-mediated gene delivery for the treatment of muscular dystrophy. A new basic research initiative for 2009-2010 is the study of the molecular pathology of muscle atrophy due to nerve injury, funded by a new VA merit review award to Dr. Clemens. Clinical trials in Duchenne muscular dystrophy (DMD) (Dr. Clemens with Dr. Abdel-Hamid (pediatric neurology)) include involvement in a multi-center academic trials group devoted to the study of therapeutic agents for patients with DMD and a large natural history study of DMD over the full age spectrum of the disease. In addition, Drs. Clemens and Zivkovic continue to participate in a Genzyme-sponsored trial of enzyme replacement therapy for late-onset Pompe disease.

The other major area of research involves ALS including clinical trials (R+ pramipexole) (Drs. Lacomis and Zivkovic), cognitive dysfunction, imaging, and magnetoencephalography in ALS (Dr. Zivkovic), biomarkers, and epidemiology. (Dr. Lacomis). Dr. Lacomis serves as the Medical Director of the University of Pittsburgh Center for ALS Research directed by Robert Bowser, PhD.

New research initiatives for 2009-2010 include participation in the following multicenter studies for ALS (Dr. Lacomis – PI): (1) A Phase III clinical trial of Ceftriaxone (2) a Phase IIb-III study of KNS-760704 and (3) expansion of the ALS biomarkers study to include DNA analysis. There will also be a study of utilization of non-invasive ventilation in ALS (Dr. Albert (PI)).

Drs. Lacomis and Zivkovic are working with Dr. Terry Heiman-Patterson at Drexel University and Dr. Zachary Simmons at Pennsylvania State University with the newly formed Pennsylvania ALS Consortium which will eventually expand to other centers in Pennsylvania. So far, a patient registry has been formed. The goals will be to share data, tissue, and obtain funding for multi-center studies in Pennsylvania. Dr. Zivkovic is also a co-investigator in Dr. Strotmeyer’s NIH-funded study of “Peripheral nerve function decline in an aged cohort.” Drs. Clemens and Zivkovic are initiating a new industry sponsored trial of an alternate approach to late-onset Pompe patients using a molecular chaperone approach (on clinical hold currently). Drs. Clemens and Abdel-Hamid continue with DMD trials through participation in a multi-site academic network. Dr. Clemens has an active role on the leadership team of this academic research network, the Cooperative International Neuromuscular Research Group (CINRG).

16

Neurooncology Program

The Adult Neurooncology Program is the major regional referral center for patients with central nervous system tumors, cancer metastatic to the nervous system, and patients with neurologic complications of cancer. Frank Lieberman, MD (Associate Professor of Neurology and Hematology/Oncology and Director of the Adult Neurooncology Program) provides inpatient consultation care for inpatients at the UPMC Shadyside and Presbyterian campuses. In 2007, the Hillman Cancer Center opened the Multidisciplinary Neurooncology Clinic, comprised of neurology, neurosurgery, and radiation oncology faculty, all combining to provide coordinated multispecialty care to patients with brain tumors. The Adult Neurooncology Program provides comprehensive neurologic care for patients with cancer, including management of seizure disorders, cancer related pain syndromes, neurologic side effects of chemotherapy and radiation therapy, and paraneoplastic neurologic disorders. Neurooncology faculty members administer chemotherapy for patients with primary brain tumors and oversee and care for patients participating in clinical trials through the University of Pittsburgh Cancer Institute's participation as a member institution in the North American Brain Tumor Consortium and the Radiation Therapy Oncology Group.

The neurooncology program participates in a number of varied studies:

• The ongoing Novocure T-100 trial and other industry sponsored clinical trials for primary brain tumors.

• In collaboration with Dr. Lieberman, Dr. Hideho Okada, Associate Professor of Neurosurgery, is directing an innovative program testing a novel approach to immunotherapy of malignant gliomas using a vaccine based on glioma-associated peptides.

• The development of more effective therapies for patients with skull base and spinal chordomas has become a major research focus of the Adult Neurooncology Program. In collaboration with the Neurooncologic Neurosurgery faculty, Drs. Lieberman and Deric Park (Neurosurgery) care for patients with complex skull base meningiomas, and are members of the multidisciplinary group focusing on treatment of skull base and spinal chordomas.

• The Adult Neurooncology Program is collaborating with other members of the Unified Brain Tumor Consortium to evaluate novel MRI and PET imaging techniques in assessing treatment response to molecularly targeted therapies, including the use of 7T MRI to monitor the effects of anti-angiogenic therapies on the vascular anatomy of malignant gliomas.

The Adult Neurooncology Program also provides training in neurooncology for neurology residents, neurosurgery residents, hematology/oncology fellows, and medical students. Residents and fellows attend the neurooncology clinics at the Hillman Center as well as participate in the neurooncology inpatient consultation service at UPMC Shadyside. Dr. Lieberman directs a weekly multidisciplinary Neurooncology tumor board which guides the treatment of complex cases throughout the UPMC Cancer Center network.

Division of Vascular Neurology: The Division is synonymous with the UPMC Stroke Institute and its activities are described under the Stroke Institute activities.

Department Institutes and National Center Affiliations

Alzheimer Disease Research Center

The ADRC at the University of Pittsburgh, currently directed by Oscar Lopez, MD, was established in 1985 by a grant from the National Institute on Aging (NIA). The center initially focused on behavioral, neuropsychological and neuropsychiatric changes over the course of the disease and has evolved into a broadly based, full-service dementia research center, fulfilling its missions in excellent patient care and follow-up, clinical,

basic, and translational research, and education of students, residents, fellows, faculty, community physicians, and the lay community. Areas of research specialization include neuropsychiatric symptoms and manifestations of Alzheimer’s disease and other dementias, neuropathology, neuroimaging and new

17

neuroimaging modalities, genetics, examination of factors that can alter the clinical course of the disease, and the overlap of Alzheimer’s disease with other neurodegenerative disorders. A wide range of basic and clinical research studies within the University community and with external collaborating institutions are supported by patients, data, biological materials, or expert consultation from the ADRC.

Current research studies include:

• Exploration of alterations in the brain at the early stages of AD and presymptomatic AD (including the risk state of mild cognitive impairment)

• Examination of the neuropathological changes in Lewy body disease and its overlap with the presence of AD

• Study of genetic risk factors for AD and the genetic risks associated with the development of psychiatric symptoms, especially psychosis in AD

• Functional neuroimaging studies to make more accurate diagnoses of AD, including PET assessment of noninvasive imaging of amyloid utilizing new ligands (Pittsburgh Compound B, PIB) sensitive to amyloid in vivo

• Examination of neuroimaging effects of some of the established AD medications on cerebral blood flow and other metabolic markers in AD and PD.

The clinical research component of the ADRC includes an evaluation and treatment program for individuals experiencing memory impairment. Accurate diagnoses are established through an interdisciplinary approach with evaluations in neurology, psychiatry, neuropsychology, medicine and social work. After diagnosis, eligible subjects are followed longitudinally and participate in additional ADRC research studies. Currently, cutting-edge neuroimaging studies and several experimental therapeutic trials are ongoing in Alzheimer’s disease and related dementias. The ADRC participates in several national consortia including the Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative, the Alzheimer’s Disease Genetics Initiative, and the National Alzheimer’s Collaborative Center.

American Parkinson Disease Association Center for Advanced Research

The University of Pittsburgh School of Medicine was named an American Parkinson Disease Association Center for Advanced Research in 2006. The APDA is the nation’s largest grassroots Parkinson’s organization and has been providing patient and caregiver support, free educational materials and scientific research support for 45 years. As an Advanced Center, Pitt is part of a network of eight APDA centers at major universities

and healthcare centers across the country. J. Timothy Greenamyre, MD, PhD, Professor and Vice-Chair of Neurology, Chief of the Movement Disorders Division, and Director of the Pittsburgh Institute for Neurodegenerative Diseases, directs the Pitt APDA Center for Advanced Research.

Center for Advanced Brain Magnetic Source Imaging (CABMSI)

Magnetoencephalography (MEG) is the most modern and powerful technique for studying brain functions non-invasively. The University of Pittsburgh Medical Center obtained a cutting-edge Elekta-Neuromag Vectorview 306 MEG system and established the Center for Advanced Brain Magnetic Source Imaging (CABMSI) at Presbyterian Hospital, thereby laying a foundation for remaining at the forefront of medical technology, service and research.

The CABMSI is an extra-departmental entity focused on clinical and research applications of MEG. It operates as a self-sustained module that “fits and feeds” the UPMC system: a resource center that provides a logistical framework for all clinical applications of MEG as well as the widest spectrum of research applications, from basic and applied research to clinical research. The Center and MEG Program are directed by Anto Bagić, M.D., M.Sc., (Neurology & Neurological Surgery). Clinical operations continue to be focused on the currently approved clinical indications for MEG: localization and better characterization of epileptic foci when other means are inadequate and pre-surgical functional brain mapping (PSFBM), both headed by Dr.

18

Bagić. At the request of and with support from the Department of Neurological Surgery, Dr. Bagić has been working to establish a full set of clinical protocols for PSFBM and full integration of MEG/MSI findings within neuronavigational systems utilized by the Department of Neurosurgery, as well as their combination with other neuroimaging techniques in the form of multimodal imaging leading to further improvements in post-surgical outcomes.

No single imaging method provides sufficient understanding of brain’s network complexity. Thus, improvements of each imaging modality, as well as combining the data from different modalities have been used increasingly. Adequately trained researchers capable of assimilating and applying the increased complexity of individual modalities and the multimodal data is a critical precondition for increasing the readiness of the neuroscience community to address the current and future scientific challenges. To fill this gap, NIH Training Grant T90/R90 for a Multimodal Neuroimaging Training graduate program was funded for five years; starting in June 2007. It includes a combination of MRI, fMRI, PET, MEG, EEG, and optical imaging. Seong-Gi Kim, Ph.D. (biophysicist, Center for Neuroscience at the University of Pittsburgh) and William Eddy, Ph.D. (statistician, Carnegie Mellon University) serve as Program Co-Directors.

Over the last year a broad spectrum of MEG research was catalyzed, from the study of sensory-motor interaction for establishing optimal locations for implantable electrodes for controlling prosthetic limbs to amyotrophic lateral sclerosis (ALS) and including a variety of cognitive studies (language, different memory paradigms, face recognition, reward paradigms, mental coherence). Most recently, in collaboration with the UPMC Hand Transplant team of Dr. W. P. Andrew Lee (Chief, Division of Plastic Surgery), Dr. Bagić initiated a longitudinal study of brain plasticity in hand transplant recipients. Meantime, sustained collaborative efforts involving a group of accomplished scientists from University of Pittsburgh, UPMC, Carnegie Mellon University (CMU) and Intel on using MEG for language-based brain computer interface (BCI) were formalized in the form of collaborative agreement. The magnitude of submitted or ongoing projects spans from internal pilots, a VA Study, submissions to foundations and other smaller funding entities, to NIH RO1 grants. In addition to several smaller agency- and foundation-funded projects, and NIH-funded R03 and R21, CABMSI’s first NIH RO1 involving MEG was awarded this year.

Efficient CABMSI operation has been possible thank to the support from UPMC, Elekta-Neuromag Oy (Helsinki, Finland), and tremendous dedication and efforts of Mrs. Anna Haridis, MPA, R.EEG/EP. T, MEG Coordinator.

Center for ALS Research

The University of Pittsburgh Center for ALS Research was designated by Dr. Arthur Levine in 2006. Robert Bowser, PhD (Pathology) is the director and David Lacomis, MD (Neurology) is the medical director. The primary purpose of the center is to promote collaboration among University of Pittsburgh scientists and clinicians who share an interest in motor neuron disease research thereby expanding basic, clinical, and

translational research in amyotrophic lateral sclerosis. Two short-term goals are to obtain NIH funding via a center grant and to recruit an additional ALS researcher. Current collaborative projects include identification of cerebrospinal fluid and serum biomarkers using mass spectroscopy in patients with ALS and a pilot epidemiology project. By comparing ALS patients to controls, it is hoped that a diagnostic panel of biomarkers can be identified. The evolution of these biomarkers in ALS patients is also being studied to determine if they might provide insight into disease mechanisms and offer another way to monitor efficacy of treatment. A panel of protein markers has been identified and is undergoing validation and conformation in a large multicenter study. With colleagues in the School of Public Health, the Center is performing an epidemiology study of risk factors for ALS in Allegheny and the six surrounding county with emphasis on environmental exposures. The center was one of three sites that conducted a phase IIb futility trial of R+ pramipexole in ALS. The Center is also one of 20 others participating in a phase II study of a variant of R+ pramipexole called KNS-760704-CL201 and will begin enrollment in a phase III trial of ceftriaxone. Additional goals include participation in center-driven studies of the utilization of non-invasive ventilations and multicenter study of the epidemiology of ALS and on additional multi-center drug trials for ALS. We joined with Pennsylvania State and Drexel

19

Universities in forming a PA ALS Consortium and hope to expand it in order to facilitate epidemiologic and other research across the state.

Commonwealth of Pennsylvania Center of Excellence for Detection, Diagnosis, and Intervention in Dementia

The DDID, currently directed by Judith Saxton, PhD, is a four year research grant funded by the Commonwealth of Pennsylvania and is a collaboration/partnership among Pennsylvania universities, private companies, and community organizations serving the

elderly. The Center will 1) screen for cognitive impairment in the community, especially the medically underserved, using person-friendly automated testing; 2) determine dementia diagnosis with positron emission tomography (PET) using the amyloid imaging ligand “Pittsburgh Compound B” (PIB) & computer analysis of magnetic resonance (MR) images that may aid in diagnosis; and 3) examine biological samples for biomarkers of diagnosis and disease severity, using cutting-edge techniques to do drug discovery in novel cell-based systems to identify new treatments for dementia.

The primary purpose of the community-based clinical research is to develop and implement effective ways of screening the elderly population for cognitive impairment using a simple and non-threatening tablet computer for testing. Normal cases and cases with suspected cognitive impairment will subsequently be referred to the University of Pittsburgh Alzheimer’s Disease Research Center (ADRC) for thorough evaluation to validate the accuracy of the computerized screening technique. Populations targeted for assessment and determination of norms will include more than 600 subjects from rural areas of southwestern Pennsylvania, urban areas with a special focus on African-American subjects, and a standard volunteer control group in the ADRC. Associated cutting-edge detection and diagnosis techniques will be utilized with this population, including positron emission tomography (PET) scans of fluorodioxyglucose (FDG) for energy activity in the brain and Pittsburgh Compound B, which labels deposits of beta amyloid, the protein deposited in the brain in Alzheimer’s disease (AD). Finally, the MR scans performed as part of the evaluation, will undergo analysis by a new Carnegie-Mellon University Robotics Institute technique termed future learning. In preliminary studies, this technique appears to classify people into categories of normal, mild cognitive impairment (MCI), or AD by analysis of a single, one-time scan.

The basic research aspects involve development of a high-speed throughput analysis technique to find characteristic diagnostic signatures in alteration of tau protein, a key protein significantly altered in AD and leading to neuronal death. In addition to utilizing these live cell assays to develop diagnostic tests, they will be developed to detect compounds which would interfere with the pathological changes and lead to more effective therapies. High throughput screening of biochemical compounds will also be achieved using the most up-to-date robotic techniques to screen thousands of compounds for diagnostic tests or new lead compounds with which to treat AD. Finally, detection of a biomarker that represents an oxidized lipid will be explored. Biological samples from MCI, AD and normal subjects will be utilized to develop a specific signature for altered lipids in AD with the intention of finding a diagnostic marker or a presymptomatic disease marker in those who would go on to develop AD. These studies will also attempt to replicate other reported oxidized lipid markers to strengthen knowledge in this important area. All the basic research aims will exchange promising compounds and samples to maximize the ability to detect novel diagnostic tests and potential interventions.

Geriatric Research Education and Clinical Center The Geriatric Research Education and Clinical Center (GRECC) is funded by the Department of Veterans Affairs and provides an integrated program of basic biomedical, clinical and health services research, education of trainees and practitioners, and clinical demonstration

projects designed to advance knowledge regarding care of the elderly, with an emphasis on stroke. The research component of the GRECC consists of three elements; (1) basic science, (2) health services research, and (3) rehabilitation research. The basic science component is focused on the identification of novel genes whose products play a role in regulating cell death after ischemia, and the development of strategies to reduce expression of neurotoxic response genes or enhance expression of neuroprotective gene products in response to

20

stroke. Health services research is directed at addressing the overuse of medications in the elderly VA population (geriatric polypharmacy). Rehabilitation research includes studies designed to determine the optimal parameters for rehabilitation of aphasia resulting from stroke, determine the degree that hearing impairment contributes to cognitive dysfunction in the elderly, and to develop a quality-of-life instrument for stroke survivors. Clinical studies of acupuncture in elderly patients with chronic pain due to osteoarthritis are also underway. The GRECC faculty accounted for over $6,800,000 in research expenditures from externally funded research grants during the fiscal year in addition to the GRECC’s $1,800,000 VA core funding. The education component of the GRECC is designed to ensure that existing knowledge in geriatrics and new research findings are integrated into clinical practice and disseminated locally, regionally and nationally, and consists of two elements; (1) postgraduate fellowship training in geriatrics for physicians and trainees in affiliated health science fields, and (2) continuing medical education in geriatrics for physicians and other health service practitioners. There were more than 35 GRECC trainees in the last fiscal year and approximately 1000 attendees at GRECC CME activities. There were two active GRECC clinical demonstration projects: 1) The Pittsburgh Intensive Residential Aphasia Treatment and Educational program (PIRATE) is a novel residential outpatient aphasia rehabilitation program. PIRATE provides a 17 day program of intensive aphasia treatment for veterans who reside at the John Heinz Community Living Center in Aspinwall during treatment. 2) The GRECC has developed a Driving Evaluation Clinic that assesses the ability of elderly veterans to drive. This clinic focuses on medical and cognitive assessment in elderly veterans. These clinical demonstration projects are intended to pilot novel ways of delivering care to elderly veterans.

Dr. Steven Graham, Professor of Neurology, is Director of the GRECC. Other Neurology faculty members in the GRECC are Jun Chen, MD, Edward Burton MD, and Gaodong Cao, PhD. Faculty from the Department of Medicine, Divisions of Geriatric Medicine and General Internal Medicine, Psychiatry and Communications Sciences Departments in the School of Rehabilitation Sciences are also members of the GRECC.

Morris K. Udall Center of Excellence for Parkinson’s Disease Research

Current therapy for Parkinson’s disease (PD) focuses on short-term reduction of motor symptoms. Although several treatments are currently being studied for their possible neuroprotective or neurorestorative effects, they have shown only modest benefit at best, are likely to involve significant technical problems, and/or will be quite costly. However, several recent studies of human populations and of animal models suggest a simpler approach: physical exercise. Based on these and other findings, the Center has developed

the following set of hypotheses:

Overall Center Hypotheses: Oxidative stress and mitochondrial impairment can lead to the progressive loss of DA neurons. Exercise will attenuate the incidence and progression of PD, acting in part through increased expression of neurotrophic factors, including GDNF, BDNF, and MANF, which in turn activate intracellular survival cascades, including Ras/ERK and PI3K/Akt. The attenuation results in part from the protection of DA neurons against cellular insult, the restoration of DA neurons already affected by the toxins and compensatory changes in surviving DA neurons.

The Center is in the process of being restructured in order to most effectively explore these hypotheses. It will now consist of three projects and a core, as well as affiliations with other research and training units.

The Administrative Core provides administrative services, assistance with both oral and written scientific communication, as well as coordinating training, outreach, and services in which Center members engage. These include two NIH-sponsored training grants focused on translational research, and a 1 term, 40-hr seminar on the neurobiology of disease at the University of Pittsburgh. In addition, members of the Center are involved in several other forms of training and outreach at various levels. Additionally, the Center is prepared to train any member of the Udall Center on the method in use within its own Center and to provide its reagents to them.

21

Pittsburgh Institute for Neurodegenerative Diseases

It is estimated that approximately one in four Americans will suffer from a neurodegenerative disease, and virtually all Americans will have a family member with one of these conditions. Unfortunately, the underlying mechanisms of neurodegeneration—and how they lead to disease—are not well understood. The complexity of these diseases makes it impossible for any single scientist to find the cause or cure. Instead, it will require an integrated, collaborative, interdisciplinary approach—

involving interactive groups of scientists and clinicians—to make headway towards cures. This was the vision of Drs. Michael Zigmond and Robert Moore when they approached the Scaife Foundations with their idea to create the Pittsburgh Institute for Neurodegenerative Diseases (PIND).

Ultimately established with generous gifts from the Scaife Family Foundation and the DSF Charitable Foundation, the PIND brings together in one place scientists and clinician scientists from diverse disciplines and perspectives—and several School of Medicine departments (Neurology, Pharmacology, Geriatric Medicine & Structural Biology)—to collaborate on studies of neurodegenerative disorders. Currently, there are 12 independent laboratory groups – approximately 100 faculty, postdocs, students and staff – within PIND laboratories. Of these, half of the principal investigators are physician-scientists.

By virtue of both philosophy and architecture, the PIND is a center where there are no walls between individual scientists, and where there are no barriers between basic scientific inquiry and translation of the latest findings into new treatments. As such, the mission of the PIND is to transform cutting-edge science into novel therapies and diagnostics that directly benefit individuals affected by neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, stroke, Huntington’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease). The PIND’s research portfolio includes investigations into mechanisms of neural cell death; new genetic models of neurodegenerative disease; and methods for protecting the nervous system with drugs, physical interventions and gene therapy.

Last year, extramural grants to PIND investigators totaled almost $7,500,000. New grants to PIND faculty include a Program Project Grant to Drs. Chen, Hastings, Chu, Cao and Greenamyre; R01 grants to Drs. Perez and Palladino; and a VA Merit Award to Dr. Burton. The mission of the PIND is bolstered by and integrated with clinical programs in the Department of Neurology, including the Alzheimer’s Disease Research Center, the Comprehensive Movement Disorders Clinic, the UPMC Stroke Institute, and the Muscular Dystrophy Association ALS Center. The Department of Neurology is active in clinical research in neurodegenerative diseases, coordinating or participating in therapeutic trials in Alzheimer’s disease, stroke, and ALS, and it is a site for trials for both the Parkinson Study Group and the Huntington Study Group. We have been designated the American Parkinson Disease Association as an Advanced Center for Parkinson Disease Research.

In addition to supporting research activities, the PIND is the headquarters of Support Programs in Neurodegenerative Disorders and Stroke (SPINS). Composed of PIND researchers and regional leaders of the Alzheimer’s Association, the American Parkinson Disease Association, the National Parkinson Foundation, the ALS Association, the Huntington’s Disease Society of America, and the American Stroke Association, SPINS members meet at a yearly conference to focus on issues common to those affected by neurodegenerative diseases, such as depression, physical access and therapy, caregiver stress, and feeding and swallowing problems. Together, the PIND, SPINS and the Department of Neurology clinical programs are making sure and steady progress in addressing the multiple challenges, which neurodegenerative diseases present.

The PIND is directed by Dr. Tim Greenamyre, who is Professor and Vice-Chair of Neurology, UPMC Endowed Chair & Chief of the Movement Disorders Division and Director of the APDA Advanced Center for Parkinson’s Disease Research.

22

The UPMC Stroke Institute

The UPMC Stroke Institute is the first JCAHO certified stroke center in Western Pennsylvania. The Stroke Institute continues to lead as a major referral center, provider of high quality acute stroke management, and participates in progressive clinical research trials. Lawrence R. Wechsler, M.D., Division Chief and Director of the UPMC Stroke Institute, leads the program, which focuses on quality patient care using a multi-

disciplinary team approach, flourishing clinical research program, and ongoing educational efforts for health professionals and the community at large.

The Stroke Institute is comprised of a stroke-specific clinical service which sees over 1300 acute cerebrovascular patients on the in-patient service. The outpatient Stroke clinic is staffed by the stroke specialists, fellows, and 1 nurse practitioner. Multiple medical and ancillary services are coordinated to provide the patient with a comprehensive approach to care and to promote the best outcome for the patient. Dr. Ken Uchino is the Fellowship Director for the UPMC Stroke Institute, an ACGME neurovascular fellowship, which sponsors 2 stroke fellows and one interventional fellow. The fellows, residents, medical students and visiting physicians from abroad enjoy a rich educational experience supported by multiple resources and experts from other disciplines interested in cerebrovascular disease and research.

Drs. Maxim Hammer, Ken Uchino and Vivek Reddy are stroke specialists who support fellowship, resident and medical student education, attract novel clinical trials, and bring the Stroke Institute a wealth of clinical knowledge and new energy that inspires others to produce high quality care and strive for a high quality of cerebrovascular scientific knowledge. Dr. Hammer assumed leadership of stroke services at the UPMC Mercy campus with the addition of outpatient stroke office in October 2008. Dr. Tudor Jovin has been extremely productive in his role as a stroke interventionalist. His approach to acute stroke has pushed new limits and expanded interventional approaches through clinical research trials. Dr. Reddy also holds responsibilities for the development of the electronic medical record program. Dr. Syed Zaidi completed his neurovascular fellowship in June 2008 and joined the UPMC Stroke Institute as the 6th attending physician with his primary practice located at UPMC Mercy. In July 2009, Dr. Mouhammad Jumaa will complete his Vascular Fellowship and join the UPMC Stroke Institute as faculty.

Throughout the year the Stroke Institute faculty and staff provide education for health professionals and the community at large. An annual CME program is provided aimed at physicians to provide current information on medical surgical management and update clinical trial activity. Additionally, the fourth annual all day nursing conference with CUE’s focusing on stroke was provided this year. The Institute supports community programs and provides stroke screenings in many local settings. Both faculty and staff are active on the local, state and national level providing education and participating in legislative activities to promote stroke care.

The unique UPMC hospital system allows the faculty and staff to work with up to 12 UPMC community-based hospitals, improving the standards of stroke care. The Stroke faculty now provides on-site acute stroke management at both UPMC Mercy and UPMC Shadyside hospitals. Telemedicine equipment for 24/7 stroke assessment has also been introduced at UPMC Passavant/Passavant-Cranberry, UPMC St. Margaret, UPMC Braddock, UPMC McKeesport, UPMC Magee, UPMC Southside, UPMC Horizon, and UPMC Northwest and UPMC Bedford. In 2008, the institute began to expand services to non-UPMC affiliated hospitals and now provides telemedicine to regional hospitals such as Monongahela Valley Hospital and Jefferson Regional Medical Center as well as Washington County Hospital in Hagerstown, MD. Since implementation of telemedicine within UPMC, over 350 urgent stroke consults have been conducted via telemedicine, and over 90 patients have been treated with IV thrombolytics. Depending on the site capability, patients are either transferred to UPMC PUH for ongoing specialty stroke care or remain at the local hospital for post thrombolytic stroke care. Both Lawrence Wechsler, MD and Lori Massaro, CRNP, Clinical Supervisor, hold positions on the UPMC Stroke Oversight Committee that was formed to improve stroke care as a UPMC system initiative.

23

Veterans Administration Neurology Service

The VA Neurology Service is a busy clinical in-patient and out-patient service within the Medical Specialties Service Line at the VA Pittsburgh Healthcare

System (VAPHS). We provide out-patient and in-patient services to veterans with dementia, movement disorders, headache, epilepsy, stroke, multiple sclerosis, neuromuscular disorders, neurological complications of medical diseases and other neurological conditions. We perform out-patient lumbar punctures for diagnosis and botulinum toxin injections for the treatment of focal dystonias. We have a TOUCH program for natalizumab infusions.

The clinical services of VAPHS include out-patient clinics at University Drive and Highland Drive VAMC facilities, in-patient consultations at the University Drive, Highland Drive and Heinz VAMC facilities, an in-patient service at the University Drive VAMC facility and an EEG Laboratory at the University Drive VAMC facility. We are a referral center for VAMC facilities in Erie, Butler, and Altoona, PA and Clarksburg, WV. The VAPHS EEG Laboratory was accredited by the American Board of Registration of Electroencephalographers and Evoked Potential Technologists (ABRET) during this past year. The VAPHS EEG Laboratory is the only Pittsburgh-area EEG Laboratory and one of only two VA EEG Laboratories nationally to receive ABRET accreditation.

We are fortunate to have a group of expert sub-specialists from the department of neurology who work together as the group of VA neurologists. A few examples are mentioned here. Dr. David Hinkle directs our local movement disorders center, which participates in the central VA Parkinson's Disease, Research, Education and Clinical Center (PADRECC). Dr. Clemens is the director of our local multiple sclerosis effort, participating in the VA Multiple Sclerosis Centers of Excellence. Dr. Steven Graham is director of the Geriatrics Research, Education and Clinical Center (GRECC), a VA institute focused on multi-disciplinary aspects of geriatrics care and research. The VA neurology division participates in the education component of the GRECC as a clinical training site for geriatric psychiatry fellows throughout the year. We also serve as a training site for the geriatrics fellowship programs at UPMC and St. Margaret’s Hospitals.

The VA Neurology Service is a principal training site for our neurology residency program. On a rotating basis, two residents are stationed at the VA to provide in-patient and out-patient care on an academic teaching service attended by one of our attending neurologists. A third resident position is employed to accommodate 4-5 of the first-year neurology residents in their weekly continuity of care clinic. The residents also benefit from the contributions to the didactic training program provided by VA physicians, especially including instruction in EEG reading by Dr. Anne Van Cott. The VA neurology service further contributes to the educational mission of the neurology department by serving as a clinical rotation site for medical students in their third year of training.

Both clinical and basic research are significant components for most neurologists on the VA service and several hold VA research grants as described on their individual faculty summaries. Dr. Clemens was awarded a new VA Merit Review award this year; Dr. Živković serves on the Research and Development Committee and Dr. Van Cott received the 2009 Outstanding Professional Employee (Medical/Scientific) Bronze Award in the Excellence in Government Awards Program sponsored by the Pittsburgh Federal Executive Board.

The VA Neurology Faculty for 2008-2009 was comprised of Dr. Paula Clemens, Chief of Service and Drs. Ed Burton, Miguel Estevez, Kathy Gardner, Steven Graham, David Hinkle, Eric Ogren, Anne Van Cott and Saša Živković.

24

Research and Scholarly Activities

Research and Scholarly Activities

Cognitive and Behavioral Neurology Division

Oscar Lopez, MD Professor of Neurology and Chief, Cognitive and Behavioral Neurology

Dr Lopez continues actively involved in research. He is the Scientific Director of the University of Pittsburgh Alzheimer’s Disease Research Center, the principal investigator of the NIH-funded grant entitled “Predictors of Alzheimer’s disease in mild cognitive impairment” and he is co-investigator in other 5 NIH-funded projects, and consultant in another three.

Dr. Lopez is conducting a large-scale study in the clinical diagnosis of mild cognitive impairment (MCI), which is considered an intermediate state between normalcy and dementia. His findings are relevant to an understanding of the symptom profile and nosology of MCI. The results of his prospective epidemiological study allow us to

conclude that idiopathic MCI is not a distinct clinical syndrome, but is the earliest manifestation of Alzheimer’s disease (AD).

Dr Lopez has examined whether plasma Aβ amyloid levels can be predictors of conversion to dementia in normal individuals from the Cardiovascular Health Study (Neurology 2008; 2008; 70:1664-1671). In an unadjusted prospective model in normal subjects, both Aβ1-40 and Aβ1-42 levels in 1998-99 were associated with incident AD in 2002-03 (longitudinal analysis). However, in the fully adjusted multivariate model, neither Aβ1-42, Aβ1-40, nor their ratio were associated with incident AD. However, adjustment had a very small effect on point estimates for Aβ1-42, from OR: 1.61 (p= .007) in the unadjusted model to OR: 1.46 (p= .08) in the fully adjusted model. In 2002-03 (cross-sectional analysis), only the unadjusted models showed that both peptides were associated with AD. We concluded that plasma Aβ levels are affected by age, and systemic and CNS vascular risk factors. After controlling for these conditions, Aβ-40 and Aβ1-42 are weak predictors of conversion to AD in normal subjects, and only weakly associated with AD in cross-sectional analysis. Consequently, plasma levels of Aβ do not appear to be useful biomarkers for AD.

With respect to AD and related dementias, Dr. Lopez continues conducting large scale studies in the clinical diagnosis of AD and its treatment. He has examined the long term effects memantine and cholinesterase inhibitors (ChEIs) in AD patients (Journal of Neurology, Neurosurgery, and Psychiatry 2009; 80: 600-607). Previous studies have shown that patients using ChEIs have a delay in nursing home (NH) admission compared to those who were not using the medication, but there are no long-term studies of the effects of memantine in combination with ChEIs use in AD. In this study, we examined the effect of memantine in combination with ChEIs on the natural history of AD in 943 Probable AD patients who had at least one follow-up evaluation at the ADRC of Pittsburgh. Compared to those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95%CI: 0.27 - 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95%CI: 0.11 - 0.72) (memantine+ ChEI vs. ChEI alone). ChEIs alone, or in combination with memantine had no significant effect on time to death. This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the natural history of AD by extending time to nursing home admission.

Dr. Lopez has conducted studies using continuous arterial spin-labeled MRI. This is a non-invasive MRI technique that detects microvessel blood flow. Dr. Lopez’ group has found that cognitively normal individuals with hypertension had diminished blood flow in areas of the brain that are also target of Alzheimer’s disease. This led to the hypothesis that the cerebral vascular disease caused by hypertension may create a vulnerability state for neurodegeneration. His group also found that individuals in the transition from normalcy to AD have increased blood flow in specific brain regions, suggesting that the human brain may be able to mount a compensatory vascular/cellular mechanism in the early stages of Alzheimer’s disease. This has important implications for the design of Alzheimer’s disease symptomatic or disease-modifying therapies

26

Judith Saxton, Ph.D. Associate Professor of Neurology

Dr. Judith Saxton is a neuropsychologist with more than twenty-five years experience in the assessment of older patients with cognitive problems. Dr. Saxton is Principal Investigator of an NIA-funded study entitled “Cognitive Assessment of Primary Care Patients”. The major goal of this study is to investigate the utility of cognitive testing in the Primary Care setting. Both clinical outcomes and clinical practice will be investigated in this five-year study that will involve more than 500 subjects over age 65 and 24 community primary care physicians. One innovative aspect of the study is the use of computer tests to identify older patients with mild cognitive impairment. Dr. Saxton is also Director of the Clinical Core of the Alzheimer’s Disease Research Center and Co-Director of the Education and

Information Core. She also works with colleagues on two studies of the Pittsburgh compound-B (PiB), in which positron emission tomography (PET) is used to identify amyloid deposition in the brains of living AD subjects. These studies involve subjects across the spectrum of cognitive difficulties ranging from normal healthy elderly to patients in the most severe stages of AD. Dr. Saxton is Director of the Clinical Core of the Program Project Grant “In Vivo PiB PET Amyloid Imaging: Normals, MCI & Dementia”. Over the past three years Dr. Saxton has published two chapters and 14 papers (and one, in press) in peer-reviewed journals.

Dr. Saxton’s main area of interest is in the cognitive disorders of aging. She is the author of the Severe Impairment Battery (SIB) and developed a short form of the SIB which allows the cognitive assessment of patients with more profound dementia (Am J Geri Psych; 2005, 13:11; 1-7). The SIB is in use both nationally and internationally and has been translated into more than twelve languages. Dr. Saxton and colleagues are also working on the development of a computer test, the Computer-based Assessment of Mild Cognitive Impairment (CAMCI), which is a brief assessment of cognition designed to identify individuals at the earliest possible stages of cognitive change (Postgraduate Medicine, 2009). Dr. Saxton has also recently submitted a grant to the National Institutes of Health to study the health and cognitive impact of medication discrepancies in older outpatients which will be reviewed at the end of 2009 and, if funded, work will begin on this grant in 2010.

In the coming year Dr. Saxton will continue work on her study of mild cognitive impairment in primary care patients and will be developing the CAMCI. She will also continue to work with colleagues on studies of Pittsburgh compound-B and, finally, she will work with Dr. Mary Ganguli from the Department of Psychiatry, on Dr. Ganguli’s study to investigate the characteristics, and proportion within the population, of older individuals with mild cognitive deficits that do not constitute dementia.

Epilepsy Division

Anto Bagić, MD, MSc Assistant Professor of Neurology and Chief, Epilepsy Division Director, Center for Advanced Brain Magnetic Source Imaging Director, University of Pittsburgh Comprehensive Epilepsy Center Director, UPMC Epilepsy Monitoring Unit

During the 2008-2009 academic year Dr. Bagić delivered several lectures on epilepsy and magnetoencephalography (MEG) to neurology residents and students, taught 4 lectures in the MS1 Neuroscience Course, one lecture in the MS4 Clinical Pharmacology Course, as well as other seminars and presentations.

Dr. Bagić conducts an Outpatient Epilepsy Clinic and had 50% attending responsibilities in the Epilepsy Monitoring Unit (EMU) and further developed a

monthly Vagal Nerve Stimulator (VNS) Clinic. In addition to directing the EMU, which reached the highest productivity level in its history leading to its expansion to 6 monitored beds, his new major responsibility is to

27

build the Epilepsy Division while he continues to direct and further develop the Center for Advanced Brain Magnetic Source Imaging (CABMSI) at Presbyterian University Hospital that he founded upon his arrival at the Department in 2005.

During the past year, Dr. Bagić’s efforts led to an improved insurer environment and significant growth in the field of clinical applications of MEG in epilepsy and resulted in diverse research MEG collaborations that range from internal pilot studies to the first NIH-funded R01 and R03 grants. There has been a significant increase in collaborations with some of the leading investigators from Carnegie Mellon University (CMU) and Intel that are currently focused on Language-Based Brain Computer Interface (BCI). Dr. Bagić started investigating hand transplant recipients using MEG when the Hand Transplant Program enrolled its first participant in March 2009.

The MEG community of the University of Pittsburgh and CMU is proud that the first doctoral and master program graduates successfully defended their theses focused on research with MEG. Furthermore, after successfully presenting 5 posters at the Biomag 2008 (International Conference on Biomagnetism; Sapporo, Japan) and winning a Young Investigator Award our members are submitting research papers originating at the CABMSI to major scientific journals. It is hoped that our submissions will double for an upcoming Biomag 2010 (Dubrovnik, Croatia). During 2008-2009, a Pittsburgh MEG Special Interest Group (MEG SIG) expanded with the arrival of several undergraduate and graduate students from University of Pittsburgh and Carnegie-Mellon University.

On the national level, Dr. Bagić is very active within the American Clinical MEG Society (ACMEGS), where he is a Founding member, serves on the Board of Directors, as a treasurer and chairs the Practice Parameters Committee that is working on establishing the first guidelines in the field of clinical MEG. This is considered one of the vital steps in propelling MEG technology from clinical research to clinical routine.

During the past academic year, Dr. Bagić published the only human study demonstrating the potential efficacy of non-invasively applied hypothermia in treating medically uncontrolled epileptic seizures (Acta Neurol Scand). His MEG findings on patients with Autosomal Dominant Temporal Lobe Epilepsy with Auditory Features provided cardinal evidence for alteration in language processing in this population (Neurology). Two out of his 7 publications are focused on public perception, attitude and knowledge about epilepsy that reported some novel findings that have profound implications on the strategies of improving public attitude towards persons with epilepsy aimed at decreasing their stigmatization (Epilepsy & Behavior).

Dr. Bagić’s research is focused on applications of MEG in studying epilepsy, language, cognition and brain plasticity in response to a hand transplantation. One of his major interests in clinical neurophysiology is the role of high frequency oscillations (HFO) in cognitive processes and neurological disorders, with a focus on epilepsy. While keeping his productive research relationship with the NINDS/NIH, Dr. Bagić is a co-investigator or consultant on over 15 MEG-based proposals ongoing at UPMC CABMSI, including NIH-funded R01 and R03 grants. One of his new research activities will be within an NIH-funded multicenter trial aimed at comparing therapeutic efficacy of radiation and surgery in treating temporal lobe epilepsy (“ROSE” trial).

During the next year, Dr. Bagić will focus on establishing MEG pre-surgical functional brain mapping (PSFBM) clinical services within the CABMSI, further accelerating the MEG Clinical and Research program, accelerating surgical epilepsy program and resuming his research on HFO. Academically, Dr. Bagić will continue to increase his teaching role within the Residency Program, Clinical Neurophysiology Fellowship Program, MS1 Neuroscience Course, MS4 Clinical Pharmacology, Multimodal Neuroimaging Course and Multimodal Neuroimaging Training Program. One of Dr. Bagić’s short-term goals is funding a staff scientist position in the CABMSI and establishing an epilepsy fellowship.

28

Richard Brenner, MD Clinical Professor of Neurology

Dr. Brenner served as a faculty member of the Clinical EEG course at the American Academy of Neurology in 2008 in Seattle, WA and presented “The EEG in Encephalopathy and Coma.” He was an invited speaker at the Innsbruck Colloquium on Status Epilepticus, Innsbruck, Austria in 2009 and presented “How useful is EEG and EEG monitoring in the acutely ill and how to interpret it?”

He continued as a member of the Editorial Board of the Journal of Clinical Neurophysiology, as well as serving as a reviewer for several journals, including Epilepsia and Clinical Neurophysiology. Dr. Brenner served as the director of the EEG Laboratory at the University of Pittsburgh Medical Center. He held weekly

teaching conferences for clinical neurophysiology fellows, neurology residents, as well as medical students on the neurology rotation. He taught an introductory EEG course to incoming neurology residents in July. He continued to read EEGs with the clinical neurophysiology fellows and neurology residents.

His EEG text, EEG on DVD-Adult: An Interactive Reading Session, a program simulating an EEG reading session was highlighted by the American Academy of Neurology catalog in 2008 and 2009, as well as being displayed at the 2009 Annual Meeting. Designed primarily as a teaching tool for clinical neurophysiology fellows and neurology residents, it will be helpful to neurologists who interpret EEGs and neurologists and electroneurodiagnostic technologists who are preparing for board examinations.

Dr. Brenner is a co-author of Atlas of EEG in Critical Care to be published in 2009. This is geared towards all healthcare professionals involved in critical care medicine. Although it may be of particular interest to those in neurology, epilepsy and clinical neurophysiology, it is also appropriate for intensivists interested in maintaining brain health during critical illness of any etiology.

Gena Ghearing, MD Assistant Professor of Neurology

Dr. Ghearing has been continuing to work to increase the activity of the adult surgical epilepsy program which is now averaging approximately one surgery per month. Many of these cases have been complicated cases which require prolonged extraoperative intracranial EEG monitoring and cortical stimulation studies. The program is also incorporating subtraction ictal SPECT, MEG, PET, 3T MRI and functional MRI into the evaluation with the cooperation of colleagues. We have continued the weekly epilepsy surgery conference through video conferencing with our colleagues at Children’s Hospital of Pittsburgh. This has allowed the exchange of information and facilitated advances among those interested in epilepsy who work in neurology, neurosurgery, MRI, nuclear medicine, MEG, and other interested groups.

Dr. Ghearing’s activities this year included serving as attending on the Epilepsy Monitoring Unit service, the Neurology Ward service and the Neurology Consult service, as well as seeing patients in the epilepsy clinic and working in the EEG lab. These rotations include teaching medical students, neurology residents, clinical neurophysiology fellows, and occasional medicine, neurosurgery, and psychiatry residents, and lead to writing three reports with interested residents. One of these reports has been submitted for a poster presentation at the 2009 American Epilepsy Society meeting, and a poster was presented on orbitofrontal seizures by a resident Dr. Ghearing mentored at the 2008 American Epilepsy Society meeting. Dr. Ghearing also presented multiple lectures to neurology residents on topics related to seizures as well as giving other lectures on epilepsy to other audiences including medical students, critical care fellows, and psychiatry residents. Dr. Ghearing received the Excellence in Teaching Award from the Neurology Residents in 2009. Dr. Ghearing also served on the admission selection committee for neurology residents and the Epicare Oversight committee.

29

Dr. Ghearing is one of the Radiosurgery vs. Lobectomy for Temporal Lobe Epilepsy: A Phase III Clinical Trial (ROSE trial) group members. In addition, Dr. Ghearing is working with colleagues in neurosurgery and bioengineering to record human cortical activity using micro-electrocorticography electrodes. She also continues her research in ictal asystole and is preparing manuscripts related to treatment of ictal asystole with cardiac pacing and what role decreased cerebral hypoperfusion may play in seizure termination.

Rick Hendrickson, PhD Assistant Professor of Neurology

Dr. Hendrickson continued to provide clinical neuropsychological services for the Epilepsy Division. His cognitive assessments are part of comprehensive pre-surgery evaluations for epilepsy patients referred to the Department of Neurosurgery for improved seizure control via resective surgery. He also evaluates patients with difficult to control seizures referred to the Epilepsy Monitoring Unit for differential diagnosis.

In the last year, Dr. Hendrickson’s research contributed to a paper that he co-authored on patients with epilepsy and he remained active on another study of people with epilepsy. Dr. Hendrickson also assisted with a paper presented at a recent

neurology conference on cognitive dysfunction in patients with amyotrophic lateral sclerosis (ALS). In addition, he participated in a multi-site research protocol providing neuropsychological testing for the Stroke Division.

Dr. Hendrickson is currently a co-investigator on a funded study with Dr. Sasa Živković as the primary investigator. He performs cognitive assessment of veterans with ALS, who also undergo a magnetoencephalography (MEG) evaluation. He also is a co-investigator on a recently submitted grant proposal on cognitive functioning of ALS patients, again utilizing MEG. He has tentative plans for an additional research project evaluating patients with a neurodegenerative dementia, similar to the above studies.

He plans in the next year to proceed with other research evaluating cognitive correlates and magnetoencephalography with Dr. Bagić. Dr. Hendrickson will provide neuropsychological services similar to the past, but due to the increased demands of the Epilepsy Center, anticipates primarily focusing his clinical responsibilities in that area.

Anne C. Van Cott, MD Assistant Professor of Neurology

In the past academic year, Dr. Van Cott has continued her clinical and research work in epilepsy. Her recent research effort has focused on the treatment of elderly epilepsy patients and quality of life issues in individuals with seizures. With her collaborators at the University of Pittsburgh, she continues here CDC funded research in improving self management in individuals with epilepsy and is investigating the potential use of computers and the internet for patient education. An active member of the VA Treatment in Geriatric Epilepsy Research (TIGER) Project, she was a senior author on a Journal of the American Geriatrics Society addressing epilepsy risk factors in older veterans for new-onset epilepsy. She presented information at the American Academy of Neurology (AAN) 2008 annual

meeting that addressed suicide in older veterans treated with antiepileptic medications. She continues as co-investigator on a VA funded study that examines the use of antiepileptic drugs in older veterans. Dr. Van Cott is serving as a site investigator in a pharmaceutically sponsored trial examining the use of a newer antiepileptic drug in the treatment of patients with seizures over the age of 65.

Dr. Van Cott continues to care for veterans with epilepsy and was awarded the 2009 Outstanding Professional Employee (Medical/Scientific) Bronze Award in the Excellence in Government Awards Program sponsored by the Pittsburgh Federal Executive Board. She spear-headed efforts by the Pittsburgh VA Research Office's to

30

obtain accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP). These efforts were rewarded when the accreditation was awarded last summer. She continues to serve as the director of the EEG laboratory at the VA Pittsburgh Health Care System.

Dr. Van Cott has always enjoyed educating fellow health care providers and the public. She frequently lectures on the treatment of epilepsy in the elderly. In the fall of 2008, she was an invited speaker for the 28th Annual Multidisciplinary Aging Conference sponsored by Cambria-Somerset Council for Education of Health Professionals on the topic of Seizures in the Elderly Population. She serves on the Professional Advisory Board of the Epilepsy Foundation (EF) of Western/Central PA. She also continues to plays an active role in the education of residents, specifically with regards to the neurological exam and electroencephalography interpretation and serves as a mentor to two residents. In the spring of 2009 she was a faculty facilitator for Integrated Case Studies (ICS) Course University School of Medicine.

Dr. Van Cott also is an active member in several national organizations. In March of 2009, Dr. Van Cott was elected a Fellow Member of the American Academy of Neurology (AAN) in recognition of her research and educational contributions to the field of epilepsy and the neurology community. In fall of 2008 she was asked to serve as a member of NIH/NINDS Epilepsy Common Data Elements (CDE) Working Group and is the Chair of the Electrophysiology Subgroup of NIH/NINDS Epilepsy CDE Working Group.

General Neurology Division

John J. Doyle, MD Associate Professor of Neurology and Chief, General Neurology Division

Dr. Doyle became Residency Program Director for the Department of Neurology in October, 2006. He has supervised resident recruitment since, and all available positions have been successfully filled with excellent applicants. He directed the course entitled “An introduction to clinical neurology” (“boot camp”) each year for PGy-2 residents who were starting formal neurology training.

Dr Doyle’s chief interests lie in clinical neurology and neurologic education. He sees patients in the outpatient clinic where most of his clinical sessions include neurology residents who are fulfilling training requirements. As the goals in the clinic are to foster the clinical application of basic neurologic science, the mastery of clinical

neurology, including the interpretation and judicious use of neurologic diagnostic tests, and offering effective treatment where available, Dr. Doyle anticipates that by the time the residents complete their training, they will be competent to enter practice. At the present time, he supervises eight neurology residents on a weekly basis.

A board requirement for neurology residency training is that formal education be devoted to basic neuroscience including neurophysiology. Dr Doyle, along with other faculty, teach basic science courses for neurology residents that meets approximately 45 weeks per year. Instruction is given in neurophysiology, including nerve excitability, synaptic function, neuropharmacology and neurochemistry, and systems analysis including motor, sensory and visceral motor functions. Other courses in this series, which encompasses a three-year cycle, include neuroanatomy, neuropathology, and neurogenetics. This course is offered yearly and is aimed at fostering clinical excellence through the application of up-to-date neuroscience. The content and emphasis of the course is changed yearly because of rapidly evolving research in the neurosciences. Dr. Doyle instructs neurology residents, residents in other disciplines such as psychiatry and physical medicine, and medical students on the neurology in-patient consultation service. His commitment is ten months per year. On average, more than 50 consultations are seen each week.

Dr Doyle is also involved in medical student education. To this end, he participated in six 2-hour group sessions in problem-based learning during the neuroscience course, three additional small- group seminars, and delivered lectures to the entire first-year medical student class on “Disorders of Consciousness” and “Principles of Neurologic Localization”.

31

Dr. Doyle was appointed Chief of the Division of General Neurology during 2005, and one of his goals is to upgrade the program of instruction in clinical neurology. One of the ways he will achieve this is to divide the body of knowledge into key areas which each resident will be expected to master prior to graduation. Dr Doyle has worked with Dr. Alan Humphries on ongoing revisions to the neuroscience course for the first-year medical students, and he and Dr. Lisa Roeske-Anderson deliver grand rounds on a monthly basis in a clinical case format.

Angela Lu, MD Clinical Assistant Professor of Neurology

Dr. Lu serves as a general neurologist providing daily out patient clinical care. Her practice at the new UPMC Mercy satellite location has allowed the department to increase its clinical productivity and expand its reach to patients in an under-served community.

Dr. Lu completed her fellowship training in clinical neurophysiology at the University of Pittsburgh Medical Center in 2008. She utilizes this expertise in the diagnosis and management of both neuromuscular diseases and epilepsy. Dr. Lu performs EMG studies at Mercy with frequent referrals from her colleagues in neurosurgery. In addition, she interprets EEG studies at UPMC Presbyterian

Hospital, providing overnight call coverage once a week for emergency and continuous studies.

Dr. Lu actively participates in teaching neurology and neurosurgery residents during EEG reading days, often providing guidance on management based upon the EEG or instructing them on basic EEG reading during elective rotation. She has also participated in medical student teaching activities—including having students rotate through her clinic—and has offered to serve as a mentor for any interested students in the Neurology and Neurosurgery Interest Group (NANIG).

Eric Ogren, MD Assistant Professor of Neurology

Dr. Ogren joined the Pittsburgh VA Healthcare System and the University of Pittsburgh School of Medicine in 1993 following seven years of service with the VA Healthcare System of San Francisco. He provides inpatient and outpatient neurological services for the Pittsburgh and Butler Veterans Administration Healthcare Systems. He sees patients at the Oakland VA Hospital, the Highland Drive VA Neuropsychiatric Hospital, the H. John Heinz III Progressive Care Center and the Butler VA Hospital. He supervises housestaff at the Oakland VA Neurology Clinics. He is also part of the Neurobehavioral program at the Highland Drive VA and is a consultant to the Polytrauma team.

Lisa C. Roeske-Anderson, MD Assistant Professor of Neurology

Dr. Roeske-Anderson joined the Department of Neurology in 1999 and maintains a busy general neurology practice in Oakland with a special interest in neuromuscular diseases. She performs EMG/NCS and supervises the IVIG treatments for patients with demyelinating peripheral neuropathies such as Guillian-Barr syndrome and chronic inflammatory demyelinating polyneuropathy. Her teaching contributions include rotating clinic sessions with medical students and neurology residents. With her colleague John Doyle, MD, she organized a neurology grand round series in 2007 that focuses on complex in-patient and out-patient clinical cases. She is also the Neurology representative to the University’s Diversity Committee.

32

Asim Roy, MD Clinical Assistant Professor of Neurology

Dr. Roy joined the Department of Neurology in July 2008 after working as an Assistant Clinical Professor of Neurology at Tufts School of Medicine at Baystate Medical Center in Springfield, MA for 2 years. He finished his neurology residency at Georgetown University Hospital in Washington D.C. in 2005 and completed a sleep fellowship at Cleveland Clinic Hospital in 2006.

Dr. Roy is an active member of the Sleep Medicine Department which is overseen by the Pulmonary Department. He provides evaluation and treatment for patients with sleep disordered breathing, narcolepsy, insomnia, parasomnia, circadian rhythm disorder and restless legs syndrome. He provides a supervisory role to the nurse

practitioners in the sleep clinic and teaches the sleep fellows and visiting fellows on common sleep disorders. Roy also has been involved in teaching about sleep deprivation and safety issues involved during residency and fellowship training. He has been a proponent of reduced work hours and a safer environment for residents and fellows during training.

Dr. Roy has been active in the clinical training of Neurology residents via the outpatient clinics, inpatient Neurology ward service and he will be supervising the weekly Neurology Resident Continuity clinic. He participates in medical student education in the outpatient clinics and during the inpatient services.

Over the course of the 2009-2010 academic year, Dr. Roy plans to continue his clinical activities and involvement in the Sleep Medicine Department and General Neurology clinic. Other plans include curriculum development for the residents with clinical skills teaching and assessment, and a deeper involvement in medical student teaching.

Headache Division

Kathy Gardner, M.D. Assistant Professor of Neurology

Dr. Gardner's research is focused on the genetics of both common and rare hemiplegic forms of migraine. She has an ongoing cohort of migraine families and hemiplegic migraineurs for linkage and mutation analysis. She has established collaborations to help with the collection at headache centers at University of Oklahoma Health Sciences Center. She is the PI for this multi-center study funded by the American Headache Society/ Pfizer and is responsible for oversight and protocol renewals at Children’s Hospital and the VA. The hemiplegic migraineurs are referred through NIH-sponsored Genetests website, where she is the author of the monologue on Familial Hemiplegic Migraine (FHM). Dr. Gardner also has a study ongoing at the Children’s Hospital NF clinic to characterize headache types and

frequency in subjects of all ages with NF-1.

Dr. Gardner and colleague Robert Shapiro, MD, PhD, of Burlington, Vermont led a group of medical and research professionals to Washington, DC, in March 2009 for a second visit to call for stronger support from the NIH for headache and migraine research. The event, called Headache on the Hill, was developed by Gardner and Shapiro as part of an advocacy action plan and modeled after the successful AAN Neurology on the Hill advocacy events. The event was endorsed by the American Academy of Neurology, World Health Organization, and multiple international societies.

33

Miguel Estevez, MD, PhD Assistant Professor of Neurology

Dr. Estevez joined the Department of Neurology in 2001 as an Instructor and was appointed Assistant Professor in 2005. He was the recipient of a Burroughs-Wellcome Career Development Award in 2001 and a Veterans Administration Career Development Award in 2002 for his research in migraine headaches. In 2004 he was chosen a University of Pittsburgh Senior Vice Chancellor Seminar Series Speaker on “Migraine-related effects of P/Q Channel function in C. elegans.” Concurrent with his research pursuits, Dr. Estevez was a staff physician with the VA Pittsburgh Health System. During the past academic year he devoted himself to patient care and training residents and medical students at the Department of Neurology Headache Center in Oakland.

Robert G. Kaniecki, M.D. Assistant Professor of Neurology and Chief, Headache Division

During the academic year 2008-2009 Dr. Kaniecki directed the expansion of The Headache Center at a new 3700 square-foot facility. He continues to personally evaluate, with the assistance of 2 physician assistants, over 300 patients each month. The Headache Center at the University of Pittsburgh has developed into one of the

es inpatient headache management programs and continues to recruit for additional faculty to staff the Headache program.

In addition to his cl es, Dr. Kaniecki continues to participate in 2 irman of the scientific review committee for the Department

of Neurology. He delive earch at the annual scientific meetings of the American Headache Soci Neurology. In 2008 he assumed the position of Abstracts Editor for the jo

Dr Kaniecki serves on thNeurology and remains afor the first-year medicalfourth-year medical studKaniecki is an active teacin Teaching” award fromKaniecki remains active i2008-2009 academic year

ear, Dr. Kaniecki expects to continue his active clinical duties

largest headache programs in the country, and it continues to provide an assortment of medical options for the management of headache, as well as the interventional procedures of neural blockade and botulinum toxin delivery. Dr. Kaniecki also overse

inical responsibiliti006 he has served as chaclinical research. Since red poster presentations of his resety and the American Academy of urnal Headache.

e residency selection committee and the executive committee for the Department of ctive in medical education. He delivers the headache and pain pharmacology lectures students and also participates in didactic and clinical education of second, third, and ents. Many residents participate in preceptorships at the Headache Center, and Dr her on rounds, in lecture, and with journal club venues. He received the “Excellence the neurology residents in 2007. Outside the University of Pittsburgh system Dr n continuing medical education, delivering 25 invited CME presentations during the .

During the course of the upcoming academic yand participation in medical educational programs. He intends to expand the educational opportunities in headache for the neurology residents here at the University of Pittsburgh. Plans for participation in two major multi-center clinical trials are also in progress, and he will continue to participate in single institutional clinical studies involving the diagnosis and treatment of patients with headache.

34

MA

ichael Soso, MD, PhD ssistant Professor of Neurology

DHsB

Barbara VC of Neurology

r. Soso specializes in the treatment of headache at the Headache Center in Oakland. e has also had a long-time interest in facial pain. He teaches residents and medical

tudents in addition to his work as a protocol evaluator on the Institutional Review oard.

ogler, MD linical Assistant Professor

D ache Center in August mIrmeVcc

te for Neurodegenerative Diseases

r. Vogler joined the Department of Neurology at the UPP Head2006. Since this time she has worked with numerous University of Pittsburgh

edical students and neurology residents both in the outpatient and inpatient setting. n addition to her clinical responsibilities, Dr. Vogler is director of the clinical esearch section of the Headache Center. She has entered the center into several ulticenter clinical trials which provide patients with the opportunity for increased

xposure to new and upcoming treatments for headaches. In the upcoming year, Dr. ogler intends to continue participating in further clinical research trials as well as

ontinue her pursuit of the development of an infusion center in order to provide omprehensive care to headache patients.

Movement Disorders Division

Sarah B. Berman, MD, PhD Assistant Professor of Neurology Pittsburgh Institu

Dr. Berman has been a member of the neurology faculty since 2005, after completing neurology residency and fellowship training at the Johns Hopkins University. She continues to be an active member of the Movement Disorders Division and treats patients with Parkinson’s disease and other movement disorders as part of the Comprehensive Movement Disorders Clinic. In addition, she continues to evaluate and manage patients with deep brain stimulators implanted for Parkinson’s disease, tremor, and dystonias. She oversees management and programming of stimulators, other aspects of treatment, and evaluations and referrals for new patient candidates.

ia, the energy-producing organelles in cells, are very dynamic in neurons, undergoing frequent division (fission) and fusion, and being transported in a regulated fashion. These processes are critical for synapse function and formation, programmed cell death mechanisms, and protection of mitochondrial DNA, and specific defects in mitochondrial fusion genes cause neurodegenerative diseases. In addition, mitochondrial fission has been implicated in an acute model of PD. However, these mitochondrial processes have been very difficult to study directly, particularly in the brain. Using novel methodology, Dr. Berman’s laboratory directly studies the role of mitochondrial dynamics in

Since 2008, she also evaluates patients at the Alzheimer’s Disease Research Center.

Dr. Berman is also a principal investigator with the Pittsburgh Institute for Neurodegenerative Diseases (PIND), where she continues to be engaged in an active research program focusing on the role of mitochondria in neurodegenerative diseases, particularly Parkinson’s disease (PD). Dr. Berman’s research focuses on the role of mitochondrial dynamics in neurodegenerative diseases. Mitochondr

35

neurotoxicity of PD mod esults have suggested that neurotoxicity can be affected by altering mitochondrial dy

Dr. Berman has receivedas the American Parkinsdisease, and she receivefrom her research at the or Neuroscience Annual Meeting in 2008, and further work will be presented at the Society for Neuroscience Annual Meeting in 2009.

Dr. Berman has continu as an active participant this year in the clinical training of residents and medical students, through lectures for neurology residents, for the first-year medical student neurosciences course, and for the third-year medic udent neurology lecture series. In addition, she has provided lectures around the academic community, including the Department of Psychiatry, the School of Pharmacy, and a continuing

fe orders. She gave a university-wide seminar as one of the presenters selected for th ncellor’s Research Seminar series.

She also provided teachiclinics. She continued heBoard of Directors and SFoundation of Western P

Over the course of the 2involvement in neurodecontinue her clinical actiDivision. She plans to activities through involvforums with local patien

Edward A B P Assistant Professor of Neurology

degenerative Diseases

els and aging, and recent rnamics.

funding from the NIH National Institute of Neurologic Disorders and Stroke as well on Disease Association to study mitochondrial dynamics in a model of Parkinson’s

d pilot funding from the Alzheimer’s Disease Research Center. She presented results Society f

ed

al st

rence on movement dismedical education cone School of Medicine’s 2008 Senior Vice Cha

ng to residents and medical students during inpatient attending duties and outpatient r involvement in service to the Parkinson’s disease patient community and sits on the cience Advisory Board of the National Parkinson Foundation chapter, the Parkinson ennsylvania, as well as their Outreach Committee.

009-2010 academic year Dr. Berman plans to continue her research into mitochondrial generative diseases and will continue to publish and present her findings. She will vities and expansion of the deep brain stimulator program in the Movement Disorders continue resident and medical student teaching activities, and community service ement with the local Parkinson’s patient advocacy group and educational outreach

t support groups.

urton, MBChB, MD, DPhil, FRC

Pittsburgh Institute for Neuro

Dr. Burton’s clinical interest is in movement disorders, in particular Parkinsyndromes (Parkinson’s disease, PD; multiple system atrophy, MSA; and progr

sonian essive

by the degeneration ooligodendrocytes. In dy

supranuclear palsy, PSP) and dystonia. Each of these diseases is associated with different pathology, clinical manifestations and presumably pathogenesis. In the degenerative Parkinsonian syndromes PD and PSP, deposition of aggregated proteins within neurons (α-synuclein in Lewy bodies in PD; Tau in neurofibrillary tangles in PSP) is thought important in pathogenesis, because rare cases of familial PD and PSP-like syndromes are caused by mutations in the α-synuclein and Tau genes respectively. In MSA, α-synuclein deposition is observed in glia, suggesting that nteractions between glia and neurons may underlie pathogenesis, a notion supported f neurons observed in transgenic mice expressing α-synuclein ectopically in stonia, there is frequently no observable neuropathology, and the most common

disruption of important i

genetic form of generalized dystonia is caused by mutations in the DYT1 gene that encodes an endoplasmic reticulum protein of unknown function.

A central aim of Dr. Burton’s research work is to understand the mechanisms underlying pathogenesis in these conditions and to develop therapies to avert disease progression or effect symptomatic improvement. It is difficult to model the full complexity of neurological disease in vitro, since the diseases affect specialized neuronal populations and involve neuronal-glial interactions, necessitating in vivo techniques. The lab has taken two different approaches to these studies:

1. The zebrafish has many potential advantages for the study of these conditions: in addition to presenting an appropriate substrate for modeling disease (the zebrafish is a vertebrate and its nervous system retains the

36

same basic divisions and neuronal specializations of the human brain, in addition to glial cell populations of relevance to disease pathogenesis), the zebrafish is especially suitable for screening approaches to

al and molecular techniques. Initial results suggest

and Chief, Movement Disorders

identify modifier mutants, neuroprotective compounds and experiments looking at gene-environment interactions. The Burton lab has developed transgenic zebrafish models of tauopathy and synucleinopathy, supported by grants from the NINDS, Pittsburgh Foundation and CurePSP. They have also identified the zebrafish DYT1 homologue and developed tools to study its function in vivo, supported by the Bachmann-Strauss Foundation and the Dystonia Medical Research Foundation. They are currently analyzing these models using a panel of neurobehavioral, biochemicthat many key features of the relevant diseases are recapitulated by these models, which therefore appear promising as a means to understand pathogenesis and develop treatments.

2. The Burton lab has developed recombinant viral vectors that target the α-synuclein transcript in vivo and which substantially knock down α-synuclein expression after intra cerebral inoculation. In collaboration with J. Timothy Greenamyre MD PhD, they are now testing these vectors for their effects on behavior, dopaminergic neurochemistry and PD-like pathology in a rodent model of Parkinson’s disease, caused by exposure to exogenous toxins that provoke α-synuclein deposition.

J. Timothy Greenamyre, MD, PhD Professor and Vice-Chair for Academic Affairs Director, Pittsburgh Institute for Neurodegenerative Diseases

Dr. Greenamyre, Chief of the Movement Disorders Division, established the Comprehensive Movement Disorders Clinic, which serves as the focal point for clinical care, research and teaching of disorders, such as Parkinson’s disease, Huntington’s disease, tremor and dystonia. The Movement Disorders Division now consists of 7 clinician-investigators, 2 medical assistants and 3 clinical coordinators. Dr. Greenamyre maintains an active clinical practice and is an investigator in several

med as one of America’s Top ctors in America.

i tive Diseases (PIND), an interdepartmental, interdi3. The PIND consists of environment – and is dedand Huntington’s diseaseon defining disease memodalities.

In terms of teaching, Drmedical students. He is

dy Group and the Parkinson Study Group. His

clinical trials. In 2009, Dr. Greenamyre was naPhysicians and as one of the Best Do

rector of the Pittsburgh Institute for NeurodegeneraDr. Greenamyre is Dsciplinary institute that occupies the 7th floor of the new Biomedical Sciences Tower approximately 100 faculty, postdocs, students and staff in an open-lab, collaborative icated to the study of neurodegenerative diseases, such as Parkinson’s, Alzheimer’s s, as well as ALS, MS and other related disorders. In the PIND, there is an emphasis chanisms with the ultimate goal of developing new diagnostic and therapeutic

. Greenamyre continues to lecture in the Movement Disorders series for 1st year the PhD thesis advisor for an MD-PhD student and serves on several PhD thesis

committees. Dr. Greenamyre serves as the primary mentor on 5 K-awards for junior faculty and is the supervisor of 6 postdoctoral research fellows.

Dr. Greenamyre is engaged in both clinical and basic laboratory research. His work is funded by NINDS, NIEHS, the American Parkinson Disease Association, the Parkinson’s Disease Foundation and the Michael J. Fox Foundation. He is an investigator in the Huntington Stulaboratory investigates basic mechanisms of neurodegeneration. He is a member of the Scientific Advisory Board of the Michael J. Fox Foundation and the Advisory Board of the Neurological Institute “C. Mondino” in Pavia, Italy. He is Editor of Neurobiology of Disease and a member of the editorial boards of several other scientific journals.

37

David A. Hinkle, MD, PhD Assistant Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases

Dr. Hinkle joined the University of Pittsburgh Neurology faculty in 2004 after completing his Neurology residency and fellowship training at the University of Pennsylvania. He has been an active member of the Movement Disorders Division through his participation in the Comprehensive Movement Disorders (CMDC) and Dystonia Clinics, his role as the Course Director for the annual CMDC continuing medical education activity entitled “Parkinson’s Disease (PD) and other Movement Disorders: Update for the Clinical Practitioner,” and through his outreach activities

andaddDiso ational Parkinson’s Disease Research and Education Centers, and attends on the UPMC inpatient neurology consultation service. He is an active

ica , Geriatrics, and Internal Medicine students, residents, and fellows thraround campus, including

Dr. Hinkle runs a basic (PIND), and is currently sacute and chronic neurodinterested in how DJ-1, areduce neurotoxicity undStudies in the Hinkle labmediated neuroprotectionneurons against rotenonneuroprotective. Dr. Hink nal meetings and has had two

ical Disorders and Stroke (K08), the Parkinson Disease Foundation (International Research Grant),

rative Diseases

with the local Parkinson’s disease and dystonia lay communities. Dr. Hinkle organizes and lectures in the Neurology resident Movement Disorders lecture series,

serves as the Clinical Advisor for the Pittsburgh Chapter of the Dystonia Medical Research Foundation. In ition to these activities, Dr. Hinkle also attends at the Veterans Administration Movement rders/Dementia clinic, is the VA PD Consortium Director of the N

l training of Neurology, Psychiatryparticipant in the clinough these outpatient and inpatient services. He also lectures in a variety of capacities the medical school Neuroscience course.

science laboratory within the Pittsburgh Institute for Neurodegenerative Diseases tudying the potential role of astrocytes in the neuroprotective response of the brain to

egenerative disorders (with a focus on stroke and PD, respectively). He is particularly gene that causes familial PD when mutated/silenced, may act through astrocytes to er in vitro and in vivo experimental conditions that are relevant to each disorder. over the past year have begun to elucidate a role for astrocytic DJ-1 in astrocyte-, as siRNA-targeted knock-down of this gene renders astrocytes less protective of e than their wild-type counterparts, astrocytic DJ-1 over-expression is more le has recently presented this work at several internatio

2009 publications result from these studies. His lab plans to investigate the mechanisms of these findings over the next year using in-cell Western analysis, quantitative PCR, array-based gene expression profiling, mitochondrial dynamics/physiology, and transgenic mouse technologies. The lab has also set up a collaboration with the Pitt Drug Discovery Institute to screen for small molecules that may stimulate astrocyte-mediated neuroprotection. There will be two technicians, one visiting scholar, and one post-doctoral fellow in the lab as of the summer of 2009, but no graduate students. Dr. Hinkle’s lab is funded by the National Institute of Neurologand the American Parkinson’s Disease Association (George C. Cotzias Fellowship).

Eric K. Hoffmann, PhD Research Assistant Professor Pittsburgh Institute for Neurodegene

Eric K. Hoffman, PhD, is initiating investigations to further define the role of oxidative damage in the neurodegenerative process associated with Parkinson’s disease (PD). Research efforts are focusing on the analysis of the transcriptional regulation of genes implicated in the etiology of PD. Luciferase reporter gene assays are being developed to measure the promoter activity of two genes associated with PD; the alpha-synuclein and transferrin receptor 2 genes. Specific DNA sequences within the promoter regions of these genes are being tested to determine their responsiveness to oxidative stress and elevated iron levels. Once elucidated, this information will be a valuable asset in the study of how expression of these genes is

modulated in cell culture and animal models of oxidative stress and neurodegeneration. Other studies in progress are aimed at elucidating the role of human cytomegalovirus (CMV) beta 2.7 (2.7β) RNA in protecting

38

neuronal cells from roten evidence indicates that infection of cells with human cytomegalovirus (CMV) e environmental toxin rotenone and that this protection is likely due to l complex I. Ongoing studies are utilizing the cloned Coverexpress the 2.7β RNHoffman has recently cmitochondrial iron trans(3):417-432. 2009.

In the coming academicoxidative stress and neresponse to oxidative strproteins that have been im

one-induced cell death. Recent can be neuroprotective against th interaction of the viral 2.7β species with mitochondria

MV 2.7β gene to create stably transfected human dopaminergic cell lines that A in an effort to better define the role of complex I in rotenone-induced toxicity. Dr. oauthored the results of a study entitled “A novel transferring/TFR2-mediated

port system is disrupted in Parkinson’s disease. Neurobiology of Disease. June;34

year, Dr. Hoffman plans to continue his research efforts on the mechanisms of urodegeneration. Studies will focus on inducible antioxidant gene expression in ess and RNA interference methods as a means to further define the function of plicated in the etiology of Parkinson’s disease.

Samay Jain, MD Assistant Professor of Neurology Clinical Director, Movement Disorders Division

Dr. Jain joined the Department in July 2006 as Clinical Director of the Movement Disorders Division and Assistant Professor of Neurology. He works in the

olars Program, a National Institute of Health Career Development Award. This project is a collaborative effort between the Pittsburgh

e D. Pepper Older Americans Independence Center, and the Biometrics Research Pro treatment of Parkinson disease with assessments of non-motor features using a clinical trial for treating Tourette syndrome funded by the Tourette Syndrome Association as well as pharmaceutical sponsored trials for Tourette syndrome aParkinson disease with sucoordinating studies aboPittsburgh Graduate Scho

Dr. Jain has established movement disorder patienand research purposes. Hand health care personne

Comprehensive Movement Disorders Clinic at University of Pittsburgh Medical Center and the Tourette’s Syndrome Clinic in Children’s Hospital of Pittsburgh. Dr. Jain received a B.A. in Cognitive Science and M.D. from the University of Virginia. He then went to the Cleveland Clinic for his Residency in Neurology, followed by a Movement Disorders fellowship in the Neurological Institute at Columbia University. While in New York, he also completed a filmmaking workshop at the New York Film Academy which resulted in two documentaries about individuals

with movement disorders. These short films have been shown to patients, physicians, health care providers and general audiences in several states as well as other countries, and are part of the Creativity and Parkinson Project. In addition to working full-time as a neurologist specializing in movement disorders, he is also working on a documentary about creativity in the lives of patients with Parkinson disease and participates in activities with local Parkinson disease support groups.

Dr. Jain is interested in developing accurate and early clinical diagnosis techniques and therapy for movement disorders as well as complications later in disease. He has presented research pertaining to Parkinson disease, Tourette syndrome, essential tremor, dystonia, myoclonus, encephalitic movement disorders, historical neurology and pediatric movement disorders. Currently he is investigating the non-motor features of Parkinson disease with funding through the Multidisciplinary Clinical Research Sch

rative Disease, the Claude Institute of Neurodegengram to improve diagnosis and clinical and physiologic measures. He is also developing

nd Parkinson disease. Dr. Jain is designing and conducting a trial for exercise in pport from the Claude D. Pepper Older Americans Independence Center. He is also ut Parkinson disease with the Department of Epidemiology in the University of ol of Public Health.

a movement disorder research registry for patients and a protocol for videographing ts. These videos are archived in a database where they are used for clinical, teaching e coordinates movement disorder video rounds for faculty, staff, medical education

l. These rounds serve as a platform for discussion of movement disorders seen in clinic and for establishing a collaborative and educational environment for patient care. Dr. Jain also regularly teaches medical students, and helps coordinate a rotation for residents in the Movement Disorders division.

39

Robert Y. Moore, MD, PhD Professor of Neurology

Dr. Moore is a specialist in sleep and movement disorders and has long been a researcher in those disorders. He is currently PI of Project 3 of two studies.

In Vivo Amyloid and Dementia in Synucleinopathies (Project 3 of NIA P01 AG-25204): Synucleinopathies are now recognized as major causes of dementia. The principal synucleinopathies are the overlapping clinical entities of Parkinson disease

ntia reflects predominantly a single process or a complex one w nges coexisting with one or more of the other pathologies. The

o clinical and neuropsychological evaluation and positron emission tomogr c rate for glucose (rCMRglu) using the tracer [F-18]fl ution of amyloid deposition to dementia in PD and DLB.OH-BTA-1 (more commoare to determine the follothe role of amyloid deposcerebral metabolism corrunderstanding the pathopand PIB uptake analyzedcontrols. The PIB data sh(amyloid load) whereas so

(PD), including Parkinson disease with dementia (PDD), and dementia with Lewy bodies (DLB). PDD and DLB are the most common causes of dementia after Alzheimer disease (AD). There is a large overlap in the post-mortem pathology of PDD, DLB and AD and the contribution of AD-like amyloid pathology to PDD and

DLB is not clear. It is important to know whether a PDD or DLB demeith Alzheimer cha

assess amyloid load combined with aphy (PET) determination of region

intent of this project is tal cerebral metaboli

uorodeoxyglucose (FDG) to determine the contrib Amyloid deposition/load will be measured using PET along with the tracer [C-11]6-nly known as Pittsburgh Compound-B, or PIB). The overall objectives of the project

wing: 1) the contribution of amyloid deposition to the dementia in PDD and DLB; 2) ition in the conversion of PD to PDD; 3) the contribution of amyloid deposition and

elated with clinical evaluation, neuropsychological testing and structural imaging, to hysiology of dementia associated with synucleinopathies. Data have been collected for 10 PD, 8 PDD and 8 DLB subjects and compared with scans from 10 healthy ow that PD subjects and PDD subjects do not differ from controls in PIB retention me DLB subjects show significantly higher uptake compared to the controls whereas

others have normal uptake implying that there is more than one path to dementia in DLB. From this it can be concluded that dementia with synucleinopathies differs from Alzheimer disease with respect to amyloid deposition. We will complete data accumulation this year and initiate a full analysis of the data.

PET, Posturographic and Clinical Markers of Early PD (Project 3, PO1 NS 19608.): The causes of Parkinson's disease (PD) are being unraveled and rational neuroprotective therapy is becoming a reality. Neuroprotective

aminergic brain PET imaging using a ligand for the dopamine

t a

therapies are likely more effective if given early in the course of the disease rather than late but by the time a clinical diagnosis of PD is made, a significant loss of dopaminergic neurons has already occurred. Therefore, identification of very early disease has become crucial to obtaining maximal advantage from treatments that have the potential of significantly slowing the progression and eventually providing secondary prevention of PD. The NIH Parkinson's Disease Research Agenda states that the availability of biomarkers of PD that are reliable indicators of risk, disease state, and disease severity would accelerate research on the development and testing of therapies. A biomarker, to be useful in screening large populations to identify very early disease, should be inexpensive, easily administered, and sufficiently sensitive and specific to avoid unacceptable false negatives or positives. The major aim of this study is to develop biomarkers of PD that can be used to identify at-risk individuals (initially first degree relatives [FDR] of patients with PD). The plan is to follow a multi-tiered approach to the diagnosis of preclinical or prodromal PD using a strategic combination of diagnostic tests. The first part of the research consists of recruiting patients with early PD to validate the test battery. This is followed by recruitment of FDR of patients with PD. Subjects will be screened using a PD test battery followed by postural motor system analysis with the screening directed to selecting FDR’s who have abnormalities shown on the test battery. Doptransporter will then be used as the gold standard for the diagnosis of very early PD.

A test battery consisting of the motor UPDRS, grooved pegboard test, foot tap, finger tap, postural adjustment and olfactory discrimination (UPSIT 40) has been administered to 60 patients with PD (Hoehn and Yahr stages 1-3), and 50 age and sex matched controls. Following the test battery administration, DAT PET was performed. Bradykinesia assessed by the UPDRS bradykinesia score, grooved pegboard and foot tap all correlated highly with striatal dopamine denervation as assessed by DAT PET (p<.001-.03). There was no

40

significant correlation wit justment in the A-P dimension correlated highly with putamen DAT binding here was no correlation with mediolateral adjustment. Impairment of olfactory disdeveloped a simple test fin PD. In summary, dist lfaction, correlated highly with nigof the study has been initbattery and 9 have abnorcollected indicates that understanding of the path

h tremor or rigidity. Postural ad(r=-.73; p=.0003) but t

crimination also correlates with putamen DAT binding (r=.65; p<.001). We have or olfactory discrimination that is sensitive and specific for the olfactory impairment urbances of motor function, bradykinesia and postural adjustment, and orostriatal neuron degeneration as demonstrated by DAT PET. The FDR component

iated with more than 75 asymptomatic FDR’s of PD patients screened using the test mal results on the test battery. Analysis of their PET data is in progress. The data a simple screening battery for PD can be developed. They also enhance our ophysiology of PD.

Valerie Renee Suski, DO Clinical Assistant Professor of Neurology

Dr. Suski joined the Department of Neurology in January 2008 after completing her Neurology residency at Virginia Commonwealth University Health System/Medical College of Virginia and a clinical Movement Disorders fellowship at Duke University.

Dr. Suski is an active member of the Movement Disorders Division providing evaluation and treatments including botulinum toxin and deep brain stimulator programming to patients with a wide variety of movement disorders. She will be the new director of the UPMC Huntington's Disease Clinic starting July 2009. This is a multidisciplinary clinic consisting of physicians, social workers, genetic counselors,

and clinical trial coordinators that provides care for both patients with Huntington's disease and their families. She is a new member of the Huntington’s Study Group and is currently participating in 3 Huntington’s disease clinical trials.

Dr. Suski recently started providing the services of the Movement Disorders Clinic through Telemedicine to remote community locations where this subspeciality is needed. She is especially interested in non-motor complications in Parkinson's disease, atypical Parkinsonism, dystonia, tremor and Huntington's disease. She is also extremely active in service to the Parkinson Support Group community in the Western Pennsylvania region.

Dr. Suski has been active in the clinical training of Neurology residents via the outpatient clinics, inpatient Neurology ward and consultation services and she will be supervising the weekly Neurology Resident Continuity clinic. Dr. Suski participates in medical student education, teaching them in the outpatient clinics and during the inpatient services.

Over the course of the 2008-2009 academic year, Dr. Suski plans to continue her clinical activities and involvement in the Comprehensive Movement Disorders Clinic. She is currently applying to the Parkinson’s Study Group in the hopes of increasing the Parkinson’s disease clinical trials at UPMC. Other plans include curriculum development for the residents with clinical skills teaching and assessment, and a deeper involvement in medical student teaching.

41

Neuroimmunology/Multiple Sclerosis

Rock Heyman, M.D. Assistant Professor of Neurology Chief, Division of Neuroimmunology/Multiple Sclerosis

Dr. Rock Heyman provides direct clinical care for over 1500 people with Multiple Sclerosis (MS) and related disorders throughout the region. He has a system for comprehensive care which includes not only on site and in system multi-disciplinary care, but also integrates support services from many other health and community programs including innovative programs to address domestic violence issues and

n animals of people with MS. He has developed the center, where both FDA approved and

dNational MS Society (NMClinical Advisory Comm n (Chairman), and Task Forces regarding the relationship of the NMSS with the Pharmaceutical Inational office is with thChairman of the Educatioannual meeting. RegionaTrustees (executive comm

l therapy, and occupational therapy students as well other regional health care professionals.

g enduring CME materials for physicians as well as educational works (brochures, videos) for patients nical care he provides at the Kaufmann Building site or Presbyterian University Hospital

.

fection). He has served as both a treating physician and blinded examiner in trials of MS and is certified in the use of the EDSS and MSFC rating scales.

Dr Heyman plans continued expansion of his and his division’s services in all aspects of his mission, clinical care, education, research, and advocacy.

even support for companiodepartment of neurology’s on site infusion investigational agents are given.

Dr. Heyman is an active advocate for people with MS as well as health care researching MS. He devotes his efforts at the national level to working with the SS), serving on their Medical Advisory Board (executive committee), Council of

ittee Chairme

professionals treating an

ndustry and with the new Comprehensive Care Center Affiliation process. His other e Consortium of MS Centers, where he is a member of the Broad of Trustees and n Committee. He directs the research platform and poster presentations at the CMSC lly Dr. Heyman serves the Allegheny District Chapter of the NMSS on the Board of ittee), medical advisor, research advocate, and chairman of the Clinical Advisory

Committee.

Dr. Heyman’s educational efforts also center on Multiple Sclerosis. He lectures to the University of Pittsburgh medical, physicaDr. Heyman is the lecturer for the medical school’s classes on MS and related disorders and teaches in all of the first year medical school neuroscience small group sessions and problem based learning sessions. He has assisted in the development of course materials for the Neuroscience Course problem-based learning and small group neurology conferences. He has presented numerous CME programs regionally and nationally as well as producinnationally. The cliusually also involves teaching medical students, neurology residents, and may involve fellows in clinical MS care and spinal cord injury medicine. Dr. Heyman believes strongly in patient education and he supports numerous patient support and education groups throughout the region and assists with both regional and national media issues regarding MS

Dr. Heyman is involved in all of the division’s 8 multi-center research trials, as either a principle or co-investigator. He currently and supports research activities related to MS and Neuroimmunology in the departments of Urology (researching Botulinum toxin effectiveness for Neurogenic bladder), Physiatry (looking at mobility and assistive technology use in people with MS), and Infectious Disease (NIH study of cerebral function in people with HIV in

42

Galen W.Associate Professor of Neurology

clerosis Research cal Neurology

Mitchell, M.D.

Director of Multiple SDirector of Medical Student Education for Clini

Dr. Mitchell maintains a clinical practice primarily specializing in autoimmune

T tential influence on peripheral T cell transmigration and the immune pathogenesis of

l depend on the relationship among the peptide, HLA molecules and T cells. Dr. Mitchell’s group

tes, macrophages and natural killer (NK) cells, a subpopulation of

12 given orally once

tors (8 in number) that it modulates. This selectivity may decrease it’s possible side effects for the patient.

Dr. Mitchell conducted grand rounds as well as seminars at research and educational symposia and meetings providing information for primary care physicians and neurologists. He conducted a series of lectures for the Neurology residents on autoimmune diseases and on evidence-based medicine. As director of medical student education, he served on several committees, including the Neuroscience Clerkship Design Committee, Medical Student Clinical Skills Course Design Committee, Student Promotions Committee, Department of Neurology

diseases and cares for patients on the inpatient and consult services during the year. As director of Multiple Sclerosis research at UPMC, Dr. Mitchell serves as primary investigator on many studies. His group has just completed two trials involving the detection and subsequent effect of neutralizing antibodies to interferon beta on its use as an immune modulating agent in patients with multiple sclerosis; study results are pending. The research group is currently recruiting relapsing-remitting MS patients for the study of a new medication (FTY720) that effects adhesion molecules and cells in the lymph nodes, with poblocks the adherence of

MS. One of these trials compares FTY720 to placebo and the other to Avonex®. They are also preparing to enter a similar trial for patients with primary progressive MS. The research group is just starting a trial with MBP 8298. This is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients. The apparent mechanism of action of MBP8298 is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved wilis also studying MBP8298 in subjects with Secondary Progressive Multiple Sclerosis. The trial represents a randomized, multicenter, placebo-controlled double-blind study. Another trial they are just beginning involves BG00012. Although its exact mechanism of action is not known, this oral fumarate is thought to inhibit immune cells and molecules and may be protective against damage to the central nervous system. The compound has been used safely for years to treat psoriasis, an autoimmune condition which affects the skin and joints. In this study, the group will evaluate the efficacy and safety in patients with Relapsing-Remitting Multiple Sclerosis when compared to placebo and an active reference(Glatiramer Acetate). Dr. Mitchell and his group are preparing to study Alemtuzumab, a recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarily-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocygranulocytes, and tissues of the male reproductive system. This randomized, rater- and dose-blinded study compares two annual cycles of intravenous low- and high-dose Alemtuzumab to three-times weekly subcutaneous interferon beta 1a (Rebif) in patients with Relapsing Remitting Multiple Sclerosis who have relapsed on therapy. Finally, Dr. Mitchell and his group are conducting a phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF3daily in patients with relapsing-remitting multiple sclerosis, BAF312 acts on the lymphocytes to inhibit their migration to the location of the inflammation. BAF312 is similar to FTY720, but may be more selective in the particular sphingosine-1-phosphate recep

43

Education Committee and the Curriculum Committee. He continued teaching the 3rd year students on Neurology emphasizing t nd treatment of patients with neurological disease. He also taught a “The Neurological Evaluation.”

During the next year, Dr th the addition of new research projects. Habout evidence-based mehopes to represent the DeMitchell will also continuneurology residents and f

he entire neurological evaluation process a course to the 1st year medical student entitled

. Mitchell will continue his clinical duties and research studies wie also plans to continue teaching at local, national and international levels, speaking dicine, MS and its immune mechanisms and treatment. Through these endeavors, he partment of Neurology in a positive light and give it more national recognition. Dr. e to serve on numerous education committees as well as teach the medical students,

ellows.

Neuromuscular Diseases

David Lacomis, MD Professor of Neurology and Pathology Chief, Division of Neuromuscular Diseases Director, Clinical Neurophysiology Fellowship Program

Dr. Lacomis is the director of the Muscular Dystrophy Association Clinic and MDA-ALS Center, specializing in myasthenia gravis, amyotrophic lateral sclerosis (ALS), and muscle diseases. He is also the co-director of the EMG Laboratory at UPMC Presbyterian and the director of the Autonomics Laboratory. Dr. Lacomis continues to direct the Clinical Neurophysiology Fellowship Program and mentored three fellows this year. He remained active in teaching medical students in the Neuroscience Course and housestaff from Neurology and Pathology. He is also in charge of the Neuromuscular Pathology Service and trained three neuropathology

fellows in nerve and muscle pathology. Dr. Lacomis was again named among the Top Doctors by Pittsburgh Magazine and in Best Doctors nationally.

He has been involved in a number of major research projects in the past year. He is a co-investigator with Robert Bowser, PhD in the study of ALS biomarkers in the cerebrospinal fluid and serum using mass spectrometry proteomics. Dr. Lacomis has recruited patients, performed clinical evaluations and lumbar punctures, and assists with the current data analysis phase of the project. So far, a number of proteins such as transthyretin, neuroendocrine protein 7B2, VGF, chromagranin B, osteopondin, and cystatin C have been found to be either elevated or reduced in the CSF of patients with ALS versus controls. In particular, cystatin C and transthyretin levels appear to be decreased in ALS patients compared to controls, and cystatin C levels appear to correlate with disease activity. These studies have also moved into a multi-center validation phase, and Dr. Lacomis is the site principal investigator for this study. In addition, he serves as the site principal investigator in a Phase II trial of KNS-760704 (R+ pramipexole) for ALS, and will be starting a phase III study of ceftriaxone in ALS. He is a co-investigator in a pilot epidemiology study in ALS; and, in conjunction with Drs. Heiman-Patterson at Drexel University, Zachary Simmons from Penn State, and Sasa Živković at the University of Pittsburgh, Dr. Lacomis has formed a PA-ALS Registry for epidemiology and other research studies. In collaboration with PI Chet Oddis, MD, from Rheumatology, he serves as a co-investigator in a large NIAMS-funded study using rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis. Dr. Lacomis is the evaluator of muscle pathology specimens from all sites and serves on the Steering and Adjudication Committees. Evaluation and data analysis are ongoing. His collaboration with Anne Reed, MD, at the Mayo Clinic, on the immunopathologic features of dermatomyositis resulted in a recent publication.

Dr. Lacomis served on the Scientific Advisory Committee for the Myasthenia Gravis Foundation of America, and is on the editorial board of the Journal of Clinical Neuromuscular Diseases. He is on the Examination Committee for Clinical Neuromuscular Pathology for the United Council for Neurologic Subspecialties and the Clinical Neurophysiology Examination Committee for the American Board of Psychiatry and Neurology.

44

Chitharanjan Rao, MD, MRCP (UK) Assistant Professor of Neurology

Dr. Rao joined the Department of Neurology in July 2006, after completing his

especially interested in inherited neuropathies and hereditary spastic paraplegias. He is also involved in service to the Charcot-Marie-Tooth Disease patient communi nia region.

n the clinical training of Neurology, Psychiatry, and Internal t logy ward and consultation services. He

supervises the weekly Ne the annual Neurology board review course for the residents. D nical Neurophysiology and Neuromuscular fellow e for the fellows, which became a part of the corEMG course sponsored medical student educationin the problem–based lear

Neurology residency at Saint Louis University and a neuromuscular fellowship at Wayne State University. He has been an active member of the Neuromuscular Division where he evaluates and treats patients with neuromuscular conditions. He provides electrodiagnostic services to patients with a wide variety of neuromuscular disorders and started an electrodiagnostic service at the Magee Women’s Hospital. He is

ty in the Western Pennsylva

Dr Rao has been active ihe outpatient clinics and inpatient Neurourology Resident Continuity clinic and co

Medicine residents via nducts

r Rao is actively involved in the hands-on training of the Clis. He initiated and conducts the weekly EMG case conferenc

e curriculum for the residents training in July 2007. He also teaches in the annual by the Physical Medicine and Rehabilitation department. Dr Rao participates in by teaching in the outpatient clinics and during the inpatient services. He is involved ning sessions during the medical school neuroscience course.

Saša Živković, MD Associate Professor of Neurology

In the academic year July 1, 2008 through June 30, 2009, Dr Živković continued his clinical and research work focusing on amyotrophic lateral sclerosis, peripheral neuropathy and neurologic complications of organ transplantation. He was promoted

antation with Drs. Benjamin Eidelman and Kareem Abu-Elmagd were accepted for

e

to the rank of Associate Professor in Neurology in January 2009.

Dr. Živković specializes in the treatment of patients with neuromuscular disorders and participates in the work of the MDA Neuromuscular Clinic and MDA-ALS Multidisciplinary Clinic. Since November 2004 he has treated patients with neuromuscular and other neurologic diseases at VA Pittsburgh. He also performs electrodiagnostic testing in Presbyterian Hospital EMG lab and performs approximately 300 EMG and nerve conduction studies annually. Dr. Živković was

also active in clinical research as a member of the North-Eastern ALS Consortium (NEALS), National ALS Research Group (ALS RG) and National VA ALS Consortium. He was a co-investigator on a treatment trial of R(+)-pramipexole in ALS (PI D. Lacomis) and he continued to serve as a site co-principal investigator on a treatment trial of late onset Pompe’s disease (PI P. Clemens).

Dr. Živković authored a review on paraproteinemic neuropathies with Drs. Lacomis and Lentzsch and the manuscript was accepted for publication in Leukemia and Lymphoma. In collaboration with Drs. Lacomis, Delios and Lentzsch he has published a case report in Annals of Hematology describing a rare case of small fiber neuropathy in a patient with multiple myeloma. Results of clinical trial of sodium phenylbutyrate in ALS (site PI) were published in journal Amyotrophic Lateral Sclerosis. He has also authored with Dr Kenneth McCurry a study on neurologic complications of lung transplantation that was published in the Journal of the Neurological Sciences. Results of a long-term study on neurologic complications of intestinal and multivisceral transplpublication in Clinical Transplantation. He continued collaboration with Drs. Anto Bagić and Rick Hendrickson on cognitive dysfunction in ALS and potential use of magnetoencephalography in a pilot grant funded by the UPMC ALS Center. He also continued his clinical research on neurologic complications of organ transplantation in collaboration with Dr. Abu-Elmagd, Thomas Starzl Transplantation Institute, and th

45

evaluation of neuromusc n the elderly in collaboration with Dr. Else Strotmeyer, Graduate Sch

Dr Živković actively pateaches in the course Neuresidents and clinical neAdditionally, he continue“Distal symmetric polynAmerica (Best Doctors, Scandinavica, Clinical NNeurosurgery and Psychi

In academic year 2009-2 ials of ALS at UPMC with Dr. David Lacomis, and

Director, Adult Neuro-Oncology Program UMPC Cancer Center

ular function and peripheral neuropathy iool of Public Health.

rticipates in the education of medical students at the University of Pittsburgh, and roscience and Clinical Neuroscience Clerkship. He has also been teaching neurology urophysiology fellows in EMG lab, outpatient clinics and inpatient consult service. d to serve as an editorial consultant for the online database PIER for the chapter on

europathy”. Dr Živković was selected again by his peers as one of Best Doctors in Inc.). He continued to serve as ad hoc reviewer for journals Acta Neurologica eurology and Neurosurgery, Journal of Neuroimaging,, and Journal of Neurology, atry.

010, Dr. Živković will participate in clinical treatment tr will continue clinical research of cognitive dysfunction in ALS at UPMC and VA

Pittsburgh HCS. He will also continue research on neurologic complications of organ transplantation, and on decline of peripheral nerve function in elderly. He will be site PI for a Pittsburgh site of worldwide amyloidosis registry THAOS.

Neuro-Oncology Program

Frank S. Lieberman, MD Associate Professor of Neurology and Medical Oncology

Dr. Lieberman is director of the adult neuro-oncology program at UPMC Cancer

nant gliomas, the

mclinical trials consortium Radiation Therapy Oncol

rofessor of Neurosurgery, Dr. Lieberman is a

Centers. His clinical and research efforts in 2008-2009 encompassed both the treatment of primary CNS tumors and the neurological complications of cancer. Brain tumor translational investigations focus on the application of molecular genetic techniques and functional imaging techniques to develop strategies for individually optimized molecularly targeted treatment of patients with maligmost common brain tumors in adults.

Dr. Lieberman serves as institutional principal investigator for UPMC in the Adult and in the Collaborative Ependymoma Research Network, the only multicenter for the study of ependymoma. He is a member of the CNS tumor committee for the ogy Group, and the institutional principal investigator for RTOG brain tumor trials at

UPMC Cancer Centers. Dr. Lieberman serves on the clinical advisory board for the International Chordoma Foundation and was a participant in the First and Second International Chordoma Research Symposia in 2007 and 2008 respectively.

In collaboration with Hideho Okada, MD, PhD, Assistant P

Brain Tumor Consortiu

coinvestigator for the institutional gliomas peptide-based vaccine trial in patients with recurrent malignant gliomas and 2 new vaccine trials for patients with low grade gliomas. In collaboration with Gary Marsh, PhD, Department of Biostatistics, Dr. Lieberman is co-investigator in the largest occupational exposure study involving human gliomas conducted to date, involving the Pratt Whitney plants in Hartford, CT. In collaboration with Robert Sobol, PhD, Dr. Lieberman is investigating DNA repair mechanisms as modulators of glioma sensitivity to chemotherapy with temozolomide. The refinement of neuroimaging techniques to allow for earlier discrimination of treatment response in clinical trials of malignant gliomas is a major investigational priority. In collaboration with Drs. Fernando Boada, Eric Schwartz, and Erik Weiner, Dr. Lieberman is evaluating the use of MR H1 proton spectroscopy, Na+ triple filtered quantum spectroscopy, Dynamic contrast enhanced MRI, and gradient echo ultrahigh field strength (7T) imaging in patients being treated with antiangiogenic therapies. Dr. Lieberman is also involved in collaborative study of a novel PET technique using a tracer which is selectively sequestered in apoptotic tumor cells, in which the tracer is being assessed as a marker of treatment response in brain metastasis from non-small cell lung cancer.

46

Dr. Lieberman directs the clinical Neuro-Oncology program for UPMC Hillman Cancer Center, is director of the neuro-oncology rotation at UPMC Hillman-Shadyside for neurology residents and fellows and is an

nce 2006. He currently serves on the committee designing and

Guodong Cao,Research Assistant Profess

attending for Neurology housestaff morning report one day per week. He provides neuro-oncology consultation service for UPMC Presbyterian, Magee, and Shadyside hospitals. He attends on the neurology consultation service at UPMC Presbyterian. He directs the Neuro-Oncology Tumor Board; a weekly CME category 1 approved academic teaching case management conference, and a monthly Neuro-Oncology Tumor Board conference at UPMC Shadyside which is a case presentation and topic review format for the oncology community. He also serves on the bioethics committee at UPMC Shadyside.

Dr. Lieberman is a member of the Society for Neuro-Oncology and has been a member of the scientific review committee for the annual meetings siadministering the subspecialty neurooncology board examination for the American Academy of Neurology. He is a member of the American Association of Cancer Researchers, American Society of Clinical Oncology, and the American Academy of Neurology.

Research Division

PhD or of Neurology

Dr. Cao’s research focuses on the molecular mechanismsassociated with cerebral ischemia and explores novel interven

of neuronal cell death r the treatment especially in

t tin would not reduce brain tissue loss, but would significantly incre

ing.

tions foof stroke and he’s been very productive in the past academic year,funding applications. Erythropoietin has robust neuroprotective effects against cerebral ischemia both in animal models and in stroke patients. However, a significant challenge for the future clinical use of EPO in CNS injury is how to overcome the side-effects associated with its blood stimulating effects. Dr. Cao generated a novel EPO mutant that is neuroprotective but completely lacks erythropoietic activity. In 2008, the NIH awarded Dr. Cao a R21 grant to study the therapeutic effects of this novel molecule against ischemic brain injury. Recently Dr. hat delayed administration of erythropoieCao’s laboratory found ase oligodendrogenesis and maturation of oligodendrocytes, attenuated white matter

injury and improved behavioral neurological outcomes in neonatal model of hypoxia/ischemia. This finding has translational value for the treatment of neurological functional recovery of post-stroke patients. Recently, Dr. Cao received a funding notice (VA Rehabilitation Research and Development) from the Department of Veterans Affairs to study the neurorecovery effect of mutant EPO after a clinically-related delayed administration approach. A Program Project Grant (PI: Greenamyre) in which Dr. Cao is the director of Molecular Core is in pend

In addition to his research, Dr. Cao participated in teaching and supervising graduate and postdoctoral students. He has taught a Neuropharmacology course for graduate students and has mentored more than five postdoctoral students. Dr. Cao serves as ad-hoc referee for nine journals, including the Journal of Neuroscience, Journal of Cerebral Blood Flow and Metabolism and European Journal of Pharmacology. In addition, Dr. Cao participated in the NIH Challenge grant review (Emphasis Panel/Scientific Review Group ZRG1 BDCN-T). In 2008, Dr. Cao obtained a co-appointment as Research Biologist from VA Pittsburgh Healthcare System.

47

Jun Chen, MD Professor of Neurology

Dr. Chen’s laboratory is interested in molecular mechanisms of neuronal cell death associated with cerebral ischemia and Parkinson’s disease. The work focuses on determining the role of programmed cell death and mitochondrial dysfunction using various in vivo and in vitro disease models. The main theme of this research is that elucidation of the signaling mechanisms underlying the pathologic neurodegenerative processes in the brain may explore new targets for therapeutic

• Discovered a novel mitochondrial-d pathway that mediates the neuroprotective effect of HSP27 against ischemic neu

• Discovered that RP-1 and calpain signaling mediates the AIF-dependent cell n

• Continued resear biogenesis as a novel neuroprotective response in the b

• Continued invesischemic neuron

Dr. Chen has actively parand MD/PhD programs graduate study courses (C3375).

Dr. Chen has continued tNIH, AHA, and VA, an

iate Professor of Neurology

intervention of the disease. The lab is currently investigating the specific signaling molecules and pathways that trigger mitochondrial apoptosis and the downstream cell death-execution cascades in neurons.

During the academic year July 2008 – June 2009, Dr. Chen’s laboratory made major research progress:

ependent signaling ronal injury

cross-talk between PA neuronal apoptosis ch that shows rapidly increased mitochondrial

death pathway i

rain following hypoxic-ischemic injury tigations showing that NAD replenishment confers marked neuro-protection against al injury via enhancement of DNA repair

ticipated in teaching graduate students. He is a training faculty member of the CNUP and a dissertation advisor for graduate students. Dr. Chen teaches two different ell and Molecular Neurobiology MSNBIO 2100 and Neuropharmacology MSMPHL

o serve at both national and international levels. He is a member of study sections at d also serves as a reviewer or consul member for various international science

foundations. He is the Chair of American Heart Associate Brain-2 Committee. He is an elected member of the Board of Directors of the International Society of Cerebral Blood Flow and Metabolism and serves as the chairman of the membership committee of the society. He serves as an editorial board member for Journal of Neuroscience, Journal of Cerebral Blood Flow and Metabolism, Stroke, Neurobiology of Disease, and Translational Stroke Research.

Paula R. Clemens, MD AssocChief, Division of Veterans Affairs

During the academic year from July 1, 2008 to June 30, 2009, Dr. Clemens provided leadership for the Neurology Service at the Pittsburgh VA Healthcare System. She directs an in-patient, out-patient and consultation service with 8 part-or full-time neurologists and 3 neurology resident physician positions. The active teaching service also comprised third and fourth year medical students, geriatrics fellows and a speech pathology clinical doctorate student during the course of the year.

Dr. Clemens pursues basic and clinic research focused on discovering and improving treatment of skeletal muscle diseases. In her basic research laboratory, research

projects include gene replacement and gene editing studies for muscular dystrophy in utero, characterization of the molecular pathology of muscle wasting in cancer cachexia and modulation of NF-κB signaling pathways for treatment, gene transfer and peptide-mediated strategies to interfere with NF-κB activation and ameliorate the dystrophic phenotype and modulation of the immunity induced by viral vector-mediated gene delivery for the treatment of muscular dystrophy. She is actively involved in the training programs of pre-doctoral students

48

working in her laboratory a number of thesis committees. Her collaborators include faculty in the Departments of O Microbiology and Molecular Genetics. Human clinical research studies directed byfor late-onset Pompe disetherapeutic agents for pastudies, including a studypulmonary outcome meaŽivković and Hoda Abdmentored a masters-levedystrophin mutations.

Dr. Clemens co-directs th rated Case Studies. This entirely problem-based learning course is bas

iones in the first two years to the clinical electives that begin in the third year of medical

scho

In t cneuroher train gadm

and participates inrthopedics, Pediatrics and

Dr. Clemens include a Genzyme-sponsored trial of enzyme replacement therapy ase and involvement in a multi-center academic trials group devoted to the study of tients with Duchenne muscular dystrophy. She is involved in several continuing in non-ambulatory Duchenne muscular dystrophy patients focused on cardiac and sures. This effort involves collaborators in the Neurology department, Drs. Sasa el-Hamid, and 2 clinical study coordinators. During this past year, Dr. Clemens l graduate student in genetic counseling in a comparative analysis of human

e second year medical student course, Integed on selected clinical cases presented from a computer interface developed by the

Laboratory for Educat al Technology at the University of Pittsburgh and provides a bridge from the core basic science cours

ol training.

he oming year, Dr. Clemens will continue her basic and clinical research program in the treatment of muscular disease, which includes active involvement in the graduate training programs. She will continue

clinical activities as a neuromuscular specialist, her involvement in the neurology residency clinical in program, her co-directorship of the medical student course, Integrated Case Studies, and her role as the inistrative head of the neurology service at the Pittsburgh Veterans Administration Healthcare System.

Steven H. Graham, MD, PhD Connolly Family Chair in the Stroke Institute Professor and Vice-chairman for Research Director, Geriatric Research Educational and Clinical Center

Dr. Graham’s research focuses on the mechanisms by which neurons die after stroke and brain trauma. New insights into the mechanisms by which cyclooxygenase 2 (COX2), the enzyme that is the target of drugs such as Vioxx, injures neurons after anoxia in vitro were obtained during the 2005-2006 academic year. These results suggest that prostaglandins, not the peroxidase activity of the enzyme itself, are responsible for COX2’s toxic effect on neurons. Other ongoing research projects address the role of the Fas cell death receptor in stroke and brain trauma. An adenovirus associated viral vector that expresses cFLIP-L, an endogenous inhibitor

of Fas-induced cell death, has been constructed and is being tested in models of ischemia in vitro. Dr. U rain Trauma Center that addresses the role of the Fas death

receptor in traumatic brai S for five years. Dr. Graham is the Director of the Geriatric Research, E C) at the VA. The GRECC recruited several new research faculty inclResearch he oversees theMS1 Neuroscience cours

Dr. Graham will continuanoxia, focusing on the recruit new faculty and fu

niversity of Pittsburgh BGraham’s project in then injury was refunded by the NINDducational and Clinical Center (GRECuding Guodong Cao, Research Assistant Professor of Neurology. As Vice-chair for rapidly growing research program of the Department. Dr. Graham teaches in the

e.

e his studies regarding the mechanism by which COX2 directly injures neurons after role of prostaglandins in exacerbating cell death. As GRECC Director, he plans to rther develop its research program in cerebrovascular disease.

49

Teresa G. Hastings, PhD Associate Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases

Dr. Hastings is a member of the Pittsburgh Institute for Neurodegenerative Diseases (PIND). Her work continues to examine the role of dopamine oxidation, ROS formation, protein modification, and mitochondrial dysfunction in the selective vulnerability of dopaminergic neurons. The goal of her work is to identify therapeutic agents to prevent neurodegeneration associated with Parkinson’s disease, drugs of abuse, and aging in general. Using proteomic techniques, 2-D gel electrophoresis and mass spectrometry, Dr. Hastings’ laboratory is identifying

drial selenoproteins in preventing neurotoxicity.

as training faculty on three institutional training grants including "NINDS Postdoctoral Training in the

d irector),” “NIH Medical Scientist Training Program (C.A. Wiley, Di roscience" (A.F. Sved, Director).

Dr. Hastings is the Chair ber of the Department of Neurology the Executive Committee for the PittsbuSteering Committee for th

mitochondrial and intracellular proteins that show changes in expression, oxidative modification, or aggregation following exposure to dopamine and other oxidative

stressors. This is an important step in linking alterations in critical protein structure and function to the death of the neuron. New projects in the lab include examining the neuroprotective effect of dietary selenium and the role of mitochon

Dr. Hastings is active in the Center for Neuroscience (CNUP) Graduate Program. This year she served on 14 graduate student committees and was the dissertation advisor for one graduate student. She is the Director and lecturer in Block 1 of the CNUP graduate course Cellular and Molecular Neurobiology. She also lectures in other courses. In addition to training graduate students, Dr. Hastings also mentored of two postdoctoral fellows and one medical student. She is a member of the CNUP Education and Curriculum Committee and serves

egenerative Disease (M. Zigmond, Drector) and "NIH Predoctoral Training in Basic Neu

Neurobiology of Neuro

of the MSTP/CNUP Admissions/Recruitment Committee and a mem Promotions Committee, the Tenure Stream Review Committee andrgh Institute for Neurodegenerative Diseases (PIND). She is also a member of the e NIH Institutional Predoctoral Training Grant.

Milos D. Ikonomovic, MD Associate Professor of Neurology

Over the past academic year, Dr Ikonomovic and his research team have made several major advances in their studies examining the pathobiology of two inter-related neurodegenerative conditions, traumatic brain injury (TBI) and Alzheimer’s disease (AD). Utilizing a controlled cortical impact model of experimental TBI and a mouse model of AD, as well as human brain tissue and spinal fluid samples from severe TBI and AD patients, the laboratory has been examining the relationship between neuronal degeneration and β-amyloid (Aβ) aggregation, which is increased after TBI but is also a major pathogenic factor in AD.

Dr. Ikonomovic is Principal Investigator on a NIH-funded project “TBI, Amyloid

ove functional deficits and histopathologic outcomes after TBI in experimental animals. In collaboration with Dr. Dixon and Dr. Steven DeKosky (Co-I) the team determined that simvastatin, administered at a clinically relevant time delay (3 hr) after TBI, significantly blunted post-injury Aβ increases, while concomitantly reducing hippocampal tissue damage and microglial activation, and improving behavioral outcome in mice. This provides support for the use of statins in human TBI and indicates that such therapy may, by reducing post-injury Aβ load, reduce the risk of developing AD later in life. The study was presented at the National Neurotrauma Conference in July 2008, and is currently in press in the Annals of Neurology.

Metabolism and Statin Therapy” (PO1 “Emerging Therapeutics for TBI: Acute to Chronic Changes”, NS30318, E. Dixon, PI), investigating the effects of statins and caspase inhibitors on changes in Aβ peptide levels and associated toxic-metabolic cascades, and whether such interventions can impr

50

Another ongoing experim es the effects of small molecule anti-amyloid agents and immunotherapies on amy protein (APP) transgenic mice. Dr. Ikonomovic is Principal Investigator wering Small Molecule Aβ-binding agents in AD” (Uhistological and immunoformation of Aβ plaquesbeneficial effects and wil

Dr. Ikonomovic is also Pbehavioral and histologiantagonist) intervention fthat dosages in the rangethis injury model. This st

ewal of the study “Neurobiology of Mild

w se er

ental investigation examinloid levels in brains of Aβ-precursoron a subproject of the NIH-funded study “Amyloid-LoO1 AG028526, W.E. Klunk, PI). Over the past year his laboratory conducted several histochemical studies testing an array of anti-amyloid compounds that may prevent , the hallmark pathology lesions in AD. A number of these compounds have shown l be examined further to develop novel early preventative treatments for AD.

rincipal Investigator on a study funded by Forest Research Institute that examines cal outcomes of memantine (a moderate-affinity uncompetitive glutamate receptor ollowing controlled cortical injury in rats. The results of these experiments indicated of 5-10 mg/kg were most effective in countering the histological deficits induced by udy has been extended to examine the effect of this “optimal” dose of memantine on

rats’ behavioral recovery after brain trauma; this will provide the necessary framework for future clinical trials using memantine in human TBI.

Dr. Ikonomovic is Co-Principal Investigator on a NIH-funded renCognitive Impairment” (AG014449; S. DeKosky, PI). This proposal seeks to examine alterations in synapse number, Aβ metabolism, and cholinergic enzymes in a clinically well-characterized population of Catholic nuns with mild cognitive impairment, normal aging, and AD. Correlative analyses across multiple brain regions in these subjects showed that in-vitro radiometric binding of Pittsburgh Compound-B (PiB) correlated directly with Aβ concentration, and inversely with MMSE (global cognitive) scores. Thus, PiB binding reflects accurately the progressive increase in Aβ concentration during the transition from NCI to MCI to mild-moderate Alzheimer’s disease. Furthermore, anti-amyloid therapies may prevent or delay cognitive decline in AD. The results of this study were presented at the Society for Neuroscience conference in November 2008.

During the next academic year, Dr. Ikonomovic will continue with work on his current studies and several neresearch investigations. He continues to train students in his laboratory and to organize the Alzheimer’s diseajournal club. He serves as an associate editor for Cardiovascular Psychiatry and Neurology and as a reviewfor the Alzheimer’s Association.

Rehana Leak, PhD Research Assistant Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases

Dr. Leak’s research focuses on the role of minor stressors in eliciting defensive adaptations. Working with MN9D and PC12 dopaminergic cells, she has shown that mild levels of oxidative stress from 6-hydroxydopamine or stress from the widely used proteasome inhibitor MG132 protect against subsequent higher levels of injury from a number of toxins. She has also studied this phenomenon in vivo in rodent models of Parkinson’s disease with a grant from the American Parkinson’s Disease Association and has expanded her work to primary cultures of cortex and midbrain. Her goals are to study endogenous adaptations to stress as a function of brain region and to characterize the impact of aging on this process. It is possible that the reason

neurodegenerative diseases are so protracted in their course is due, among other variables, to successful adaptations against cellular stress, an ability that might be lost with advancing age.

With Dr. Michael Zigmond and Dr. Judy Cameron at the Primate Center of University of Pittsburgh Dr. Leak is working on an aged primate model of Parkinson’s disease, where treadmill exercise is used in the hope of ameliorating toxicity from mitochondrial dysfunction in order to understand underlying protective mechanisms in a nervous system closer to that of humans.

51

Anthony K.F. Liou, PhD Research Assistant Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases Dr. Liou is currently continuing his research focus on using molecular and cell biology methods to identify key proteins that participated in the cell death process in response to toxins such as H2O2, MPTP and 6-OHDA in neuronal cells and

. His goal for the next academic year is to develop reagents (from small

subsequently examine the extent of protection by regulating these proteins in rodent Parkinson’s disease models. To date, neurotrophic factors, such as GDNF have been shown to confer protection against cell death induced by the aforementioned toxins in neuronal cells as well as ameliorate clinical symptoms of Parkinson’s disease in patient. Therefore, elucidating the protective mechanism utilize by these factors to overcome neurodegeneration is an alternative approach to identify suitable

therapeutic candidates for this disease. Thus far, a couple of proteins have been identified that play a pivotal role in the degeneration processproteins to peptide mimetic) to neutralize the pro-death impact from these key proteins in neuronal cells and rodents.

In addition, Dr. Liou has initiated the project on functional characterization of the gene Leucine-rich repeat kinase 2 (LRRK2). LRRK2 is a gene that causes clinical symptoms identical to Parkinson’s disease when mutated in specific locations. During the past academic year, he has observed that two LRRK2 mutations, Y1699C and G2019S, unlike LRRK2 wild-type gene product, are unable to activate the ERK pathway to attenuate cell death induced by oxidative stress in neuronal cells. Further functional characterization will be continued in the next academic year.

Ruth G. Perez, PhD Assistant Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases

The Perez laboratory’s research focuses on identifying novel targets for therapeutic ce the normal function of neurons that are most at risk for

) and related disorders. To this end the normal function of α-s. Using cellular models and

omany enzymes, includintransgenic mouse modelphosphorylation state andphysiological role for α-

s as a model for the impact

impact aging are disease pathogenesis. All of these projects hold promise for elucidating discoveries for optimizing health and preventing disease onset or progression.

intervention to enhanneurodegeneration in Parkinson’s disease (PDsome of the PD-related work focuses on elucidatingsynuclein (α-syn) with regard to dopamine (DA) neuronbiochemical assays she and her colleagues discovered that α-syn inhibits both the phosphorylation-state and activity of two key enzymes in DA synthesis: the rate limiting enzyme, tyrosine hydroxylase (TH), and the next enzyme in the pathway, the aromatic amino acid decarboxylase (AADC). This inhibition by α-syn occurs by m the laboratory, that α-syn activates the phosphatase PP2A, which dephosphorylates g TH and AADC in the cells under study. The newest findings, using multiple s, demonstrate that α-syn overexpression, or knockdown, dramatically shifts the /or activity of TH and also affects PP2A activity in vivo. These findings support a

syn as a normal inhibitor of TH by activation of PP2A in dopaminergic cells. New studies are exploring the impact of increasing α-syn expression by viral transduction in mice in order to measure the impact of soluble or aggregated α-syn on the regulation of DA synthesi

another major finding fr

of Lewy body formation on DA homeostasis. Another project is exploring the role of the α-syn-homologous-chaperone-protein, 14-3-3, in the co-regulation of DA synthesis by siRNA methodologies both in vitro and in vivo. Another project is using proteomics to identify α-syn interacting proteins that contribute to the regulation of DA synthesis in the brain. New collaborations are looking at the function of α-syn and 14-3-3 outside the nervous system and how that may

52

Amanda D. Smith, PhD Research Assistant Professor of Neurology

Pittsburgh Institute for Neurodegenerative Diseases

Dr. Smith has continued to investigate how experience may alter the vulnerability of dopamine neurons in the substantia nigra to toxic insult and the mechanisms therein. This work has been extended to investigating the use of running as a therapeutic intervention for the DA deficiency produced by intracerebral infusion of 6-hydroxydopamine (6-OHDA) in a rat model of Parkinson’s disease and the role that insulin like growth factor-1 (IGF-1) and stress hormones play in this neuroprotection. The group has observed that 7 days of voluntary running results in an increase in 2 pro-survival kinases, phospho-ERK1/2 and phospho-Akt, in the striatum that correlates with an attenuation of the loss of tyrosine hydroxylase in the striatum.

Exercise increases the levels of several trophic factors. One trophic factor that is increased in the periphery that crosses the blood brain barrier and gains access to the central nervous system is IGF-1. It has been shown that a single bolus infusion of IGF-1 into the striatum 6 hrs prior to infusion of 6-OHDA into the same striatal region, reduces the extent of the damage by 70%. Further, intrastriatal infusion of IGF-1 increases the activation of ERK1/2, Akt and its downstream targets. The potential role of IGF-1 in exercise induced

eurology

protection against 6-OHDA toxicity and the relation between kinase activation and IGF-1 and exercise induced protection against oxidative stress are currently underway.

Over the course of the next year, Dr. Smith will continue to investigate how experience alters the vulnerability of the nigrostriatal pathway to toxic insult. She has begun examining age as a variable in the toxic effects of dopaminergic neurotoxin and whether the neuroprotective effects of therapy are attenuated with advanced age.

Olga Vergun, PhD Research Assistant Professor of NPittsburgh Institute for Neurodegenerative Diseases

Dr. Vergun’s interest is in role of mitochondria in neuronal pathology. One of her projects focuses on the mechanisms of mitochondrial degradation in neurons and its consequences for neuronal survival. The goal for the next academic year is to determine whether neuronal mitophagy selectively removes damaged mitochondria and whether failure of specific mitochondrial functions initiates mitochondrial degradation. This exploratory project has been supported by the UPMC Health System Competitive Medical Research Fund.

Michael J. Zigmond, PhD Professor of Neurology Pittsburgh Institute for Neurodegenerative Diseases

Over the past year (2008-2009), Dr. Zigmond and his research team have continued their studies of cellular and animal models to examine Parkinson's disease (PD). A major focus of the lab is the role of intracellular signaling cascades in determining the viability of dopamine neurons, whose loss is associated with the motor symptoms of PD. They hypothesize, for example, that trophic factors (e.g., GDNF and BDNF) and moderate levels of cellular stress can both stimulate pro-survival intracellular survival cascades, including those involving the MAP kinases ERK1/2 and Akt. They further believe that endogenous trophic factor expression can be enhanced by exercise, which in turn can reduce the functional deficits normally caused by

53

exposure to toxins such a TP, or pesticides, that otherwise attack dopamine neurons. This reduction in deficit trophic factor effects, including protection of the dopamin

The Zigmond lab is alsosubsequent cellular stresshave found in preliminaryand restraint stress – maksubtoxic concentration ofunction) greatly reduced

In the coming year, Dr. Ziand exercise-induced alte

s 6-hydroxydopamine, MPs may result from one or more of a variety of e neurons themselves.

interested in the impact of stressors on the vulnerability of dopamine neurons to . These studies have involved both in vivo and in vitro models. For example, they studies that several stressors – including maternal separation, traumatic brain injury, e animals more vulnerable to 6-hydroxydopamine. On the other hand, exposure to a f 6-hydroxydopamine, methamphetamine, or MG132 (an inhibitor of proteasomal the vulnerability of dopaminergic cells to a subsequent challenge.

gmond and his team will continue to focus on the mechanisms underlying the stress- ration in the vulnerability of dopamine neurons to stress. For example, studies are

underway to determine if conditional knockouts of a specific trophic factor receptor or inhibition of kinase activation will block neuroprotection seen with exercise or GDNF or increase the toxic effects of oxidative stress. Results from these and related studies should provide insights into new treatment modalities for PD.

Vascular Neurology Division

Max Hammer, MD Assistant Professor of Neurology

Dr. Hammer joined the Neurology faculty in 2003. He is Board certified in Neurology as well as in Vascular Neurology. His interests are in both clinical practice and clinical research. He balances outpatient clinics with frequent hospital

rvice. In addition to teaching medical students, residents, and e hospital neurologists, emergency

vneurosonology rotation fo

Dr. Hammer’s research ipreparing a research prot ed effects of hypothermia and intra-arterial therapy for acute stroke. It is hoped that this pilot study will lead to Phase 2 and 3 studies in the future, and ultimately receive NIH support. In addition, Dr. Hammer is continuing research in vascular dementia, a field in which he does int colleagues in Psychiatry and Neuropsychology.

Dr. Hammer organized th nual Stroke Update conferences at UPMC and is working to create two new regiona ics pertaining to stroke care; the second will focus on str

duty on the Stroke Sefellows, he lectures frequently to outsidphysicians, and EMS personnel.

Dr. Hammer is the new Director of Stroke services at UPMC Mercy hospital. There, he is building an inpatient and outpatient stroke practice, as well as a neurovascular ultrasound lab, and a center for vascular dementia research and treatment. Also, he e neurocritical care rotation for neurology residents, and is developing a new elective r neurology residents.

nterests lie predominantly in acute stroke, but partially in vascular dementia. He is ocol, the first of its kind, to study the combin

has created a new electi

erdepartmental research with

e 2007, 2008, and 2009 anl conferences as well. The first will focus on medical eth

oke center organization.

54

Tudor Jovin, MD Assistant Professor of Neurology and Neurosurgery Director, Neuroendovascular Fellowship Program

Tudor G. Jovin, M.D. is the UPMC Neuroendovascular Fellowship Program Director and co-director of the UPMC Center for Neuroendovascular Therapy. In addition to his clinical responsibilities as a vascular neurologist at Presbyterian University Hospital, Dr. Jovin has significantly contributed to the growth of the interventional neuroradiology service, especially in the area of ischemic stroke-related procedures such as extracranial carotid stenting, extracranial vertebral stenting, intracranial

Dr. Jovin has earned numerous awards cluding the William Oldendorf Award of the American Society of Neuroimag ng the ischemic core and penumbra in acute stroke assessed with hnology. His pioneering work describing high recanalization

e artery occlusion resulted in the “Best Scientific Paper Award” from the S l Neurology in early 2007.

Dr Jovin serves on the exSection as the project woof Vascular and Interventof the American Society

stenting and acute stroke intervention.

As one of the first neurointerventionalists in the country with neurology background training, Dr Jovin has shown strong commitment to the advancement of this field by training several other neurologists and neurosurgeons in neurointerventional procedures. Dr. Jovin’s research in the area of stroke-related interventions has resulted in over 50 published articles.

and honors during his career, ining for innovative work describi

the Xenon-CT-CBF tecrapy of acute stroke due to carotid ociety of Vascular and Interventiona

rates in endovascular th

ecutive committee of the American Academy of Neurology, Interventional Neurology rk group leader for practice related issues, is a founding board member of the Society ional Neurology, where he also serves as the Secretary and is a Member of the Board of Neuroimaging.

Vivek K. Reddy, MD Assistant Professor of Neurology Medical Director, Hospital Information Technology, UPMC

Dr. Reddy is involved in a variety of clinical and educational activities as part of the department of neurology. His clinical work involves outpatient services, focusing on the continuing care and evaluation of patients with cerebrovascular disease. He also

ords to improve quality of care. He has been involved in several implementations of electronic medical records across the system.

Dr. Reddy provides educational supervision to residents and medical students and gives several lectures to medical students and residents during the academic year. He also participates as a facilitator and presenter in the school of medicine’s annual course, The Basic Science of Care.

is very involved in the inpatient clinical stroke service, focusing on standardization of clinical practice and approach to stroke care. He has been very involved in the creation and enhancement of stroke order sets and protocols at UPMC Presbyterian and UPMC Shadyside, which have served as the basis of order sets for other UPMC hospitals.

In addition to his clinical work, Dr. Reddy is the Medical Director for Hospital Information Technology for UPMC. His role extends across all the UPMC facilities and involves guiding the direction, improving utilization of electronic medical rec

55

Ken Uchino, MD Assistant Professor of Neurology Director, Vascular Neurology Fellowship Program

Dr. Uchino continues to do research in acute stroke treatment, particularly the quality of acute stroke care and treatment in rural and community hospitals. He is also evaluating the use of telemedicine in improving the quality of care. Dr. Uchino is the principal neurologist for the NIH-funded Quantitative Occlusive Vascular Disease Study, which is investigating the relationship between blood flow and stroke risk among patients with carotid artery occlusion. Dr. Uchino teaches students, residents, and two stroke fellows and is the Director of the Vascular Neurology

logy

fellowship program.

Lawrence R. Wechsler, MD Interim Chair, Department of NeuroProfessor of Neurology and Neurosurgery Division Chief, Stroke and Director, UPMC Stroke Institute

Lawrence Wechsler, M.D., Professor of Neurology and Neurological Surgery at the University of Pittsburgh School of Medicine is director of the University of Pittsburgh Medical Center (UPMC) Stroke Institute and Interim Chair of the

ny clinical trials of treatments for stroke as an investigator or member of the steering committee. Dr. Wechsler holds memberships in several organizations, including the

A troke Association, American Society of Neuroimaging and the American Academy ief of the Journal of Neuroimaging from 1999-2007. He chairs the Stro logy and serves as President of the American Society of Neuroimaging. Dr. Wechsler has authored or co-authored numerous articles related to stroke a

Dr. Wechsler developed Since 2006, Telemedicinacute stroke assessment anon-UPMC facilities now

, MD

Department of Neurology. He also serves as Vice President for Telemedicine in the Physician Services Division and Director of the UPMC Center for Telehealth.

Dr. Wechsler’s interests include acute stroke therapy, imaging and telemedicine. He participates in ma

American Neurological ssociation, American Sof Neurology and was Editor-in-Chke Systems Work Group at the American Academy of Neuro

nd stroke therapy.

and implemented the telemedicine program for acute stroke assessment at UPMC. e has been implemented in all UPMC system hospitals in order to provide access to nd treatment by faculty of the UPMC Stroke Institute. Additionally, several other utilize telemedicine for stroke care.

Syed ZaidiAssistant Professor of Neurology

Dr. Zaidi specializes in Vascular Neurology and works out of UPMC Mercy and Presbyterian Hospitals. As a vascular neurologist Dr. Zaidi provides specialized care to patients presenting to our hospitals with strokes, either due to cerebral ischemia or

lding.

Dr. Zaidi completed his neurology training at the Cleveland Clinic Florida. He subsequently finished fellowship training in vascular neurology at the UPMC

Presbyterian University Hospital. As an Assistant Professor in Neurology, Dr Zaidi is actively involved in several stroke trials. He is involved in training fellows, residents and medical students.

hemorrhage. As part of UPMC Stroke Institute, Dr. Zaidi evaluates and manages acute stroke patients via the Telemedicine network which currently is connected to multiple facilities in western Pennsylvania and Maryland. He also has regular outpatient clinic at the Mercy Professional Bui

56

Study Sections and Advisory Committee Memberships

Sarah B. Berman, MD, PhD

Study Sections Ad Hoc Reviewer:

Sheffield Hospitals Charitable Trust, Sheffield, UK Pittsburgh Institute for Neurodegenerative Diseases, Pilot Project Grants Scientific Advisory Board, Parkinson Foundation Greater Pittsburgh Chapter

Advisory Committees Member, Board of Directors, National Parkinson Foundation Greater Pittsburgh Chapter Member, Scientific Advisory Board, National Parkinson Foundation Greater Pittsburgh Chapter Member, Steering Committee, Physician Scientist Training Program, University of Pittsburgh School of

Medicine

Guodong Cao, PhD

Study Sections NIH Emphasis Panel/Scientific Review Group ZRG1 BDCN-T (58) 2009

Jun Chen, MD

Study Sections Member, NIH NOMD Study Section Chair, Brain Review Committee 2, American Heart Association Ad hoc, NIH/NINDS Special Review Panel for Program Project Grants, 2007- Ad hoc, NIH/NINDS NRSA Fellowship Review Committee, 2007- Ad hoc, NIH/NINDS Special Review Panel for the Loan Repayment Program, 2007 – Ad hoc, VA Merit Review, 2005-

Advisory Committees Board of Directors, International Society of Cerebral Blood Flow and Metabolism Chair, International Society of Cerebral Blood Flow and Metabolism Membership Committee Member, International Society of Cerebral Blood Flow and Metabolism Finance Committee University of Pittsburgh Department of Neurology, Recruitment Committee Counsel Member, Chinese Natural Science Foundation

Paula R. Clemens, MD

Study Sections NINDS R13 Review, 3/29/09 NIAMS ARRA Review, 6/24/09

Advisory Committees Member, Scientific Advisory Committee, NIH-sponsored National Registry for Myotonic Dystrophy

and Facioscapulohumeral Muscular Dystrophy Patients and Family Members Chair, Scientific Advisory Committee for Paul D. Wellstone Muscular Dystrophy Cooperative

Research Center (MDCRC), University of Rochester, Rochester, NY Chair (6/2008 – 6/2010) Member (6/2006 – 6/2008) Musculo-Skeletal Disorders Therapy Committee American Society of Gene and Cell Therapy Member, Nominating Committee American Society of Gene Therapy, 2008-2009 Chair, Diagnostics Panel for DMD Care Considerations Centers for Disease Control and Prevention (CDC)

57

Chair, Publications Committee and member of Leadership Team Cooperative International Neuromuscular Research Group (CINRG) t Member, Executive Committee Cooperative International Neuromuscular Research Group (CINRG) Member, MDA/Insmed Steering Committee University of Pittsburgh School of Medicine

Member, Neurology Residency Task Force, University of Pittsburgh Member, Biochemistry and Molecular Genetics Graduate Training Program Member, Health Sciences Research Advisory Committee, University of Pittsburgh Member, Executive Committee, Department of Neurology Member, Neurology Faculty Promotions Committee, University of Pittsburgh Member, MD/PhD Student Advisory Committee, University of Pittsburgh Member, Neurology Faculty Recruitment Committee, University of Pittsburgh Member, Committee for Tenured Faculty Promotions and Appointments (TFPA) Member, Neurology Chair Search Committee Co-Chair, Neurology Grand Rounds Committee

Miguel Estevez, MD, PhD

Study Section, Advisory Committee Chair, Veterans Administration Research Biosafety Committee

Kathy Gardner, MD

Advisory Committees American Academy of Neurology Education Committee Advocacy for American Academy of Neurology-Congressional Legislators Advocacy Training with American Academy of Neurology Children’s Hospital of Pittsburgh

Co-Director, Neurofibromatosis Clinic Adult Neurologist for the Tuberous Sclerosis Clinic

Pittsburgh Advisor and board member, local Neurofibromatosis Clinics Association Advocate for local chapter “Emergency USA”

Steven H. Graham, MD, PhD

Study Sections Brain Review Committee, American Heart Association NINDS Board of Scientific Counselors, Division of Intramural Research, Ad hoc reviewer

Advisory Committees University of Pittsburgh School of Medicine

Ad hoc Interviewer for Resident, Fellow, and Faculty Recruits Chair, Promotions Committee, Department of Neurology Member, Executive Committee, Neurology Department

Department of Veterans Affairs Member, Department of Veterans Affairs, Office of Research and Development, Merit Review

Council Member, VA VISN 4 Research Roundtable Member, VA VISN 4 Academic Affairs Committee Member, VA Pittsburgh Healthcare System, Medical Executive Board

58

J. Timothy Greenamyre, MD, PhD

Study Sections Parkinson’s Disease Society, London, UK Ad Hoc Member, ZRG1 MDCN-A, Challenge grants panel Ad Hoc member, ZNS1 SRB-E (31), NINDS PPG Review Panel

Advisory Boards National Advisory Boards

Member, Scientific Advisory Board, Parkinson’s Action Network Member, Scientific Advisory Board, Parkinson’s Disease Foundation Member, Advisory Board, C. Mondino Institute of Neurology, Pavia, Italy Member, Scientific Advisory Board, Michael J. Fox Foundation Member, Board of Directors, Winter Conference on Brain Research Member, Neuroscience Discovery Scientific Advisory Board, Wyeth Research

University of Pittsburgh School of Medicine AOC Committee University of Pittsburgh Conflict of Interest and Entrepreneurial Oversight Committees School of Medicine MSTP Steering Committee Department of Neurology, Executive Committee Department of Neurology, Promotions Committee Search Committee, Psychiatry Chair, University of Pittsburgh School of Medicine Search Committee, Radiology Chair, University of Pittsburgh School of Medicine

Max Hammer, MD

Advisory Committees Member, Department of Neurology Residency Task Force Committee Neurology Member, Residency Program Interview Committee, Department of Neurology Member, Stroke Fellowship Program Interview Committee, Department of Neurology Member, Professional Practice Executive Committee at UPMC Mercy Member, Risk Management Review Committee, Department of Neurology Member, Incentive Plan Committee, Department of Neurology Director of Stroke Services, UPMC Mercy Hospital

Teresa Hastings, PhD

Study Section NIH, ZRG1 MDCN-A(58)R, May 2009

Advisory Committees University of Pittsburgh:

Chair, MSTP/CNUP Admissions/Recruitment Committee Member, CNUP Curriculum & Education Program Committee Member, Department of Neurology Promotions Committee Member, Department of Neurology Tenure Stream Review Committee Member, Steering Committee, NIH/NIMH Institutional Predoctoral Training Grant Member, Executive Committee for PIND

59

Rock Heyman, MD

Advisory Committees National Committees

National Multiple Sclerosis Society Council of Clinical Advisory Chairmen, Chairman Medical Advisory Board, Executive Committee Task Force Regarding the Relationship between the Society and the Pharmaceutical Industry Task Force Regarding Comprehensive Care Center Affiliations

Consortium of Multiple Sclerosis Centers Board of Trustees Chairman, Education Committee

Regional Committees National Multiple Sclerosis Society

Allegheny District Chapter Board of Trustees Chairman, Regional Clinical Advisory Committee Regional Research Advocate

University and School of Medicine Committees UPMC Committees

Member, Epicare Physician Advisory Board Director, Multiple Sclerosis Center

University of Pittsburgh School of Medicine Member, Executive Committee, Neurology Department Chief, Division of Neuroimmunology

Samay Jain, MD

Advisory Committees National Organizations

Member, Parkinson Study Group, Other Non-motor Features Working Group Member, Cardiovascular Health Study Neurology Working Group

University of Pittsburgh Physicians Member, Department of Neurology, Planning Committee of CME

University of Pittsburgh School of Medicine Ad hoc Interviewer for Resident and Faculty Recruits UPMC Institutional Review Board

Robert Kaniecki, MD

Study Sections American Academy of Neurology, Head and Facial Pain Section American Headache Society, Refractory Headache Section

Advisory Committees Member, International Advisory Board, Primary Care Network Chairman, Department of Neurology Scientific Review Committee Member, Executive Committee, Department of Neurology Member, Department of Neurology Residency Selection Committee Member, Department of Neurology Residency Task Force

David Lacomis, MD

Advisory Committees National Advisory Boards

Member, Scientific Advisory Board, Myasthenia Gravis Foundation of America

60

International Myositis Assessment and Clinical Studies Group (IMACS) Member, North East Amyotrophic Lateral Sclerosis Consortium (NEALS) Member, The Neuropathy Association, Medical Advisory Committee Member, American ALS Research Group Member, Examination Committee for Clinical Neuromuscular Pathology, United Council for Neurologic Subspecialties

University of Pittsburgh Physicians Member, Epicare Oversight Committee, Neurology Department

University of Pittsburgh School of Medicine Member, Neuroscience Course Committee Member, Executive Committee, Neurology Department Director, Clinical Neurophysiology Fellowship Training Program Member, Promotions Committee, Neurology Department

Frank Lieberman, MD

Study Sections FDA Orphan Drugs Grant Program (2009)

Advisory Committees FDA Orphan Drugs Grant Program: 2009 study section RTOG CNS Tumor Committee American Brain Tumor Consortium

Steering Committee New Drugs Committee Conflict of Interest Committee Translational Imaging Committee

Chordoma Foundation: Advisory Committee.

Oscar Lopez, MD

Study sections NIH, Aging Systems and Geriatrics Study Section (ASG). (Permanent member since 2008) NIH, Neurological, Aging, and Musculoskeletal Epidemiology (NAME) NIH, Special Emphasis Panel (3 panels)

Advisory Committees Lewy Body Dementia Association, Scientific Advisory Committee Think-Tank on EU-US Collaborative Research on Prevention of Dementia. Under the auspices of Pascual Maragall Foundation, Alzheimer International, and Ruvo’s Institute, Barcelona, Spain Prevalence and Trends of AD and Other Age-Related Cognitive Impairment in the United States Discussion Panel. Under the auspices of the Alzheimer’s Association and the National Institute on Aging

Galen Mitchell, MD

Advisory Committees Director of Medical Student Education, Department of Neurology, University of Pittsburgh School of

Medicine Co-Chair, Neuroscience Clerkship Design Committee, UPSOM Member, Retention Committee, UPSOM Member, Student Promotions Committee, UPSOM Member, Clinical Procedures Course Design Group, UPSOM Member, Department of Neurology Education Committee, current Member, Curriculum Committee, UPMC

61

Robert Y. Moore, MD, PhD

Advisory Committee Member, Presidential Committee on the National Medal of Science

Ruth Perez, PhD

Study Sections National Institutes of Health

Clinical Neuroplasticity and Neurotransmitters Study Section, ad hoc member Cell Death in Neurodegeneration, ad hoc member Conflict of Interest SEP for Program Project Grants National Science Foundation MCB Peer Review

Grant Reviews Istituto Pasteur-Fondazione Cenci, Sapienza-Università di Roma Alzheimer Association Research into Ageing, London, UK NHMRC, Australia

Chitharanjan V. Rao, MBBS, MRCP (UK), DM

Advisory Committees Ad hoc Interviewer for Resident recruits, University of Pittsburgh School of Medicine Member, Residency Task Force Committee, UPSOM Neurology Department

Judith Saxton, PhD

Advisory Committees Affiliate Member, Center for Research in Chronic Disorders, School of Nursing, (J. Dunbar-Jacob, R.N.,

PhD (P.I.) Consultant, Geropsychology Post-Doctoral Fellowship Program, VMAC Highland Drive, (Director of

Training: Dr. B. Lauber) Member, Advisory Board, Pittsburgh Geriatric Research Education and Clinical Center, (GRECC),

Pittsburgh VA Healthcare System. Reviewer, Western Psychiatric Institute and Clinic Research Review Committee

Michael Soso, MD, PhD

Advisory Committee Member, University of Pittsburgh Institutional Review Board

Ken Uchino, MD

Advisory Committees Steering Committee Member, National Quality Forum, National Voluntary Consensus Standards for

Prevention and Management of Stroke Member, University of Pittsburgh Institutional Review Board Member, University of Pittsburgh Graduate Medical Education Committee

Anne Van Cott, MD

Advisory Committees Member and Grant Reviewer, Epilepsy Foundation of America (EFA) Seizures and Seniors Initiative

Research Workgroup Committee Member, Treatment in Geriatric Epilepsy Research (TIGER) VA Project

62

Committee Member, VA Epilepsy Consortium Professional Advisory Board of the Epilepsy Foundation of Western/Central PA, Member

Lawrence Wechsler, MD

Advisory Committees National

Member, ASA Leadership Committee Chair, AAN Stroke Systems Task Force Member, AAN Practice Committee Chair, ASN Guidelines Committee Member, ASN Board of Directors Chair, ASN Program Committee Member, ASN Certification Committee DIAS Study--DMC Steering Committee, CLOSURE Trial, ACT I, CARNEROS I

University of Pittsburgh Member, CRCS Committee Member, Department of Neurology Executive Committee Member, Department of Neurology Promotions Committee

University of Pittsburgh Physicians Member, UPP Clinical Operations Committee

Michael J. Zigmond, PhD

Study Sections NIH BPNS Scientific Review Group, ZRG1 F0-1W (June 2009)

Advisory Committees National Advisory Boards:

Chair, Scientific Advisory Board, UCLA Center for Gene-Environment Studies in Parkinson Disease (Marie-Francoise Chesselet, PI)

Chair, Program Advisory Committee, NINDS Specialized Neuroscience Research Program, Univ Central del Caribe, San Juan, PR

Consultant NIH Predoctoral Training Grant in Neuroscience at University of Texas, San Antonio (David Morilak, Program Director)

Chair, Scientific Advisory Board, UCLA Center of Excellence in Parkinson’s Disease Research (Marie-Francoise Chesselet, PI)

Scientific Advisory Board, The Michael J. Fox Foundation for Parkinson’s Research Chair, Scientific Advisory Board, Columbia University Udall Center Research Program on

Parkinson's disease: pathogenesis of dopamine neuron death (Robert Burke, PI) Internal Advisory Committee, Alzheimer Disease Research Center, Univ. Pittsburgh Secretary, American Association for the Advancement of Science, Neuroscience Section

University of Pittsburgh School of Medicine Mentor, Scholarly Project, University of Pittsburgh, School of Medicine Member, Scientific Laboratory Management Course Planning Committee, University of Pittsburgh

Schools of Health Sciences Member, MD/PhD Advisory Committee Member, Training Grant Directors Committee

Saša Živković, MD

Advisory Committees Member, R&D Committee, VA Pittsburgh HCS

63

64

Research Grants, Funding, and Collaborations

Research Grants and Contract Activity

Federal Grants: Public Health Service Program Project Grants

PI Agency Name Grant Title Annual

DC Annual

IDC Clemens P National Institutes of

Health / NINDS NF-KB inhibition therapy for Duchenne muscular dystrophy

$48,422 $23,484

Graham SH National Institutes of

Health / NINDS Molecular mechanisms in traumatic brain Injury: Bench to Bedside

$97,964 $47,513

Ikonomovic M National Institutes of

Health / NINDS Molecular Mechanisms in Traumatic Brain Injury: Bench to Bedside

$97,964 $47,513

National Institutes of Health / NIA

Amyloid-lowering small molecule AB-binding agents in AD

$79,338 $38,478

National Institutes of Health / NIA

Synaptic & Cholinergic Alterations in Mild Cognitive Impairment

$240,367 $49,117

Lopez O National Institutes of

Health / NCCAM Ginkgo Biloba Prevention Trial in Older Individuals

$2,435,725 $512,742

National Institutes of Health / NIA

Alzheimer’s Disease Research Center $1,481,628 $607,923

National Institutes of Health / NIA

Alzheimer's Disease Neuroimaging Initiative

$18,111 $4,528

National Institutes of Health / NIA

Effects of docosahexaenoic acid (DHA) in slowing the progression of AD

$12,702 $3,176

National Institutes of Health / NIA

ADNI Supplement $6,500 $1,625

National Institutes of Health / NIA

NACC Minimum Data Set MDS Project $19,076 $9,824

National Institutes of Health / NHLBI

CHS Events Follow-up Study $13,719 $6,654

Moore RY National Institutes of

Health / NINDS 2CARE Study $7,710 $3,740

Uchino K National Institutes of

Health / NINDS Carotid occlusion surgery study (COSS) $20,507 $3,502

Wechsler L National Institutes of

Health / NINDS Albumin in Acute Stroke Study (ALIAS) $2,000 $970

National Institutes of Health / NINDS

Interventional Management of Stroke Study (IMS III)

$45,147 $21,896

Zigmond M National Institutes of

Health / NINDS Neuroprotection and Early Detection in PD

$45,909 $22,266

National Institutes of Health / NINDS

Survival skills and ethics workshops for neuroscientists

$4,679 $0

Program Project Grants Totals $4,677,468 $1,404,951

66

Federal Grants: Public Health Service Training Grants Zigmond M National Institutes of

Health / NIMH Training in Neurobiology of Psychiatric Disorders

$142,818 $11,425

National Institutes of Health / NINDS

Training in Neurobiology of Neurodegenerative Disease

$188,164 $15,053

Training Grants Totals $330,982 $26,478

Federal Grants: Public Health Service Grants Bagic A National Institutes of

Health / NINDS A cerebral functional unit model for multimodal imaging of neurovascular coupling

$21,301 $10,970

Berman National Institutes of

Health / NINDS Mitochondrial dynamics in neurodegeneration

$152,736 $12,218

Burton EA National Institutes of

Health A zebrafish model of multiple system atrophy

$111,935 $54,289

Cao G National Institutes of

Health / NINDS A novel modified erythropoietin for the treatment of ischemic brain injury

$150,000 $67,594

Chen J National Institutes of

Health / NINDS Neuroprotective effect of HSP27 in cerebral ischemia

$196,628 $93,618

National Institutes of Health / NIA

Regulation of autophagy in dopaminergic cell death

$13,500 $6,547

National Institutes of Health / NINDS

Inducible DNA repair in cerebral ischemia $177,188 $91,252

National Institutes of Health / NINDS

NA+-K+-CI-contransporter in cerebral ischemia

$22,875 $11,781

Clemens P National Institutes of

Health / NIAMS Analysis and modulation of immunity in gene therapy

$163,543 $56,315

Eghtesad S National Institutes of

Health / NINDS Inducing tolerance to gene transfer in dystrophic mice

$41,176 $0

Graham SH National Institutes of

Health / NINDS The role of 20 HETE in the pathogenesis of stroke

$13,907 $6,745

National Institutes of Health / NINDS

Cyclooxygenase 2 and ischemic neuronal injury

$250,000 $128,750

National Institutes of Health / NICHD

COX2-derived cyclopoentenone pro-staglandins exacerbate hypoxic ischemic brain injury by inhibiting protein disulfide isomerase and worsening endoplasmic reticulum stress

$46,895 $25,159

Greenamyre TJ National Institutes of

Health / NIA Dopamine tyrosine and their metabolites in aging and neurodegenerative disease

$7,019 $562

National Institutes of Health / NIA

Brain anatomical correlates of mobility control in the oldest old

$11,698 $5,674

67

Hammer M National Institutes of Health / NIMH

Maintenance therapies in late life depression III

$26,741 $12,969

Heyman R National Institutes of

Health / NINDS In vitro proton MRS studies: cerebral injury in HIV infection

$1,596 $774

Hinkle D National Institutes of

Health / NINDS The potential role of DJ-1 in astrocyte-mediated neuroprotection

$155,734 $12,459

Lacomis D National Institutes of

Health / NIAMS Rituximb therapy in refractory adult and juvenile IIM

$5,667 $2,748

Lopez O National Institutes of

Health / NIA In vivo PIB & PET amyloid imaging: normals, MCI & dementia

$64,620 $31,341

National Institutes of Health / NIMH

Pathways linking late-life depression to MCI & dementia

$13,469 $6,532

National Institutes of Health / NIA

Predictors of Alzheimer’s Disease in Mild Cognitive Impairment

$278,138 $135,944

National Institutes of Health / NICHD

Donepezil to promote functional recovery after stroke in cognitively impaired elderly people

$6,804 $3,504

National Institutes of Health / NIA

A multicenter trial to determine whether natural huperzine A improves cognitive function

$563 $141

Mastroberardino P

National Institutes of Health / NIEHS

Oxidative modification of brain proteins in pesticide intoxication

$83,333 $6,667

Saxton J National Institutes of

Health / NIA Amyloid pathology and cognition in normal elderly

$14,305 $6,938

National Institutes of Health / NIA

Cognitive assessment of elderly primary care patients

$348,999 $169,265

National Institutes of Health / NIA

Mild cognitive impairment: a prospective community study

$12,561 $6,092

Smith A National Institutes of

Health / NINDS Endogenous neuroprotective agents in Parkinson disease

$134,793 $10,783

Snitz B National Institutes of

Health / NINDS Imaging amyloid pathology and its functional sequelae

$1,668 $809

Uchino K National Institutes of

Health / NINDS Quantitative occlusive vascular disease study (QUOVADIS)

$84,033 $40,756

National Institutes of Health / NINDS

Randomized evaluation of carotid occlusion and neurocognition (RECON)

$311 $62

National Institutes of Health / NINDS

Insulin resistance intervention after stroke (IRIS)

$7,130 $3,458

Vosler P National Institutes of

Health / NINDS EIF4G cleavage and persistent protein synthesis inhibition following ischemia

$44,536 $0

68

Wechsler L National Institutes of Health / NINDS

Carotid revascularization endarterectomy vs. stent trial (CREST)

$25,282 $6,068

Wolk D National Institutes of

Health / NIA Recollection and familiarity in amnestic-mild cognitive impairment

$141,875 $11,350

Zigmond M National Institutes of

Health / FIC Developmental stress, exercise and vulnerability to neuronal injury

$177,786 $22,214

Zivkovic S National Institutes of

Health / NIA Peripheral nerve decline in an aged cohort $1,397 $678

Public Health Service Grants Totals $3,011,742 $1,063,026

Other Federal Grants Chen J Department of Defense Scaffolding/neural stem cells-based tissue

engineering in a traumatic brain injury model

$150,000 $73,377

Clemens P Department of Defense Clinical trial of coenzyme Q10 &

prednisone in Duchenne MD $120,904 $30,226

Department of Defense Treatment of muscle wasting -extens $66,666 $33,334 Other Federal Grants Totals $337,570 $136,937

State Grant Saxton J Pennsylvania Department

of Health Detection, Diagnosis and Intervention in Dementia

$359,388 $71,878

State Grant Totals $359,388 $71,878

Veterans Administration Medical Center Grants Chen J Veterans Affairs IPA for A. Signore $66,084 $0 Veterans Affairs IPA for A. Stetler $30,418 $0 Veterans Affairs IPA for F. Zhang $71,210 $0 Veterans Affairs IPA for W. Yin $41,157 $0 Veterans Affairs IPA for S. Wang $21,222 $0 Clemens P Veterans Affairs Service agreement for Mamaary $55,537 $0 Veterans Affairs IPA for Heng Zheng $103,640 $0 Veterans Affairs IPA for Dan Reay $111,212 $0 Estevez M Veterans Affairs IPA FOR Kathleen Morgan $15,662 $0 Graham SH Veterans Affairs IPA for Wenjin Li $39,321 $0 Veterans Affairs IPA for Marie Rose $50,648 $0 VAMC Grants Totals $606,111 $0

69

Society and Foundation Funding

Burton EA Bachman Strauss Dystonia Foundation

A zebrafish model of DYT1 dystonia $50,000 $0

Dystonia Medical Research Foundation

Dopamine neuron development in a novel zebrafish model of DYT1dystonia

$64,348 $0

RiMed Foundation Dr. Chiara Milanese's Foundation Fund $51,500 $24,977 Cannon J American Parkinson

Disease Foundation Genetic and environmental interactions in Parkinson's disease: Potential for new therapeutic pathways

$35,000 $0

Cao G American Heart

Association Erythropoietin fusion protein contain-ing protein transduction domain for the treatment of ischemic brain injuries

$59,091 $5,909

Drolet R American Parkinson

Disease Association Gastrointestinal dysfunction in the rotenone model of Parkinson's disease

$35,000 $0

Greenamyre TJ American Parkinson

Disease Association PET, posturographic and clinical marker of early PD

$125,000 $0

Picower Foundation Pathogenic mechanisms as therapeutic targets in PD

$625,000 $125,000

Michael J. Fox Foundation Characterization of E46K and A53T alpha-synuclein BAC transgenic rats

$87,455 $21,863

Parkinson's Disease Foundation

Modeling gastrointestinal dysfunction in PD

$75,000 $0

RiMed Foundation RIMED Foundation Fellow Award: Roberto DiMaio

$51,500 $24,977

Hinkle D Pittsburgh Foundation Targeting astrocytes for neuroprotective

therapies in stroke: the potential role of DJ-1

$55,857 $0

American Parkinson Disease Association

The potential role of antioxidant systems in the mechanism of DJ-1 dependent astrocyte-mediated neuroprotection

$80,000 $0

Parkinson's Disease Foundation

Potential role of neurotrophic factors in the mechanism of DJ-1 dependent astrocyte-mediated neuroprotection

$50,000 $0

Ikonomovic M Forest Research Institute Effects of memantine on neurologic

outcome in experimental traumatic brain injury

$56,133 $14,033

Jain S National Science

Foundation The dorsomedial striatum, reinforcement and declarative knowledge acquisition

$7,595 $3,911

Lacomis D Myasthenia Gravis

Foundation Development of a protocol for a clinical trial for mycophenolate mofetil in MG and development of MG-specific composite eval

$1,500 $0

ALS Association ALS Biomarkers study $9,665 $0

70

Stetler A American Heart

Association HSP27 exerts anti-apoptotic effects following cerebral ischemia via disruption of ASK1 signaling

$39,000 $0

Vergun O CMRF Degradation of neuronal mitochondria by

autophagy $25,000 $0

Vosler P American Heart

Association Eukaryotic initiation factor 4G cleavage by calpain and persistent protein synthesis inhibition following ischemia

$21,000 $0

Zigmond M Robert Wood Johnson

Foundation Effect of GDF5 on dopamine neurons under basal conditions and in response to cellular stress

$100,000 $25,000

Pittsburgh Foundation Bosin Memorial Funds for PD Research $1,000 $0 Pittsburgh Foundation Bosin Memorial Funds for PD Research $1,500 $0 Society and Foundation Funding $1,707,144 $245,670

Industry Funding Clemens P Genzyme LOTS Study $45,640 $15,972 Genzyme An open-label extension study of patients

with late-onset Pomp disease who were previously enrolled in protocol AGLU 02704

$28,973 $10,141

Genzyme Myozyme temporary access program $28,148 $9,852 Lopez O Elan AD immunotherapy program - 251 open

label $32,147 $9,644

UCAL Double blind placebo-controlled study evaluating efficacy and safety in participants' mild to moderate AD

$17,722 $4,431

Elan Phase 3, multicenter, placebo-controlled efficacy and safety trial of bapineuzamab

$17,928 $5,378

Elan A Phase 3, multicenter, randomized, double-blind, placebo-controlled group, efficacy and safety trial of bapineuzamab

$17,271 $5,181

Moore RY University of Rochester Cooperative Huntington's observational

research trial (COHORT) $16,075 $0

Saxton J ACRIN American College of Radiology Imaging

Network PA4004-imaging (ACRIN) $58,800 $14,700

Eisai Cognitive assessment of elderly primary care patients

$86,757 $13,014

Wechsler L NMT Medical Closure I Study $31,251 $6,249 Industry Funding $380,712 $94,562 Total Direct Costs $11,352,317 Total Indirect Costs $3,028,802

71

Faculty Research Collaborations Sarah Berman, MD, PhD

Yvette Conley University of Pittsburgh School of Nursing Edward Burton, MD, DPhil University of Pittsburgh Department of Neurology J. Marie Hardwick, PhD Johns Hopkins University Bloomberg School of Public Health David Hinkle, MD, PhD University of Pittsburgh Department of Neurology Fernando Pineda, PhD Johns Hopkins University Bloomberg School of Public Health

Edward Burton, MD, DPhil, FRCP

J. T. Greenamyre, MD, PhD University of Pittsburgh Department of Neurology and PIND Neil Hukriede, PhD University of Pittsburgh Department of Molecular Genetics and

Biochemistry Gonzalo Torres, PhD University of Pittsburgh Department of Neurobiology

Guodong Cao, PhD

Gregg Homanics, PhD University of Pittsburgh Department of Anesthesiology and Pharmacology

Terry Hastings, PhD University of Pittsburgh Department of Neurology Charleen T. Chu, MD, PhD University of Pittsburgh Department of Pathology Timothy J. Greenamyre University of Pittsburgh Department of Neurology Valerian Kagan University of Pittsburgh Department of Environmental and Occupational

Health Anthony Kian-Fong Liou University of Pittsburgh Department of Neurology Yanqin Gao Fudan University National Key Laboratory of Medical Neurobiology,

China Yumin Luo Xuewu Hospital Department of Neurosurgery, Beijing

Jun Chen, MD

Steven Graham, MD, PhD University of Pittsburgh Department of Neurology Teresa Hastings, PhD University of Pittsburgh Department of Neurology Michael Zigmond, PhD University of Pittsburgh Department of Neurology Tim Greenamyre, MD, PhD University of Pittsburgh Department of Neurology Charleen Chu, MD, PhD University of Pittsburgh Department of Pathology

Allan Zhao, Ph.D University of Pittsburgh Department of Cell Biology Jian Yu, PhD University of Pittsburgh Department of Pathology Lin Zhang, PhD University of Pittsburgh Department of Pharmacology Tao Cheng, PhD University of Pittsburgh Department of Pharmacology Robert SB. Clark, MD University of Pittsburgh Department of Critical Care Medicine Binfeng Lu, PhD University of Pittsburgh Department of Immunology Xiao Xiao, PhD University of North Carolina School of Pharmacy Guoyoung Yang, MD, PhD University of California-San Francisco Department of Anesthesia Dandan Sun, MD, PhD University of Wisconsin at Madison Department of Neurosurgery Steve Wilson, PhD University of South Carolina Department of Pharmacology, Physiology

and Neuroscience Paula Clemens, MD

Paul Robbins, PhD University of Pittsburgh Department of Microbiology and Molecular Genetics

Hiroyuki Nakai, MD, PhD University of Pittsburgh Department of Microbiology and Molecular Genetics

72

Jon Watchko, MD University of Pittsburgh Department of Pediatrics Laura Niedernhofer, MD, PhD University of Pittsburgh Department of Medicine Johnny Huard, PhD University of Pittsburgh Department of Orthopedics Bing Wang, MD, PhD University of Pittsburgh Department of Orthopedics Hoda Abdel-Hamid, MD University of Pittsburgh Department of Pediatric Neurology Sasa Zivkovic, MD University of Pittsburgh Department of Neurology Denis Guttridge, PhD Ohio State University Department of Molecular Virology, Immunology

& Medical Genetics Xiao Xiao, PhD University of North Carolina, Chapel Hill School of Pharmacy Joe Kornegay DVM, PhD University of North Carolina, Chapel Hill Department of Pathology CINRG investigators Children’s National Medical Center and other institutions

Miguel Estevez, MD

Kathy Gardner, MD University of Pittsburgh Department of Neurology Lewis Jacobson University of Pittsburgh Department of Biological Sciences

Kathy Gardner, MD

Chaouki Khoury MD, University of Oklahoma Health Sciences Headache Clinic James Couch MD PhD University of Oklahoma Health Sciences Headache Clinic

Steven H. Graham, MD, PhD

Jun Chen, MD University of Pittsburgh Department of Neurology Bingren Hu, PhD University of Miami Department of Neurology Patrick Kohanek, MD University of Pittsburgh Department of Critical Care Medicine C. Edward Dixon PhD University of Pittsburgh Department of Neurology Sam Poloyak, PhD University of Pittsburgh School of Pharmacy Valerian Kagan, PhD

University of Pittsburgh Department of Occupational and Environmental Health

Robert Clark, MD University of Pittsburgh Department of Critical Care Medicine Robert Hickey MD University of Pittsburgh Department of Pediatrics

J. Timothy Greenamyre, MD PhD

Jun Chen University of Pittsburgh Department of Neurology Teresa Hastings University of Pittsburgh Department of Neurology Ed Burton University of Pittsburgh Department of Neurology Valerian Kagan University of Pittsburgh Department of Environmental and

Occupational Health Fabio Blandini IRCCS Neurological Institute, Pavia, Italy Takao Yagi Scripps Institute Department of Molecular and Experimental Medicine

Theresa Hastings, PhD

Jun Chen, MD University of Pittsburgh Department of Neurology Sarah Berman, MD, PhD University of Pittsburgh Department of Neurology Ruth Perez, PhD University of Pittsburgh Department of Neurology J. T. Greenamyre, MD, PhD University of Pittsburgh Department of Neurology Guo Dong Cao, PhD University of Pittsburgh Department of Neurology Michael Cascio, PhD University of Pittsburgh Department of Molecular Genetics and

Biochemistry Valerian Kagan, PhD University of Pittsburgh Department of Environmental and

Occupational Health Tatyana Votyakova, MD University of Pittsburgh Diabetes Research Center

73

Charleen Chu, MD, PhD University of Pittsburgh Department of Pathology Clayton Wiley, MD, PhD University of Pittsburgh Department of Pathology Un Kang University of Chicago Department of Neurology Linan Chen & Xiaoxi Zhuang University of Chicago Department of Neurobiology Stephen J. Kish, PhD University of Toronto Centre for Addiction and Mental Health

Rock Heyman, MD

Wendy Leng University of Pittsburgh Department of Urology Deborah McMahon University of Pittsburgh Department of Infectious Disease

Eric Hoffman, PhD

Olga Vergun, PhD University of Pittsburgh Department of Neurology Pier Mastroberardino, PhD University of Pittsburgh Department of Neurology Jason Cannon, PhD University of Pittsburgh Department of Neurology Robert Drolet, PhD University of Pittsburgh Department of Neurology Federica Saporiti, PhD University of Pittsburgh Department of Neurology

Milos Ikonomovic, MD

Steven Graham, MD, PhD University of Pittsburgh Department of Neurology William Klunk, MD, PhD University of Pittsburgh Department of Psychiatry Chester Mathis, PhD University of Pittsburgh Department of Radiology Patrick Kochanek, MD, PhD University of Pittsburgh Department of Anesthesiology Edward Dixon, PhD University of Pittsburgh Department of Neurosurgery Steven DeKosky, MD University of Virginia Department of Neurology Katsuyoshi Mizukami, MD University of Tsukuba Department of Psychiatry, Japan Elliott Mufson, PhD Rush University Medical Center Department of Neurological Sciences Lynn Wecker, PhD

University of South Florida College of Medicine Department of Pharmacology and Therapeutics

John Morris, MD Washington University Department of Neurology MO Samay Jain, MD

Tim Greenamyre University of Pittsburgh Department of Neurology Stuart Steinhauer University of Pittsburgh Department of Psychiatry S Studenski University of Pittsburgh Department of Medicine David Lacomis University of Pittsburgh Department of Neurology Elsa Strotmeyer University of Pittsburgh Department of Epidemiology Anne Newman University of Pittsburgh Department of Epidemiology Hazem Samy University of Pittsburgh Department of Ophthalmology Peter Gianaros University of Pittsburgh Department of Psychiatry Max Levine Siena College Department of Psychology Thanh Ton University of Washington Department of Epidemiology Will Longstreth University of Washington Department of Neurology Shannon Rhodes UCLA Department of Epidemiology School of Public Health Elan D. Louis Neurological Institute, Columbia University Medical Center Evan Thacker University of Washington Department of Epidemiology Steven Frucht Neurological Institute, Columbia University Medical Center Paul E. Greene Neurological Institute, Columbia University Medical Center Cheryl Waters Neurological Institute, Columbia University Medical Center Mary Jenkins University of Western Ontario (Canada) Robert Nicolson University of Western Ontario (Canada) B. Duncan McKinlay CPRI Tourette Clinic, London, Ontario (Canada)

74

Jonathan Mink University of Rochester Medical Center Leon Dure University of Alabama at Birmingham William Ondo Baylor College of Medicine

David Lacomis, MD

Chester Oddis University of Pittsburgh Department of Rheumatology Robert Bowser University of Pittsburgh Department of Pathology Steven Albert University of Pittsburgh School of Public Health Evelyn Talbot University of Pittsburgh School of Public Health James Bennett University of Virginia Department of Neurology Zachary Simmons Pennsylvania State University Department of Neurology Terry Heiman-Patterson Drexel University, Department of Neurology Anne Reed Mayo Clinic Department of Medicine

Frank Lieberman, MD

Deric Park, MD University of Pittsburgh Cancer Institute Hematology & Oncology Paula Sherwood University of Pittsburgh Department of Acute Tertiary Nursing Gary Marsh University of Pittsburgh Department of Biostatistics Amin Kassam, MD University of Pittsburgh Department of Neurological Surgery Arlan Mintz University of Pittsburgh Department of Neurological Surgery Dade Lunsford, MD University of Pittsburgh Department of Neurological Surgery Hideho Okada University of Pittsburgh Department of Neurological Surgery Ian Pollack University of Pittsburgh Department of Neurological Surgery Ronald Hamilton University of Pittsburgh Department of Pathology Shi-yuan Cheng University of Pittsburgh Department of Pathology Eric Wiener University of Pittsburgh Department of Radiology Fernando Boada University of Pittsburgh Department of Radiology Walter Bartynski University of Pittsburgh Department of Radiology

Oscar Lopez, MD

O. Carmichael University of California-Davis Departments of Neurology and Bioengineering

Steven T. DeKosky, MD University of Virginia Department of Neurology P. Thompson University of California-LA Departments of Radiology and Neurology M Gach University of Nevada Las Vegas Departments of Health Physics, and

Internal Medicine Merce Boada Fundació ACE, Barcelona Spain V. Gudnasson Icelandic Heart Association L Launer National Institute on Aging

Robert Y. Moore, MD, PhD

Oscar Lopez, MD University of Pittsburgh Department of Neurology Nicolaas Bohnen, MD, PhD University of Michigan Department of Radiology

Ruth Perez, PhD

Amanda Smith, PhD University of Pittsburgh Department of Neurology John Rosenberg, PhD University of Pittsburgh Department of Biology Donna Stolz, PhD University of Pittsburgh Department of Cell Biology Peter Drain, PhD University of Pittsburgh Department of Cell Biology Ed Dixon, PhD University of Pittsburgh Department of Neurological Surgery Rob Sobol, PhD University of Pittsburgh Department of Pharmacology

75

Anne Andrews Pennsylvania State University Dino DiMonte Parkinson’s Institute, Sunnyvale, CA Allison McCormick Parkinson’s Institute, Sunnyvale, CA Numa Gottardi-Littel Northwestern University

Judith Saxton, PhD

Eric Rodriguez, MD University of Pittsburgh Department of Medicine Lisa Morrow, PhD University of Pittsburgh Department of Psychiatry Mary Ganguli, MD University of Pittsburgh Department of Psychiatry Steven T. DeKosky, MD University of Virginia Department of Neurology Hiroko Dodge, PhD Oregon State University Department of Public Health

Amanda Smith, PhD

Ruth Perez, PhD University of Pittsburgh Department of Neurology Michael Zigmond, PhD University of Pittsburgh Department of Neurology Amy Wagner

University of Pittsburgh Department of Physical Medicine and Rehabilitation

Anthony Liou, PhD University of Pittsburgh Department of Neurology Ken Uchino, MD

Lawrence Wechsler, MD University of Pittsburgh Department of Neurology Maxim Hammer, MD University of Pittsburgh Department of Neurology Tudor Jovin, MD University of Pittsburgh Department of Neurology Edwin Nemoto, PhD University of Pittsburgh Department of Radiology Akira Sekikawa, MD, PhD University of Pittsburgh Department of Epidemiology Amy Kao, MD, MPH University of Pittsburgh Department of Medicine

Michael Zigmond, PhD

Rehana Leak, PhD University of Pittsburgh Department of Neurology Anthony Liou, PhD University of Pittsburgh Department of Neurology Robert Moore, MD, PhD University of Pittsburgh Department of Neurology Amanda Smith, PhD University of Pittsburgh Department of Neurology Jun Chen, MD University of Pittsburgh Department of Neurology Judy Cameron University of Pittsburgh Department of Psychiatry Brian Lopresti University of Pittsburgh Department of Radiology Chester Mathis University of Pittsburgh Department of Radiology Willie Daniels University of Stellenbosch and KwaZulu Natal, South Africa Karoly Mirnics Vanderbilt University Department of Psychiatry Naftali Kaminski University of Pittsburgh Department of Medicine Richard Smeyne St. Jude Children’s Hospital Vivienne Russell University of Cape Town, South Africa

Sasa Zivkovic, MD

Anto Bagic, MD, MSc University of Pittsburgh Department of Neurology Rick Hendrickson, PhD University of Pittsburgh Department of Neurology Roxane Gross Diez, PhD University of Pittsburgh Department of Otolaryngology Suzanne Lentzsch, MD PhD Pittsburgh Cancer Institute K. Abu-Elmagd, MD PhD University of Pittsburgh Thomas Starzl Transplantation Institute Elsa Strotmeyer, PhD University of Pittsburgh Graduate School of Public Health

76

Honors, Editorial Service and Affiliations

Faculty Honors, Editorial Service, and Professional Affiliations

Anto Bagic, MD, MSc Editorial Service

Ad Hoc Reviewer American Journal of Neuroradiology Brain Research Croatian Medical Journal Epilepsy Research Journal Of Neuroimaging

Membership in Professional and Scientific Societies American Medical Association (AMA) American Academy of Neurology (AAN) American Epilepsy Society (AES) American Academy of Sleep Medicine (AASM) American Clinical MEG Society (ACMEGS), Board of Directors, Founding member International Society for the Advancement of Clinical MEG (ISACM) American Clinical Neurophysiology Society (ACNS)

Sarah Berman, MD, PhD Editorial Service

Ad hoc Reviewer Molecular Cell Journal of Neuroscience Journal of Neurochemistry Cell Death and Differentiation Journal of Neurochemical Research Neuroscience Letters Neurobiology of Disease Journal of Neuroscience Molecular Cell Antioxidants & Redox Signaling American Journal of Pathology Biochimica et Biophysica Acta – Molecular Basis of Disease

Membership in Professional and Scientific Societies American Academy of Neurology Society for Neuroscience The Movement Disorders Society American Association for the Advancement of Science

Richard Brenner, MD Editorial Service

Editorial Boards Journal of Clinical Neurophysiology

Ad Hoc Reviewer Clinical Neurophysiology Epilepsia Journal of Clinical Neurophysiology

Membership in Professional and Scientific Societies American Academy of Neurology American Clinical Neurophysiology Society American Epilepsy Society

78

Edward Burton, MBChB, MD, DPhil, FRCP Honors

Elected to Fellowship of the Royal College of Physicians of London, May 2009 Editorial Service

Ad Hoc Reviewer Age and Aging Brain Research Gene Therapy Neurobiology of Disease

Membership in Professional and Scientific Societies American Society for Gene Therapy Association of British Neurologists Royal College of Physicians of London The Movement Disorders Society The Society for Neurosciences

Lectureships Visiting Professorship in Neurology, University of Birmingham, UK, May 2009

Guodong Cao, PhD Honors

Fudan University Visiting Professor Capital University of Medicine Visiting Professor

Editorial Service Ad hoc referee

Brain Research Neuropharmacology European Journal of Pharmacology Neurochemistry International Pediatric Research Neurochemical Research Journal of Cerebral Blood Flow and Metabolism Journal of Neuroscience

Membership in Professional and Scientific Societies Society for Neuroscience American Heart Association

Jun Chen, MD

Honors Board of Directors, International Society of Cerebral Blood Flow and Metabolism 2007-2010 Endowed Chair Professorship, University of Pittsburgh 2008- Changjiang Endowed Professorship, Chinese Education Commission 2009-

Editorial board member Journal of Cerebral Blood Flow and Metabolism Stroke Neurobiology of Disease Associate Editor, Journal of Neuroscience Associate Editor, Translational Stroke Research Ad hoc Reviewer

Nature Medicine, Journal of Neuroscience Annals of Neurology PNAS USA

79

Journal of Clinical Investigation Journal of Biological Chemistry Journal of Cell Biology Journal of Neurochemistry Journal of Cerebral Blood Flow and Metabolism Stroke Brain Research Molecular Brain Research Glia Neuroscience Neurochemistry International Neuroscience Letters European Journal of Neuroscience European Journal of Pharmacology Translational Stroke Research Nucleotide Acid Research Cell Death and Differentiation American Journal of Pathology Gene Therapy Molecular Therapy Neurobiology of Disease Neuroscience Research Experimental Neurology Neurobiology of Aging

Paula Clemens, MD Editorial Service

Ad hoc Reviewer, Neurology Membership in Professional and Scientific Societies

American Society of Gene Therapy American Academy of Neurology American Neurological Association

John Doyle, MD Membership in Professional and Scientific Societies

American Academy of Neurology American Association of Neuromuscular and Electrodiagnostic Medicine

Miguel Estevez, MD, PhD Membership in Professional and Scientific Societies

Society for Neuroscience American Academy of Neurology Genetics Society America

Kathy Gardner, MD

Membership in Professional and Scientific Societies American Academy of Neurology American Association of Electrodiagnostic Medicine International Headache Society American Headache Society Society of Neuroscience Pennsylvania Neurological Society, Board of Directors

80

Gena Ghearing, MD Honors

Excellence in Teaching Award, University of Pittsburgh Neurology Residents 2009 Membership in Professional and Scientific Societies

American Medical Association, 1997-2009 American Academy of Neurology, 2000-2009 Pennsylvania Medical Association, 2009 Allegheny County Medical Society, 2009 American Epilepsy Society, 2005-2009 American Clinical Neurophysiology Society, 2005-2009

Steven Graham, MD, PhD

Editorial Service Editorial Board, Journal of Cerebral Blood Flow and Metabolism Ad hoc Reviewer

Annals of Neurology Brain Research Brain Pathology European Journal of Neuroscience Experimental Neurology F.A.S.E.B. Journal Gene Therapy Journal of Histochemistry and Cytochemistry Journal of Neurochemistry Journal of Neuroscience Journal of Neurotrauma Journal of Pharmacology and Experimental Therapeutics Molecular Brain Research Molecular Neurobiology Neuroscience Neuroscience Letters Progress in Neurobiology Stroke

Membership in Professional and Scientific Societies Society for Neuroscience American Academy of Neurology National Stroke Council, American Heart Association National Stroke Association

J. Timothy Greenamyre, MD, PhD Honors

Selected, America’s Top Physicians Selected, Best Doctors in America Distinguished Lecturer in Neuroscience and Aging, National Institute on Aging, NIH Most highly cited paper in the 10-year history of Nature Neuroscience (Betarbet et al, 2000)

Editorial Service Editor, Neurobiology of Disease Consulting Editor for Neurochemistry & Molecular Neurobiology, Functional Neurology Editorial Board, Experimental Neurology Editorial Board, Movement Disorders Reviewing Editor, ASN-Neuro

81

Ad Hoc Reviewer Journal of Biological Chemistry Journal of Neurochemistry Nature Medicine Nature Neuroscience Neuron Proceedings of the National Academy of Sciences Science

Membership in Professional and Scientific Societies American Academy of Neurology American Neurological Association Huntington Study Group Movement Disorders Society Parkinson Study Group Society for Neuroscience

Teresa Hastings, PhD Honors

Invited Speaker, Parkinson’s Disease Society, UK, SPRING Medical Research Conference 2009 “Dopamine Quinones Modify Key Parkinson-related Proteins”, Royal Society of Medicine, London, May 2009

Editorial Service Handling Editor, Editorial Board Member for Journal of Neurochemistry Editorial Board Member for Experimental Neurology Ad hoc reviewer

Journal of Neurochemistry Brain Pathology Proteomics –Clinical Applications Neuroscience Neurobiology of Disease Journal of Neuroscience Research

Membership in Professional and Scientific Societies American Academy for Advancement of Science International Society for Neurochemistry New York Academy of Sciences Society for Neuroscience Society for Free Radical Biology and Medicine

Rock Heyman, MD

Honors/Recognition Best Doctors in America, Woodard/White, Inc

Membership in Professional and Scientific Societies American Academy of Neurology, Multiple Sclerosis Section American Sleep Disorders Association Consortium of Multiple Sclerosis Centers

David Hinkle, MD, PhD Faculty Honors

2008 Excellence in Teaching Award from the Pitt Neurology Residents 2008 George C. Cotzias Fellowship (American Parkinson’s Disease Association)

Membership in Professional and Scientific Societies Movement Disorder Society American Academy of Neurology

82

American Association for the Advancement of Science Society for Neuroscience Pennsylvania Medical Society Allegheny County Medical Society Parkinson Study Group

Milos Ikonomovic, MD Professional Affiliations

Society for Neuroscience International Brain Research Organization New York Academy of Sciences International Society to Advance Alzheimer Research and Treatment

Samay Jain, MD Honors/Recognition

Movement Disorder Society Travel Grant to International Congress, 2009 Neurology on the Hill, American Academy of Neurology, 2009 First annual NINDS Clinical Trial Methods Course in Neurology, 2008

Editorial Service Reviewer Board, Journal of Pediatric Neurology

Membership in Professional and Scientific Societies American Academy of Neurology Movement Disorders Society

Tudor Jovin, MD Editorial Service

Associate Editor, Interventional Section, Journal of Neuroimaging Ad-hoc Reviewer, Journal of Neuroimaging

Membership in Professional and Scientific Societies American Academy of Neurology American Society of Neuroimaging American Association of Neurological Surgeons Society of Vascular and Interventional Neurology

Robert Kaniecki, MD

Editorial Service Abstracts Editor, Headache Ad hoc reviewer

Expert Review of Neurotherapeutics Headache Headache Care Clinical Therapeutics

Membership in Professional and Scientific Societies American Headache Society International Headache Society American Academy of Neurology Allegheny County Medical Society Pennsylvania Medical Society American Medical Association

83

David Lacomis, MD Honors

“Top Doctors,” Pittsburgh Magazine, 2009 Editorial Service

Member, Editorial Board, Journal of Clinical Neuromuscular Diseases Ad hoc Reviewer:

Journal of Clinical Neuromuscular Diseases Journal Watch Neurology Muscle and Nerve Neurocritical Care, A Journal of Acute and Emergency Care Neurology

Membership in Professional and Scientific Societies American Academy of Neurology, Active Member, Fellow American Association of Electrodiagnostic Medicine, Fellow American Neurological Association, Active Member

Rehana Leak, PhD

Membership in Professional and Scientific Societies Invited Member of PD Online Research, Fox Foundation for Parkinson's Research (2009) Society for Neuroscience

Frank Lieberman, MD Membership in Professional and Scientific Societies

American Academy of Neurology, Neuro-Oncology Section, Member Board of Medical Examiners, Neurooncology Exam Committee, Member Radiation Therapy Oncology Group, CNS Tumors Committee, Member; Society for Neurooncology, Member

Anthony K.F. Liou, PhD Editorial Services

Editor, The Open Biology Journal Membership in Professional and Scientific Societies

Society for Neuroscience

Oscar Lopez, MD Honors

America’s Top Physicians, Consumers Research Council of America Editorial Service

Editorial Board, Neuropsychology Review, Associate Editor Ad-Hoc Reviewer

Acta Neurologica Scandinavica Acta Psychiatrica Scandinavica Alzheimer’s Disease and Related Disorders Annals of Neurology Antioxidant & Redox Signaling Archives of General Psychiatry Archives of Neurology Behavioral and Brain Function Brain CNS Drugs Cognitive and Behavioral Neurology Cortex Drugs & Aging

84

European Journal of Neurology European Neurology International Journal of Geriatric Psychiatry Journal of Cognitive and Behavioral Neurology Journal of Gerontology: Medical Sciences Journal of Herbal Pharmacology Journal of Neural Transmission Journal of Neurology, Neurosurgery, & Psychiatry Journal of Neuropsychiatry and Clinical Neurosciences Journal of Neuropsychiatry, Neuropsychology, and Behavioral Neurology Journal of the American Geriatrics Society Liver Transplantation and Surgery Nature- Clinical Practice Neurology Neurobiology of Aging Neuroepidemiology Neurology Neurology-India Neuropsychologia Neuropsychology Psychiatric Research Psychiatrics-Turkey The American Journal of Cardiology The American Journal of Geriatric Psychiatry The American Journal of Psychiatry The Canadian Journal of Neurological Sciences The Journal of Psychological Assessment The Lancet Dementia and Geriatric Cognitive disorders Alzheimer’s & Dementia American Journal of Hypertension Journal of Clinical Psychiatry

Ad Hoc Grant Reviewer Alzheimer’s Association, Chicago, IL Women’s Health Research at Yale, Yale University, New Haven, CT Ministry of Education, Science, and Technology (Ministerio de Educación, Ciencia y Tecnología). Fund for Scientific and Technological Research (Fondo para la Investigatión Científica y Tecnológica). Argentina. European Research Projects on Neurodegenerative Diseases of the Central Nervous System. ERA-Net. European Funding for Neuroscience Research (NEURON). Berlin, Germany. The Neurological Foundation, Auckland, New Zealand.

Galen Mitchell, MD Membership in Professional and Scientific Societies

American Academy of Neurology Diplomate, National Board of Medical Examiners

Robert Y. Moore, MD PhD Honors

Presidential Appointment, Selection Committee, National Medal of Science, 2006-2009; reappointed for 2009-2011

Recipient of Distinguished Scientific Achievement Award from Sleep Research Society

85

Editorial Service Editorial Boards

Chronobiology International Clinical Sleep Medicine

Ad hoc reviewer Nature Nature Neuroscience Journal of Comparative Neurology Brain Research Journal of Chemical Neuroanatomy

Ruth Perez, PhD

Membership in Professional and Scientific Societies American Association for the Advancement of Science Pittsburgh Institute for Neurodegenerative Diseases Society for Neuroscience Neurotoxicity Society Joint Steering Committee for Public Policy, Society for Neuroscience

Chitharanjan V. Rao, MBBS, MRCP (UK), DM

Editorial Service Reviewer, Practical Reviews in Neurology

Membership in Professional and Scientific Societies American Academy of Neurology American Association of Electrodiagnostic Medicine American Medical Association Indian Academy of Neurology Indian Neurological Society Royal College of Physicians (London)

Lisa Roeske-Anderson, MD Membership in Professional and Scientific Societies

American Academy of Neurology Sigma Xi Scientific Research Society

Judith Saxton, PhD Editorial Service Ad hoc Reviewer

Aging and Mental Health Alcoholism: Clinical and Experimental Research Alzheimer Disease and Associated Disorders: An International Journal Archives of Internal Medicine Assessment: A publication of Psychological Assessment Resources, Inc. Dementia and Geriatric Cognitive Disorders Folia Phoniatricia et Logopaedica International Psychogeriatrics Journal of Consulting and Clinical Psychology Journal of Gerontology; Psychological Sciences Journal of Studies on Alcohol Neurology Neuropsychology: A Journal of the American Psychological Association Psychology and Aging

86

Membership in Professional and Scientific Societies Center for Neuroscience, University of Pittsburgh British Psychological Society International Neuropsychological Society National Academy Neuropsychology

Michael Soso, MD, PhD Membership in Professional and Scientific Societies

American Academy of Neurology American Headache Society

Amanda Smith, PhD Membership in Professional and Scientific Societies

Society for Neuroscience

Valerie Suski, DO Membership in Professional and Scientific Societies

American Academy of Neurology Allegheny County Medical Association American Medical Association American Neurological Association American Osteopathic Association Huntington’s Study Group Movement Disorders Society Pennsylvania Medical Society

Ken Uchino, MD

Editorial Service Ad Hoc Reviewer, Neurology Expert Opinion in Pharmacotherapy

Membership in Professional and Scientific Societies American Academy of Neurology American Association for the Advancement of Science American Medical Association American Stroke Association Japan Stroke Society World Stroke Organization

Anne Van Cott, MD Membership in Professional and Scientific Societies

Fellow, American Academy of Neurology Fellow, American Clinical Neurophysiology Society American Epilepsy Society

Lawrence Wechsler, MD Honors

“Top Doctors,” Pittsburgh Magazine, 2009 Editorial Service

Ad Hoc Reviewer Annals of Neurology Neurology Stroke New England Journal of Medicine Journal of Neuroimaging

87

Membership in Professional and Scientific Societies Society for Neuroscience American Academy of Neurology American College of Physicians American Medical Association American Society of Neuroimaging American Neurological Association

Michael Zigmond, PhD Editorial Service

Editor-in-Chief, Progress in Neurobiology Editorial Boards

Advances in Neuroscience Behavioral and Brain Functions Biogenic Amines Biological Signals Biology Image Library, Neuroscience section Engineering & Science Ethics Journal of Neural Transmission JUNE (Journal of Undergraduate Research Education) Neurobiology of Disease Neuroscience Bulletin Parkinsonism and Related Disorders Stress Synapse

Membership in Professional and Scientific Societies Society for Neuroscience American Association for the Advancement of Science

Saša Živković, MD

Editorial Service Ad Hoc Reviewer

Acta Neurologica Scandinavica Clinical Neurology and Neurosurgery Journal of Neuroimaging Journal of Neurology, Neurosurgery and Psychiatry

Membership in Professional and Scientific Societies Member, North East Amyotrophic Lateral Sclerosis Consortium (NEALS) Member, ALS Research Group Member, National VA ALS Consortium

88

Faculty Mentoring and Teaching Contributions

Faculty Teaching and Mentoring Contributions

Junior Faculty Research Mentoring

Steven H. Graham, MD, PhD

Robert Hickey, MD, Assistant Professor of Pediatrics and Emergency Medicine

NINDS K08 Career Development Award

Post Doctoral Research Mentoring

Burton Lab

Jason Cannon, PhD shRNA targeting of the endogenous α-synuclein gene Chiara Milanese, PhD Endogenous zebrafish synucleins and their expression patterns

Chen Lab

R Anne Stetler, PhD Studies cellular & molecular mechanisms of ischemic neuronal injury and novel strategies for neuroprotection; supported by NINDS and a fellowship grant from American Heart Association.

Suping Wang, M.D. Studies cellular & molecular mechanisms of ischemic neuronal injury using primary neurons. Also, preparing primary neuronal cultures for other studies.

Feng Zhang, PhD Studies cellular & molecular mechanisms of ischemic neuronal injury using rodent models of brain ischemia.

LiLi Zhang, PhD Studies cellular & molecular mechanisms of ischemic neuronal injury and in Parkinson’s disease using various molecular approaches.

Xiaoming Hu, M.D., PhD Studies mechanisms of neuron-glia interactions under conditions of ischemic injury or Parkinson’s disease

ZhongFang Weng, PhD Research projects concerning molecular mechanisms of dopaminergic cell death in Parkinson’s disease. Studies the role of mitochondrial damage and programmed cell death in the MPTP and 6-OHD neurotoxicity models.

Juan Xing, M.D. Studies cellular & molecular mechanisms of ischemic neuronal injury and in Parkinson’s disease using various molecular approaches.

Wei Yin, PhD

Research projects concerning molecular and cellular mechanisms of neuronal cell death in cerebral ischemia. Also studies the mechanism underlying mitochondrial biogenesis in neurons.

Clemens Lab

Lingzhi Cai, MD, PhD Studies toward in utero gene correction of Duchenne muscular dystrophy point mutations

Graham Lab Wen Jin Li, MD Research on the role of Cyclooxygenase-2 and other genes mediating

death in cultured neurons. Hao Liu, PhD Research projects that explore the mechanisms of neuronal death in

cerebral ischemia, these also include the role of cyclooxygenase-2 activity in neurons.

90

Greenamyre Lab Pier G. Mastroberardino, PhD Proteomic studies in Parkinson’s and Huntington’s diseases Jason Cannon, PhD Models of PD / In vivo gene transfer Robert Drolet, PhD Autonomic nervous system deficits in the rotenone model of Parkinson's

disease Laurie Sanders, PhD DNA damage in Parkinson’s disease Roberto DiMaio, PhD Mechanisms of pilocarpine-induced epilepsy Federica Saporiti, PhD Mechanisms of inflammation in PD

Hastings Lab

April A. Dukes, Ph.D. Mechanisms of toxicity associated with exposure to dopamine and rotenone.

Irene Arduini, Ph.D. Neuroprotection by selenoproteins against toxin-induced cell death

Perez Lab Haiyan Lou, PhD Studying the impact 14-3-3 and α-syn expression on PP2A and TH

activity. Also evaluating the role of α-Syn serine 129 phosphorylation in regulating α-Syn chaperone function in vitro and in vivo. Developing in vitro assays to measure the impact of α-Syn aggregation on TH and PP2A activity.

Jian Wang, MD, PhD Identifying the relative contributions of 14-3-3 and α-syn to subcellular localization and activation of TH and its impact on the regulation of DA synthesis using siRNA in cell models.

Tshianda N. M. Alerte, MD

Exploring the impact of α-syn, PP2a and 14-3-3 on TH in the α-syn knockout mice after viral delivery. Evaluation includes immunohistochemistry, confocal microscopy, and biochemical assays to measure the impact of soluble or aggregated α-syn on the regulation of TH activity and phosphorylation.

Zigmond Lab

Rehana Leak, PhD Preconditioning of dopamine cells by mild cellular stress

Amanda Smith, PhD Neurobiological and behavioral effects of stress and exercise

Anthony Liou, PhD Role of inflammatory response on neuroprotective effects of exercise

Graduate Student Mentoring

Edward Burton, MD, DPhil Jonathon Sager Cloning and characterization of Zebrafish torsins

Paula Clemens, MD Pattarana Sae-Chew

Earned PhD degree 5/09. Studies were focused on pathophysiology of cancer cachexia in murine models and viral vector-mediated therapeutic strategies for cancer cachexia.

Bhanu Munil Koppanati

Studies are focused on in utero gene transduction of skeletal muscle using viral vectors for the treatment of Duchenne muscular dystrophy in the mdx murine model.

91

Saman Eghtesad Studies are focused on the study of and modulation of immunity induced by viral vector-mediated gene delivery of dystrophin to dystrophin-deficient muscle of the mdx murine model of Duchenne muscular dystrophy.

Rakshita Charan Studies are focused on upstream modulators of NF-κB activation as a cause of the dystrophic phenotype in muscular dystrophy.

Teresa Hastings, PhD Victor Van Laar, B.S. Proteomic analysis of dopamine oxidation-induced modifications to

mitochondrial proteins: Implications for Parkinson's disease

Milos Ikonomovic, MD Jonathan Leeman, MS1 To clarify the degree to which PiB PET imaging is specific for Aβ

pathology using postmortem neuropathologic examinations.

Undergraduate Student Mentoring

Paula Clemens, MD

Lauren Hache Earned MS degree 4/09. Studies were focused on the analysis of DNA mutations causing Duchenne muscular dystrophy and on genotype-phenotype relationships in this disease.

Milos Ikonomovic, MD

Judy-April Oparaji To determine the detection threshold of PiB PET for underlying Aβ load.

Oscar Lopez, MD

Cyrus Raji, BS American Heart Association Pre-Doctoral Fellowship Award (reference number 0815464D) (Co-sponsor) to conduct a study on the effects of hypertension on brain structure. Mr. Raji received the 2009 Neuroscience Award for Medical Students from the American Academy of Neurology

Clinical Education

2008-2009 House Officers PGY 4 Co-Chief Residents Medical Education Allison Hennigan, MD University of Texas Medical Branch School of Medicine Olukayode Ogunrinde, MD University of North Carolina School of Medicine PGY 4 Residents Hebba Hefzy, MD Northeastern Ohio University College of Medicine Justin Hill, MD Medical University of South Carolina Maciej Markowski, MD Karol Marcinkowski University of Medical Sciences, Poland PGY 3 Residents Chris Cummings, MD Mount Sinai School of Medicine, New York

92

Anna Delois, MD Fundcao Tecnico-Educacional, Souza Marques, Brazil Oana Spataru, MD Universitea Ovidius Constanta, Romania Crystal Tung, MD Duke University School of Medicine Christina Vaughn, MD State University of New York-Buffalo School of Medicine PGY 2 Residents Anahita Adeli, MD Ohio State University College of Medicine Amar Bhatt, MD Drexel University College of Medicine Houman Homayoun, MD Medical University of Ohio Jacqueline Nicholas, MD Tehran University of Medical Sciences, Iran Matthew Starr, MD University of New Mexico School of Medicine

Neurology Fellows Medical School Attended Residency Training Aitziber Aleu-Bonaut, MD Interventional Neurology

University of Navarra, Spain University of Barcelona, Spain

Tawfiq Al-Lahham, MD Clinical Neurophysiology

Damascus University School of Medicine, Syria

St. Louis University

Mouhammad Jumaa, MD Vascular Neurology

Damascus University School of Medicine, Syria

University of Pittsburgh Medical Center

Simin Khavandgar, MD Clinical Neurophysiology

Tehran University of Medical Sciences, Iran

University of Pittsburgh Medical Center

Ridwan Lin, MD, PhD Vascular Neurology

Pennsylvania State University College of Medicine

Cleveland Clinic Foundation

Departing House Officers

Residents New Position Allison Hennigan, MD Clinical Neurophysiology Fellow

UPMC Medical Education Program

Olukayode Ogunrinde, MD Sleep Fellowship Stanford University

Heba Hefzy, MD Vascular Fellowship Henry Ford Hospital, Detroit

Justin Hill, MD Basic Research Buck Institute for Aging

Maciej Markowski, MD Epilepsy Fellowship UCLA

93

Fellows New Position Aitziber Aleu-Bonaut, MD Returning to Spain

Tawfiq Al-Lahham, MD Private Practice of Neurology

Mouhammad Jumaa, MD Clinical Assistant Professor of Neurology

University of Pittsburgh School of Medicine

Simin Khavandgar, MD Clinical Assistant Professor of Neurology University of Pittsburgh School of Medicine

Ridwan Lin, MD, PhD Clinical Instructor University of Pittsburgh School of Medicine

Fellowship Directors

Tudor Jovin, MD Interventional Neurology

David Lacomis, MD Clinical Neurophysiology

Ken Uchino, MD Vascular Neurology

Neurology Mentors Lawrence Wechsler, MD Ridwan Lin, MD Mouhammad Jumaa, MD

Aitziber Aleu-Bonaut, MD

David Lacomis, MD Tawfiq Al-Lahham, MD Simin Khavandgar, MD

Tudor Jovin, MD Ridwan Lin, MD

Mouhammad Jumaa, MD Aitziber Aleu-Bonaut, MD

94

Faculty Member / Class Title Course

Edward Burton, MD, DPhilParkinson's Disease Pathobiology of disease

Guodong Cao, PhDNeurodegeneration: Ischemic Stroke Neuropharmacology

Teresa Hastings, PhDNeurodegeneration: Parkinson's Disease Neuropharmacology

David Hinkle, MD, PhDDystonias and Their Treatments Neuropharmacology

Faculty Member / Graduate Student Graduate Program

Edward Burton, MD, DPhilPhD Mentor for Jonathan Sager CNUP

Paula Clemens, MDPhD Mentor for Rakshita Charan MSBMGPhD Mentor for Saman Eghtesad MSBMGPhD Mentor for Bhanu Koppanati MSBMG

Faculty Member / Program Committee

Edward Burton, MD, DPhilMaxx Horowitz--CNUP Program Member, Comprehensive Exam CommitteeJonathan Sager--CNUP Program Member, Comprehensive Exam Committee

Paula Clemens, MDLauren Drowley--CMP Program Member, Dissertation CommitteeMichael Hezel--BMG Program Member, Dissertation CommitteeBhanu Koppanati--BMG Program Chair, Dissertation CommitteeSaman Eghtesad--BMG Program Chair, Dissertation Committee

Miguel Estevez, MDJerrod Poe--BMG Program Member, Dissertation Committee

Steven Graham, MD, PhDJames Bales--CNUP Program Chair, Comprehensive Exam Committee

Michael Zigmond, PhDChristi Kolarcik--CMP Program Member, Dissertation Committee

Mentoring

Service on Committees

Faculty Participation in Graduate Level Teaching and Mentorship

Teaching

95

Faculty Member / Class Title Course or Clerkship

Anto Bagic, MD, MSc Seizures Clinical Neurosciences ClerkshipClinicle Pharmacology of Antiepileptic Drugs ILS Clinical PharmacologyBasic Mechanisms of Epilepsy NeuroscienceOverview of Seizures NeuroscienceAnti-epileptic Drugs & Treatment of Epilepsy NeuroscienceEpilepsy Review & Integration Neuroscience

Sarah Berman, MD, PhDMovement Disorders Clinical Neuroscience Clerkship Tremor & Dystonia - Pathophysiology & Treatment Neuroscience

Edward Burton, MD, DPhilMovement Disorders Clinical Neurosciences ClerkshipClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceOther Movement Disorders: Tics, Ataxis, etc. NeuroscienceMotor Systems Degeneration Neuroscience

Paula Clemens, MDGenetic Approaches to the Treatment of MD ILS Molecular MedicineCourse Orientation Integrated Case Studies

John Doyle, MDNeurology Session (2 sessions) Advanced Physical Examination 1Principles of Neurological Localization NeuroscienceClinical Conference 1: Localization of Dysfunction NeurosciencePBL1: Introduction NeurosciencePBL1: Resolution NeurosciencePBL2: Introduction NeurosciencePBL2: Resolution NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration NeuroscienceAttentional Systems & Disorders of Consciousness NeuroscienceAlzheimer's Disease - Patient Presentation Neuroscience

Kathy Gardner, MDClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration Neuroscience

Gena Ghearing, MDSeizures (4 sessions) Clinical Neurosciences Clerkship

Faculty Participation in Medical School Teaching and Mentorship

Teaching

96

Steven Graham, MD, PhDClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration Neuroscience

J. T. Greenamyre, MD, PhDMovement Disorders Clinical Neurosciences ClerkshipParkinson's Disease NeuroscienceHuntington's Disease NeuroscienceParkinson's Disease - Patient Presentation Neuroscience

Max Hammer, MDCerebral Vascular Disorders NeuroscienceClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration Neuroscience

Rock Heyman, MDClinical Conference 1: Localization of Dysfunction NeurosciencePBL1: Introduction NeurosciencePBL1: Resolution NeurosciencePBL2: Introduction NeurosciencePBL2: Resolution NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration NeuroscienceMultiple Sclerosis and Related Diseases NeuroscienceMultiple Sclerosis: Patient Presentation Neuroscience

David Hinkle, MD, PhDMovement Disorders (2 sessions) Clinical Neurosciences ClerkshipClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceParkinson's Disease - Clinical Features & Treatment NeuroscienceMotor Systems Degeneration Neuroscience

Robert Kaniecki, MDInteractions with Pharmaceutical Industry Ethics, Law and ProfessionalismHeadache: Anatomy & Pathophysiology NeurosciencePharmacology of Pain Management Neuroscience

David Lacomis, MDClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeurosciencePeripheral Nerve & Anterior Horn Cell Disorders NeuroscienceNeuromuscular Junction & Muscle Disorders NeuroscienceMotor Systems Degeneration Neuroscience

97

Oscar Lopez, MDDementia (5sessions) Clinical Neurosciences ClerkshipDelirium & Dementia NeuroscienceAlzheimer’s Dementia Neuroscience

Galen Mitchell, MDNeurology Orientation (11 sessions) Clinical Neurosciences ClerkshipMultiple Sclerosis (5 sessions) Clinical Neurosciences ClerkshipNeurological Emergencies (6 sessions) Clinical Neurosciences ClerkshipNeurology Session (4 sessions) Advanced Physical Examination 1

Robert Moore, MD, PhD Neurology Session 2Movement Disorders Clinical Neurosciences ClerkshipCase 3: A Stroke of Bad Luck - All Sessions Integrated Case StudiesCase 3: Resolution Day Integrated Case StudiesCase 5: Give this Patient a Hand - Session 1 Integrated Case StudiesCase 5: Give this Patient a Hand - Session 2 Integrated Case StudiesCase 5: Resolution Day Integrated Case StudiesCase 8: All Pumped Up Integrated Case StudiesCase 8: Resolution Day Integrated Case StudiesClinical Conference 1: Localization of Dysfunction NeurosciencePBL1: Introduction NeurosciencePBL1: Resolution NeurosciencePBL2: Introduction NeurosciencePBL2: Resolution NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceFunctional Organization of Basal Ganglia NeuroscienceMovement Disorders: Clinical Manifestations NeuroscienceMotor Systems Degeneration NeuroscienceLanguage, Communication & Executive Function Neuroscience

Ruth Perez, PhDWorkshop: Cholinergic Pharmacology Digestion and Nutrition

Chitharanjan Rao, MDPeripheral Neuropathy (4 sessions) Clinical Neurosciences Clerkship

Vivek Reddy, MDComa (5 sessions) Clinical Neurosciences Clerkship

Valerie Suski, DONeurology Session Advanced Physical Examination 1

Ken Uchino, MDStroke (5 sessions) Clinical Neurosciences ClerkshipClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration Neuroscience

98

Anne Van Cott, MDEpilepsy in Elderly ILS Clinical PharmacologyCase 2: SOB Story - Sessions 1 & 2 Integrated Case StudiesCase 2: Resolution Day Integrated Case StudiesCase 3: A Stroke of Bad Luck Integrated Case StudiesCase 3: Resolution Day Integrated Case StudiesCase 6: Damsel in Distress Integrated Case StudiesCase 6: Resolution Day Integrated Case Studies

Barbara Vogler, MDHeadache (6 sessions) Clinical Neurosciences Clerkship

Sasa Zivkovic, MDClinical Conference 1: Localization of Dysfunction NeuroscienceClinical Conference 2: Brainstem Syndromes NeuroscienceMotor Systems Degeneration Neuroscience

Faculty Member / Mentoring Role Student Mentored

Paula Clemens, MDMentored Scholarly Project Mentor Anriada Mehmeti, MS2MSP Selective Research Mentor FridmanYaron, MS4MSP Selective Research Mentor Anriada Mehmeti, MS2

Theresa Hastings, PhDResearch Elective Course Mentor Van LaarAmber, MS4

Faculty Member / Role Course

Paula Clemens, MDCourse Director Integrated Case Studies

Galen Mitchell, MDClerkship Director Clinical Neurosciences

Faculty Member / Committee Committee Role

David Lacomis, MDCourse Design Group - Neuroscience Member

Galen Mitchell, MDPromotions Committee MemberRetention Committee MS 3 & 4 Member

Robert Moore, MD, PhDCourse Design Group - Neuroscience Member

Mentoring

Leadership

Committee Membership

99

100

Grand Rounds and Special Lectures

Department of Neurology Grand Rounds 2008

September 10 Christopher Cummings, MD

Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Full Court PRES on Cerebral Venous Thrombosis”

September 17 Richard P. Brenner, MD

Clinical Professor of Neurology University of Pittsburgh School of Medicine “Change in Mental Status: R/O Status”

September 24 Rock Heyman, MD

Assistant Professor of Neurology Chief, Division of Neuroimmunology/Multiple Sclerosis University of Pittsburgh School of Medicine “Monoclonal Antibody Treatments in MS”

October 1 “In-Patient and Out-Patient HOT Cases”

Moderated by: John Doyle, MD, Associate Professor Lisa Roeske-Anderson, MD, Assistant Professor University of Pittsburgh Department of Neurology

October 8 Crystal Tung, MD

Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Is There a Fungus Among Us?”

October 15

Kathy Gardner, M.D. Assistant Professor of Neurology University of Pittsburgh School of Medicine “Update on the Neurofibromatosis Disorders”

October 22 Steven Warach, M.D., PH.D.

Senior Investigator and Chief, Section on Stroke Diagnostics and Therapeutics, National Institute of Neurological Disorders and Stroke, NIH “Identifying Novel Targets of Stroke Therapy Using MRI”

October 29 Paula Clemens, MD

Associate Professor of Neurology, Molecular Genetics and Biochemistry, Human Genetics and Pediatrics and Vice Chair for Veterans Affairs University of Pittsburgh School of Medicine “Therapeutic Advances in Muscular Dystrophy”

November 5 Allison Hennigan, MD

Resident, Department of Neurology University of Pittsburgh School of Medicine “The Curious Case of Mrs. B”

November 12 Robert Kaniecki, MD Assistant Professor of Neurology, University of Pittsburgh School of Medicine “Uncomplicating Complicated Migraines”

102

December 3

Justin Hill, M.D. Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: Molecular Mechanisms Underlying the Somatodendritic Abnormalities in the Prefrontal Cortex of Patients with Schizophrenia”

December 10 “In-Patient and Out-Patient HOT Cases”

Moderated by: John Doyle, MD, Associate Professor Lisa Roeske-Anderson, MD, Assistant Professor University of Pittsburgh Department of Neurology

December 17 John Barranger, M.D., Ph.D.

Professor of Human Genetics University of Pittsburgh Graduate School of Public Health “Fabry Disease: Important Cause of Stroke in the Young”

2009

January 7

Hebah Hefzy, M.D. Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Why Can’t He Walk Straight?”

January 14

Maciej Markowski, M.D. Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Is the Brain Biopsy Indicated?”

January 28 “In-Patient and Out-Patient HOT Cases”

Moderated by: John Doyle, MD, Associate Professor Lisa Roeske-Anderson, MD, Assistant Professor University of Pittsburgh Department of Neurology

February 4 Anne Van Cott, MD

Assistant Professor of Neurology, Pittsburgh VA Health Care System “Epilepsy in Older Individuals”

February 11

Lawrence Wechsler, M.D. Professor of Neurology and Neurosurgery Interim Chair, Department of Neurology Division Chief, Stroke and Director, UPMC Stroke Institute “Telemedicine and Acute Stroke Management”

February 18

Saša Živković, M.D. Assistant Professor, Department of Neurology University of Pittsburgh School of Medicine “Cognitive Dysfunction in Neuromuscular Disorders”

March 4

Anna Delios, M.D. Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “The Wild Card”

103

March 11 “In-Patient and Out-Patient HOT Cases” Moderated by: John Doyle, MD, Associate Professor Lisa Roeske-Anderson, MD, Assistant Professor University of Pittsburgh Department of Neurology

March 18

Christina Patterson, M.D. Resident, Department of Child Neurology University of Pittsburgh School of Medicine CPC: ''Charcot-Marie-Tooth Disease and Apparent Stroke''

March 25

Barbara Vogler, M.D. Assistant Professor of Neurology UPP Headache Center “Low Pressure Headache”

April 1 Amin Kassam, MD, FRCS(C)

Professor and Chair, Department of Neurosurgery University of Pittsburgh School of Medicine “An Obituary to Craniotomies”

April 8 Rick Hendrickson, Ph.D.

Assistant Professor of Neurology University of Pittsburgh School of Medicine “Role of Neuropsychological Testing & Evaluating Epilepsy Patients”

April 15 Miguel Estevez, MD, PhD

Assistant Professor of Neurology, UPP Headache Center University of Pittsburgh School of Medicine “Migraine-related Neurodegenerative Signals”

April 22 Robert J. Adams, MS, MD

Professor of Neuroscience and University Eminent Scientist Medical University of South Carolina Director, South Carolina Center for Economic Excellence in Stroke “Kids With Stroke: The Sickle Cell Story”

May 6 Asim Roy, MD

Clinical Assistant Professor of Neurology University of Pittsburgh School of Medicine “Creepy Crawly Sensations in the Night”

May 13

Kenneth L. Tyler, MD Reuler-Lewin Family Professor of Neurology Professor of Neurology, Microbiology, Immunology University of Colorado Health Services Center “Emerging Viral Infections of the CNS”

104

May 20 Olukayode Ogunrinde, MD Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Doc, What Is My Diagnosis?”

May 27 Deric Park, MD

Assistant Professor, Department of Neurosurgery, Medicine (Oncology) and Pharmacology and Chemical Biology University of Pittsburgh School of Medicine “Intratumoral Heterogeniety of Gliomas”

June 3 Oana Spataru, MD

Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Is This the Elvis Presley of Neurology?”

June 10 Christina Vaughn, MD

Resident, Department of Neurology University of Pittsburgh School of Medicine CPC: “Selective Saccadic Palsy”

Alzheimer’s Disease Research Center Special Lectures

October 7, 2008 Jay L. Foster Memorial Scientific Lecture in Alzheimer's Disease Peter St. George-Hyslop, MD, FRCP Professor, Department of Medicine, Division of Neurology Director, Center for Research in Neurodegenerative Disease University of Toronto “The Genetics of Alzheimer's Disease”

March 3, 2009 Walter Allen Lecture Series

Howard Aizenstein, MD., PhD. Associate Professor, Department of Psychiatry University of Pittsburgh “Magnetic Resonance Imaging Research in Alzheimer’s Disease”

Alzheimer’s Disease Research Center Topics at Noon

September 25, 2008 Howard J. Aizenstein, MD, PhD Associate Professor, Departments of Psychiatry and Bioengineering University of Pittsburgh MR Imaging Methods and Their Application to Alzheimer's Disease and Late-Life Depression

October 16, 2008 Ashok Bharucha, MD Assistant Professor of Psychiatry, University of Pittsburgh School of Medicine Clinical Epidemiology of Aggression in Nursing Home Settings

105

November 6, 2008 Anthony Zuccolotto, BS, President/CEO; Amy Eschman, MS; Gretchen Archer, MBA Psychology Software Tools, Inc MedicationIQ - Maximizing Medication Adherence among the Elderly

December 11, 2008

Beth Snitz, PhD Research Associate, Department of Neurology University of Pittsburgh Measuring Reliable Change over Time in Cognitive Test Scores

February 19, 2009 Cyrus A. Raji, BS, BA MD/PhD Candidate Departments of Pathology and Radiology University of Pittsburgh Vascular Disease and its Risk factors are a Driving Force For Age Related Brain Atrophy

March 5, 2009 Joan Monin, PhD Postdoctoral Fellow University Center for Social and Urban Research University of Pittsburgh Physiological Indicators of Perceived Suffering

April 16, 2009 Robert A. Sweet, MD Professor Departments of Psychiatry and Neurology University of Pittsburgh Genetic Variation and Trajectories of Psychosis in AD

May 21, 2009 Meryl A. Butters, Ph.D. Associate Professor of Psychiatry University of Pittsburgh School of Medicine The Role of Cerebrovascular Disease and Amyloid Pathology in the Links Between Late-Life Depression, MCI and future dementia

Department of Neurology & Pittsburgh Institute for Neurodegenerative Diseases January 9, 2009 Huanyu Dou, MD

Assistant Professor Department of Pharmacology and Experimental Neuroscience Center for Neuroviology and Neurodegenerative Disorders University of Nebraska Medical Center “A Cell-Based Nanoparticle Delivery Platform for Brain Degenerative Diseases"

106

Faculty and Staff

Members of the Faculty

Anto Bagic, MD, MSc Assistant Professor John R. Baker, MD Clinical Associate Professor

Sarah Berman, MD, PhD Assistant Professor Richard P. Brenner, MD Clinical Professor

Edward A. Burton, MD, DPhil, FRCP Assistant Professor Guodong Cao, PhD Research Assistant Professor

Jun Chen, MD Professor Paula R. Clemens, MD Associate Professor

John J. Doyle, MD Associate Professor Miguel Estevez, MD, PhD Assistant Professor

Kathy Gardner, MD Assistant Professor Gena Ghearing, MD Assistant Professor

Steven H. Graham, MD, PhD Professor J. Timothy Greenamyre, MD, PhD Professor

Maxim Hammer, MD Assistant Professor Theresa G. Hastings, PhD Associate Professor

Rick Hendrickson, PhD Assistant Professor Rock A. Heyman, MD Assistant Professor

David Hinkle, MD, PhD Assistant Professor Eric Hoffman, PhD Assistant Professor

Milos Ikonomovic, MD Associate Professor Robert Kaniecki, MD Assistant Professor

Samay Jain, MD Assistant Professor Tudor Jovin, MD Assistant Professor

David Lacomis, MD Professor Rehana Leak, PhD Research Assistant Professor

Frank Lieberman, MD Associate Professor Anthony Liou, PhD Research Assistant Professor

Oscar L. Lopez, MD Professor Angela Lu, MD Clinical Assistant Professor

Galen Mitchell, MD Associate Professor Robert Y. Moore, MD, PhD Professor

Eric Ogren, MD Assistant Professor Ruth Perez, PhD Assistant Professor

Chitharanjan Rao, MD, MRCP Assistant Professor Vivek Reddy, MD Assistant Professor

Lisa Roeske-Anderson, MD Assistant Professor Asim Roy, MD Clinical Assistant Professor

Judith Saxton, PhD Associate Professor Amanda Smith, PhD Research Assistant Professor

Michael Soso, MD Assistant Professor Valerie Suski, DO Clinical Assistant Professor Ken Uchino, MD Visiting Assistant Professor

Anne Van Cott, MD Assistant Professor Olga Vergun, PhD Research Assistant Professor

Barbara Vogler, MD Clinical Assistant Professor Lawrence Wechsler, MD Professor

108

Syed Zaidi, MD Assistant Professor Michael Zigmond, PhD Professor

Saša Živković, MD Associate Professor

New Faculty Members

Faculty Member Previous Appointment

Angela Lu, MD Neurophysiology Fellow University of Pittsburgh School of Medicine

Asim Roy, MD Clinical Assistant Professor Tufts University Baystate Medical Center

Syed Zaidi, MD Vascular Fellow University of Pittsburgh School of Medicine

Faculty Departures

Faculty Member New Position and Rank

Steven T. DeKosky, MD Professor and Chair

Vice President and Dean University of Virginia School of Medicine

Ronda Pindzola, PhD Research Assistant Professor

Retired

Renu Pokharna, MD Clinical Assistant Professor

Private practice of Neurology Pittsburgh, PA

Maria Simbra, MD Clinical Assistant Professor

Pursuing additional training

David Watson, MD Assistant Professor

Associate Professor and Director Headache Center West Virginia University

David Wolk, MD Assistant Professor

Assistant Professor Department of Neurology University of Pennsylvania

M. Firas Sioufi, MD Clinical Assistant Professor

Private practice of Neurology Orlando, FL

Olga Vergun, PhD Research Assistant Professor

Academic position in Europe

109

Department Fulltime Employees

Administration Lawrence Wechsler, MD Professor and Interim Chair Joyce Barefoot Assistant to Patricia Trimber Barbara Beatty Grants and Contracts Administrator Patrick Conway Department Administrator Michele Dennis Personnel Manager Leslie Dunn, MPH Academic Administrator PPG & State Grant Administrator Earl Humes Controller Kay Kenney Practice Coordinator Erin McCloskey Clinic Operations Manager Karen Murray Department Enrollment Specialist Sandra Pringle-Cribbs Medical Student Education Coordinator Mary Sadowski Assistant to Dr. Wechsler Rhonda Springs Receptionist Patricia Trimber Residency Coordinator Lawrence Wechsler, MD Professor and Vice Chair for Clinical Affairs Barbara Woolcott Assistant to Patrick Conway

Cognitive Disorders Division Oscar Lopez, MD Professor and Division Chief Thomas Baumgartner, Jr., MSW Social Worker Lori Cimino, RN, BSN Clinical Research Coordinator Kristen Fair Assistant to Leslie Dunn Shelley Ferson ADRC Data Manager Marita Garrett Detection, Diagnosis & Intervention Interviewer Sandy Giconi Assistant to Dr. Judith Saxton Patricia Henderson, MS, LCP Research Specialist Kim Huber, MPH, CCRC Senior Project Manager Kara Hughes Assistant to Dr. Oscar Lopez Amanda Hunsaker Urban Outreach Coordinator April Kane, MSW, LSW Licensed Social Worker Patrick Ketchel, MEd Data Base Administrator Claire McConaha PIB PET Program Coordinator Lori Macedonia, PA-C, MPH ADRC Clinic Coordinator and PA Kim Metheny, MA Research Specialist II Carolyn Mishler-Rickard, PA-C Physician Assistant Mary Ann Oakley, MA ADRC Training & Information Coordinator Marlene Paytas Clinic Administrative Assistant Beth Sarles ADRC Research Kathie Savage Administrative Coordinator Judith Saxton, PhD Associate Professor Akilah Scott Research Interviewer Aubrey Wright Research Interviewer Donna Simpson, CRNP, MPH Nurse Practitioner

Epilepsy Division

Anto Bagić, MD, MSc Assistant Professor and Division Chief Richard Brenner, MD Clinical Professor Gena Ghearing, MD Assistant Professor

110

General Neurology Division John Doyle, MD Associate Professor and Division Chief Angela Lu, MD Clinical Assistant Professor Asim Roy, MD Clinical Assistant Professor

Headache Division

Robert Kaniecki, MD Assistant Professor and Division Chief Denise Boger Patient Information Coordinator, Oakland Miguel Estevez, MD Assistant Professor Amy Gilchrist Patient Information Coordinator, Oakland Annette Kirkwood Patient Information Coordinator, Wexford John Lucking, PA Physician Assistant, Oakland Kristin McClone Medical Secretary, Oakland Kimberly McGonigle, PA Physician Assistant, Oakland Judy McKenna Medical Secretary, Oakland Michael Soso, MD Assistant Professor, Oakland Barbara Vogler, MD Clinical Assistant Professor, Oakland Barbara Wintermantel Headache Center Practice Coordinator

Kaufmann Building Clinic Staff

Erin McCloskey Clinic Operations Manager Karen Beatty Patient Information Coordinator Patricia Bednarik, MS, CCC-SLP Speech Language Pathologist Jill Bischoff, CRNP Nurse Practitioner, Epilepsy Marlene Boyd, RN Registered Nurse, Multiple Sclerosis Kenneth Coval, RN Registered Nurse, Stroke Tamiko Hanner Patient Information Coordinator Lesley Kirby Medical Assistant Alice Knight Patient Information Coordinator Jennifer McAlister Patient Service Coordinator Melanie Mielo Outpatient Practice Coordinator Becky Molczan, MSN, CRNP Nurse Practitioner, Neuromuscular Diseases Margie O’Leary, RN Registered Nurse, Multiple Sclerosis Kerry Oddis, RN Clinical Research Coordinator, Multiple Sclerosis Darlene Punjack, MA Medical Assistant Danielle Rowlands, RN Clinical Research Coordinator, Neuromuscular Camille Sewell Patient Information Coordinator Charmelle Strong, CMA Certified Medical Assistant, Epilepsy Vicki Young, RN Registered Nurse, General Neurology

Mercy Neurology

Max Hammer, MD Assistant Professor and Director of Stroke Services, UPMC Mercy Angela Lu, MD Clinical Assistant Professor Susan Robatzen Office Coordinator Syed Zaidi, MD Assistant Professor

Movement Disorders Division Tim Greenamyre, MD, PhD Professor and Division Chief Sarah Berman, MD, PhD Assistant Professor Edward Burton, MD, DPhil Assistant Professor

111

Tonya Engel, MA Medical Assistant Theresa Hayden Administrator, PIND Rick Hendrickson, PhD Assistant Professor David Hinkle, MD, PhD Assistant Professor Eric Hoffman, PhD Research Assistant Professor Samay Jain, MD Assistant Professor Larry Ivanco Research Specialist Nancy Lucarelli, MA Medical Assistant, Research Robert Moore, MD, PhD Professor Rita Brozewicz, CMA Clinical Research Coordinator Olga Vergun, PhD Research Assistant Professor

Neuroimmunology/MS Division Rock Heyman, MD Assistant Professor and Division Chief Galen Mitchell, MD Associate Professor

Neuromuscular Division

David Lacomis, MD Professor and Division Chief Betty Caldwell Assistant to Dr. David Lacomis Chitharanjan Rao, MBBS Assistant Professor Saša Živković, MD Associate Professor

Neuro-Oncology Program

Frank Lieberman, MD Associate Professor and Director, Adult Neuro- Oncology Program Shari Squeglia Assistant to Dr. Frank Lieberman

Research Division

Steven Graham, MD, PhD Professor and Division Chief Eric Abrahamson, PhD DeKosky Research Assoc Muzamil Ahmad, PhD Graham Research Associate Tshianda Alerte, MD Research Associate Beth Arnold Berman Lab Manager Qing Bai, PhD Research Associate Jason Cannon, PhD Greenamyre Post Doctoral Associate Guodong Cao, PhD Research Assistant Professor Clinton Cario Research Specialist Steven Cassady Lab Technician Sandra Castro-Scheirer Zigmond Lab Research Specialist Jun Chen, MD Professor Emma Culligan Assistant to Dr. Michael Zigmond Robert Drolet, PhD Greenamyre Post Doctoral Associate Annette Estevez, PhD Visiting Research Associate Bethann Gabris Research Associate Kathy Gardner, MD Assistant Professor Beverly Garrett Clemens Administrative Assistant Susan Giegel Zigmond Lab Manager Lauren Hache, MS Clemens Clinical Research Coordinator Ryan Hansen Clemens Fellow Teresa Hastings, PhD Associate Professor Xiaoming Hu Chen Research Associate Xiaoping Hu Greenamyre Research Associate

112

Milos Ikonomovic, MD Associate Professor Juliann Jaumotte, PhD Zigmond Lab Research Associate Niccole Larson Post Doctoral Associate Rehana Leak, PhD Research Assistant Professor Wenjin Li, MD, PhD Chen's Lab research specialist Niklas Lindgren, PhD Zigmond Post Doctoral Associate Anthony Kian-Fong Liou, PhD Research Assistant Professor Haiyan Lou Post Doctoral Associate Hao Liu, PhD Postdoctoral Researcher Pier Mastroberardino, PhD Greenamyre Post Doctoral Associate Amanda Mishizen, PhD Hastings Post Doctoral Associate Laura Montero Research Specialist Amanda Mortimer Hastings Lab Tech Steve Mullett Hinkle Lab Research Specialist William Paljug DeKosky Lab Tech Ruth Perez, PhD Assistant Professor Eugene Raggi Clemens Fellow Daniel Reay Clemens Lab Tech Marie Rose Graham Senior Lab Tech Pattarana Sae-Chew Clemens Lab Grad student Jonathan Sager, PhD Post Doctoral Associate Laurie Sanders, PhD Post Doctoral Associate Federica Saporiti, PhD Post Doctoral Associate Lan Shao Research Specialist Amanda D. Smith, PhD Research Assistant Professor Ruth Anne Stetler, PhD Chen Lab Post Doctoral Associate Patricia Strickler Assistant to Dr. Steven Graham Suping Wang, MD Chen Lab Tech Juan Xing, PhD Chen Post Doctoral Associate Wei Yin, PhD Chen Lab Research Associate Feng Zhang, MD Research Associate-Chen Lab Lili Zhang, MD Research Associate-Chen Lab Heng Zheng Clemens Lab Tech Michael Zigmond, PhD Professor

Vascular Neurology Division Lawrence Wechsler, MD Professor and Division Chief Diane Coyle Administrative Assistant Sharon DeCesare Clinical Coordinator Max Hammer, MD Assistant Professor Tudor Jovin, MD Assistant Professor Holly Kromer Data Management Lori Massaro, MSN, CRNP Stroke Clinical Supervisor Mary Anne Rothfus, RN, BSN Clinical Research Coordinator Ken Uchino, MD Assistant Professor Syed Zaidi, MD Assistant Professor

Veterans Administration, Oakland Paula Clemens, MD Associate Professor and Chief of Service Eric Ogren, MD Assistant Professor Anne Van Cott, MD Assistant Professor

113

114

Bibliography

Three Year Departmental Bibliography

Cognitive and Behavioral Neurology Division

Oscar Lopez, MD, Professor

Carmichael O, Kuller LH, Lopez OL, Thompson PM, Dutton R, Hayashi KM, Lu A, Lee SE, Lee JY, Aizenstein HJ, Meltzer CC, Liu X, Toga A, Becker JT. Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer’s Disease and Associated Disorders 2007; 9: 14-24.

Lopez OL, Kuller L, Becker JT, DeKosky ST, Sweet, RA, Gach HM. Incidence of mild cognitive impairment and dementia in the Cardiovascular Health Study Cognition Study. Archives of Neurology 2007, 64: 416-420.

Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton R, Lu A, Lee SE, Lee JY, Aizenstein HJ, Cidis-Meltzer C, Liu Y, Toga A, Becker JT. Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiology of Aging 2007; 28: 389-397.

Rosano C, Aizenstein H, Newman A, Becker JT, Lopez OL, Kuller LH. Focal atrophy and cerebrovascular disease increase dementia risk in cognitively normal subjects. Journal of Neuroimaging 2007; 148-155.

Juengst SB, Aizenstein HJ, Figurski J, Lopez OL, Becker JT. Alterations in the hemodynamic response function in cognitively impaired HIV/AIDS subjects. Journal of Neuroscience Methods 2007; 163: 208-212.

Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton R, Lu A, Lee SE, Lee JY, Aizenstein HJ, Cidis-Meltzer C, Liu Y, Toga A, Becker JT. Acceleration of cerebral ventricular expansion in the Cardiovascular Health Study, Neurobiology of Aging 2007; 28: 1316-21.

Alcantara D, Carmichael OT, Delson E, Harcourt-Smith W, Sterner K, Frost, Dutton R, Thompson P, Aizenstein HJ, Lopez OL, Becker J, Amenta N. Localized Component Analysis. Information Processing in Medical Imaging 2007; 20: 519-31.

Nakashima-Yasuda H, Uryu K, Robinson J, Xie S, Hurtig H, Arnold S, Duda J, Siderowf A, Grossman M, Leverenz JB, Lopez OL, Hamilton RA, Tsuang DW, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Monyine TJ, Lee V, Trojanowski J. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007;114: 221-229.

Lepore N, Brun CA, Pennec X, Chou YY, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. Mean template for tensor-based morphometry using deformation tensors. (IEEE Transactions on Medical Imaging) Med Image Comput Assisst Interv Int Conf Med Image Comput Comput Assist Interv 2007; 10: 826-833.

Wilkosz P, Kodavali C, Eror E, Miyahara S, Lopez OL, Ningaonkar VL, DeKosky ST, Sweet RA. Prediction of psychosis onset in Alzheimer’s diseese: The role of depression symptom severity and the HTR2A T102C polymorphysm. American Journal of medical Genetics Part B (Neuropsychiatric Genetics) 2007; 144B: 1054-1062.

Lepore N, Brun CA, Chiang MC, Chou YY, Dutton RA, Hayashi KM, Luders E, Lopez OL, Aizenstein HJ, Toga AW, Becker JT, Thompson PM. Generalized Tensor-based Morphometry of HIV/AIDS using multivariate statistics on deformation tensors. (IEEE Transactions on Medical Imaging) Med Image Comput Assisst Interv Int Conf Med Image Comput Comput Assist Interv 2008; 27: 129-141.

Irie F, Fitzpatrick A., Lopez OL, Peila R, Newman A, Kuller L, Launer L Enhanced risk for Alzheimer’s disease in persons with type-2 diabetes and APOE-4: The cardiovascular Health Study. Archives of Neurology 2008; 65: 89-93.

116

Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH. Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 2008; 39:349-354.

Lopez OL, Mehta P, Kuller LH, Sweet RA, Gach HM, Becker JT, Chang YF, Tracy R, DeKosky ST.Plasma amyloid levels and the risk of Alzheimer’s disease in the Cardiovascular Health Study. Neurology 2008; 70:1664-1671.

Hall A, Lopez OL, Becker JT, Carmichael O, Kuller L. Basal forebrain atrophy is a presymptomatic marker for Alzheimer’s disease. Alzheimer’s and Dementia, The Journal of the Alzheimer’s Association 2008; 4: 271-279 [NIH-MS99635].

Sveinbjornsdottir S, Sigurdsson S, Kjartansson O, Aspenlund T, Eiriksdottir G, Einarsson B, Sigurdsson A, Valysdottir B, Lopez OL, van Buchem M, Jonsson P, Gudnasson V, Launer L. Prevalence of cerebral micro-bleeds in the AGES Reykjavik Study. Journal of Neurology, Neurosurgery and Psychiatry 2008;79(9): 1002-1006.

Klunder AD, Chiang MC, Dutton R, Lee SE, Toga A, Lopez OL, Aizenstein HJ, Becker JT, Thompson PM. Mapping cerebellar degeneration in HIV/AIDS. Neuroreport 2008; 19: 1655-1659.

Lopez OL, Mackell JA, Sun Y, Kassalow LM, Xu Y, McRae T, Li H. Effectiveness and safety of Donepezil in Hispanics with mild to moderate Alzheimer’s disease: A 12-week open-label study. Journal of the National Medical Association 2008: 1350-1357 [NIH-MS103564].

DeKosky ST, Williamson J, Fitzpatrick A, Kronmal RA, Ives D, Saxton JA, Lopez OL, Burke G, Carlson M, Fried L, Kuller LH, Robbins J, Tracy RP, Woolard N, Dunn L, Snitz B, Nahim R, Furberg CD, for the GEM Study Investigators. Ginkgo Biloba for primary prevention of dementia: Results of the Ginkgo Evaluation of Menory (GEM) study. Journal of the American Medical Association (JAMA) 2008: 300: 2253-2262 [NIH-MS103555].

Harris P, Alcantara D, Amenta N, Lopez OL, Eiriksdottir G, Sigurson S, Gudnason V, Thompson p, Launer L, Carmichael O. Localized measures of callosal atrophy are associated with late-life hypertension: AGES-Reykjavik Study. Neuroimage 2008 43(3): 489-496.

Leverenz J, Hamilton R, Tsuang D, Schantz A, Vavreck D, Larson EB, Kukull W, Lopez OL, Galasko D, Maslaih E, Kaye J, Nixon R, Clark C, Trojanowski J, Montine TJ. Empiric refinement of the pathologic assessment of Lewy Body related pathology in demented patients. Brain Pathology 2008; 18(2): 220-224.

Dai W, Carmichael OT, Lopez OL, Becker JT, Kuller LH, Gach MH. Effects of image normalization on statistical analysis of perfusion MRI in elderly brains. Journal of Magnetic Resonance Imaging, 2008; 28(6): 1351-1360 [NIH-MS99640].

Wilkosz P, Miyahara S, Lopez OL, DeKosky ST, Sweet RA. Psychotic symptoms identify subtypes of Alzheimer’s disease: The role of cognitive impairment, depressive symptoms, and further evidence of psycosis subtypes. American Journal of Geriatric Psychiatry and Neurology 2008; 14 (4): 352-360..

Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, DeKosky ST, Sweet RA. The relationship of excess cognitive impairment in MCI and early onset Alzheimer’s disease to the subsequent emergence of psychosis. International Psychogeriatrics 2009; 21(1): 78-85 [NIH-MS103138].

Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach MH. Patterns of altered cerebral blood flow in MCI and Alzheimer’s disease. Radiology 2009; 250: 856-866 [NIH-MS99632].

Fitzpatrick A, Kuller LH, Lopez OL, Diehr P, O’Meara E, Longstreth WT, Luschinger J. Mid- and late-life obesity: Risk of dementia in the Cardiovascular Health Cognition Study. Archives of Neurology 2009; 66(3): 336-342.

117

Saczynski JS, Sigurdsson S, Jonsdottir MK, Eiriksdottir G, Jonsson P, Garcia M, Kjatarnsson O, Lopez OL, van Buchem M, Gudnasson V, Launer LJ. Cerebral infarcts and cognitive performance: Importance of location and number of infarcts. Stroke 2009; 40:677-682.

Bhalla R, Butters MA, Becker JT, Houk P, Snitz B, Lopez OL, Aizenstein H, DeKosky ST, Reynolds CF. Patterns of mild cognitive impairment following remission of depression in the elderly. American Journal of Geriatric Psychiatry 2009; 17(4): 308-316.

Ikram, AM, Seshadri S, Bis JC, DeStefano AL, Fornage M, Aulchenko YS, Beiser A, Lumley T, Folsom AR, Bos MJ, Debette S, Cushman M, Launer LJ, Shahar E, Struchalin M, Du Y, Glazer NL, Rosamond WD, Rivadeneira F, Kelly-Hayes M, Lopez OL, Coresh J, Hofman A, DeCarli C, Heckbert SR, Koudstaal PJ, Smith NL, Rice K, Kase CS, Uitterlinden AG, Rotter JI, Boerwinkle E, Psaty BM, Mosley TH, van Duijn CM, Breteler MB, Longstreth W, Wolf PA. Genome-wide Association Studies of Incident Total Stroke and Ischemic Stroke: Meta-analysis and Replication from the CHARGE Consortium. New England Journal of Medicine 2009; 360 (17): 1718-1728.

Snitz B, Saxton J, Lopez OL, Ives D, Dunn LA, Carlson MC, Fitzpatrick A, Rapp S, DeKosky ST, and GEM investigators. Identifying mild cognitive impairment at baseline in the Gingko Evaluation of Memory (GEM) Study. Aging & Mental Health 2009; 13 (2): 171-182.

Wolk DA, Price JC, Saxton JA, Snitz BE, James J, Lopez OL, Aizenstein H, Weissfeld L, Mathis C, Klunk WE, DeKosky ST. Amyloid imaging in mild cognitive impairment subtypes. Annals of Neurology 2009; 65:557-568.

Acevedo A, Krueger KR, Navarro E, Ortiz F, Manly J, Padilla-Velez MM, Weintruab S, Lopez OL, Mungas D. The Spanish translation and adaptation of the uniform data set of the National Institute on Aging Alzheimer’s Disease Centers. Alzheimer’s Disease and Associated Disorders,2009; 23: 102-109.

Lopez OL, Becker JT, Wahed A, Saxton JA, Klunk W, Sweet RA, Wolk DA, DeKosky ST. Long-term effects of the concomitant use of menantine and cholinesterase inhibitors in the treatment of Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 2009; 80: 600-607 [NIH-MS106078].

Thompson PM, Dutton R, Hayashi KM, Lu A, Lee SE, Lee JY, Lopez OL, Aizenstein HJ, Toga A, Becker JT. 3D Mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. Neuroimage, in press.

Lee C, Lopez OL, Becker JT, Raji C, Kuller LH, Gach HM. Imaging cerebral blood flow in cognitively normal aging brain with arterial spin labeling - implications for imaging of Alzheimer’s disease. Journal of Neuroimaging, in press.

Becker JT, Lopez OL, Dew MA, Sweet RA, Chang YF, Kuller, LH, Yaffe K, Barnes D, Young J, Reynolds CF. Depressed mood is not a risk factor for incident dementia. American Journal of Geriatric Psychiatry, in press.

Saxton J, Snitz B, Lopez OL, Ives D, Dunn LA, Fitzpatrick A, Rapp S, Carlson MC, DeKosky ST, and GEM investigators. CDR and cognitive test performance in an elderly community cohort. Journal of Neurology, Neurosurgery, and Psychiatry, in press.

Barnes DE, Covinsky KE, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting Risk of Dementia in Older Adults: The Late-Life Dementia Risk Index. Neurology, in press.

Raji CA, Ho A, Parikshak N, Becker JT, Lopez OL, Kuller LH, Hua X, Leow AD, Toga AW, Thompson PM. Mapping effects of body mass index, insulinemia, and diabetes mellitus on brain structure. Human Brain Mapping, in press.

118

Judith Saxton, PhD, Associate Professor

Ahn, Inn-Sook, Kim, Ji Hae, Saxton, JA, Kim, Doh Kwan. Reliability and Validity of a short form of the Severe Impairment Battery in Korean Alzheimer’s disease patients. International Journal of Geriatric Psychiatry, 2007, 22(7): 682-7..

Dodge, HH., Du, Y., Saxton, JA., and Ganguli, M. Cognitive domains and trajectories of functional independence in non-demented elderly. The Journal of Gerontology: Medical Sciences 2006, 61A 12, 1330-1337.

DeKosky, S.T., Fitzpatrick, A., Ives, D.G., Saxton, JA, et al. The Ginkgo Evaluation of memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemporary Clinical Trials 2006, 27, 238-253.

Lavery, L., Vander Bilt, J., Chung-Chou, C.H., Saxton, JA Ganguli, M. The association between congestive heart failure and cognitive performance in a primary care population of older adults: the Steel Valley Senior Survey. International Psychogeriatrics 2007, 19:2, 215-225.

Lavery, L.L., Lu, S., Chang, C-C., Saxton, JA, Ganguli, M. Cognitive Assessment of Older Primary Care Patients with and without Memory Complaints. Journal on General Internal Medicine. 2007, 22(7): 949-54.

Klunk, W.E., Price, J.C., Mathis, C.A., Tsopelas, N.D. Lopresti, B.J., Ziolko, S.K., Bi, W., Hoge, J.A., Cohen, A.D., Ikonomovic, M.D., Saxton, JA., Snitz, B.E., Pollen, D.A., Moonis, M., Lippa, C.F., Swearer, J.M., Johnson, K.A., Rentz, D.M., Fischman, A.J., Aizenstein, H.J., and DeKosky, S.T. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. The Journal of Neuroscience, 2007, 27(23):6174-6184.

Raji C.A., Becker, J.T., Tsopelas, N.D., Price, J.C., Mathis, C.A., Saxton, J.A., Lopresti, B.J., Hoge, J.A., Ziolko, S.K., DeKosk,y S.T., Klunk, W.E. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer’s disease with Pittsburgh Compound B. Journal of Neuroscience Methods, 2008, 172, 277-282.

Nieto, M.L., Albert, S.M., Morrow, L.A., Saxton, J. Cognitive Status and Physical Function in Older African Americans, Journal of the American Geriatrics Society, 2008, Nov:56(11), 2014-9. PMCID: PMC2585150.

Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., Ziolko, S.K., James, J.A., Snitz, B.E., Houck, P.R., Wenzhu, B., Cohen, A.D., Lopresti, B.J., DeKosky, S.T., Halligan, E.M., Klunk, W.E. Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. Archives of Neurology, 2008, 65(11), 1509-1517. PMCID: PMC236844.

DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A., Lopez, O.L., Burke, G., Carlson, M.C., Fried, L.P., Kuller, L.H., Robbins, J.A., Tracy, R.P., Woolard, N.F., Dunn, L.O., Snitz, B.E., Nahin, R.L., Furberg, C.D. for the Gingko Evaluation of Memory (GEM) Study Investigators. Gingko biloba for Prevention of dementia: A Randomized Controlled Trial. Journal of American Medical Association, 2008, 300, 2253-2262. NIMHSID: NIHMS103555.

Snitz, B.E., Morrow, L.A., Rodriguez, E.G., Huber, K.A., Saxton, J.A. Subjective Memory Complaints and Concurrent Memory Performance in Older Patients of Primary Care Providers. Journal of the International Neuropsychological Society, 2008, 14, 1-10. PMCID: PMC2639714

Stoehr, G.P., Lu, Shu-Ya, Lavery, L., VanderBilt, J., Saxton, J.A., Chang, C-C.H., Ganguli, M. Factors associated with adherence to medication regimens in older primary care patients: the Steel Valley Seniors Survey. American Journal of Geriatric Pharmacotherapy, 2008, 6:255-263.

Saxton, J., Morrow, L., Eschman, A., Archer, G., Luther, J., Zuccolotto, A. Computer Assessment of Mild Cognitive Impairment. Postgraduate Medicine, 2009, 121(2), 177-185. NIHMSID: NIHMS107132.

119

Dodge, H.H., Meguro, K., Ishii, H., Yamaguchi, S., Saxton, J.A., Ganguli, M. Cross-Cultural Comparisons of the Mini-Mental State Examination between Japanese and US Cohorts. International Psychogeriatrics, 2009, Feb: 21 (1): 113-122. PMCID: PMC2639652.

Wolk, D.A., Price, J.C., Saxton, J.A., Snitz, B.E., James, J.A., Lopez, O.L., Aizenstein, H.J., Cohen, A.D., Weissfeld, L.A., Mathis, C.A., Klunk, W.E., DeKosky, S.T. Amyloid Imaging in Mild Cognitive Impairment Subtypes. Annals of Neurology, in press.

Lopez, O., Becker J., Wahed, A., Saxton, J., Sweet, R., Wolk, D., Klunk, W., DeKosky, S.T. Concomitant use of memantine and cholinesterase inhibition in the treatment of Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry, published online 29 March 2009.

Saxton, J., Snitz, BE., Lopez, OL., Ives, DG., Dunn, LO., Fitzpatrick, A., Carlson, MC., DeKosky, ST., for the GEM Study Investigators. Functional and Cognitive Criteria Produce Different Rates of MCI and Conversion to Dementia, Journal of Neurology, Neurosurgery & Psychiatry, published online 11 March 2009.

Schmitt, F.A., Saxton, J.A., Xu, Y., McRae, T., Sun, Y., Richardson, S., Li, H. A brief instrument to assess treatment response in the patient with advanced Alzheimer’s disease. Alzheimer Disease & Associated Disorders – An International Journal, in press.

Snitz, B.E., Unverzagt, F.W., Chang, C-C.H., Vander Bilt, J., Gao, S., Saxton, J., Hall, K.S. Ganguli, M. Effects of Age, Gender, education and Race on Two Tests of Language Ability in Community-Based Older Adults. International Psychogeriatrics, in press. NIHMSID: NIHMS115800.

Ganguli, M., Snitz, B.E., Lee, C-W., Vander Bilt, J., Saxton, J.A., Chang, C-CH. Age and education effects and norms on a cognitive test battery from a population-based cohort: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT). Aging and Mental Health, in press. PMC in process.

Epilepsy Division

Anto Bagić, MD, MSc, Assistant Professor and Chief, Epilepsy Division

Bagić A, Boudreau EA, Greenfield J, and Sato S. Electro-clinical Evolution of Refractory Non-Convulsive Status Epilepticus Caused by West Nile Virus Encephalitis. Epileptic Disord 2007; 9 (1) 98-103.

Lerner A, Bagić A, Boudreau B, Hanakawa T, Pagan P, Garraux G, Mari Z, Bara-Jimenez W, Aksu M, Sato S, Murphy D, Hallett H. The role of cerebellum and insula In Generation Of Tics In Patients With Tourette’s Syndrome. Neurology 2007, 68(23):1979-87.

Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagić A, Luckenbaugh DA., Drevets WC, Theodore WH. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62(11):1258-64.

Bagić A, Lupu V, Tornatore C, Kessler C. Isolated Richter's transformation of the brain. J Neurooncol 2007, 83(3):325-8.

Jia W, Xu G, Sclabassi RJ, Zhu J, Bagić A, and Sun M. Detection of Magnetic Nanoparticles with Magnetoencephalography. J Magn Magn Mater 2008 (320);1472-1478.

Lerner A, Bagić A. Olfactory pathogenesis of Parkinson disease revisited. Mov Disord 2008; 23(8):1076-84.

Bagić A, Theodore WH, Boudreau A, Bonwetsch R, Greenfield J, Elkins W, & Sato S. Does Non-Invasively Applied Interictal Hypothermia Have The Potential For Lasting Therapeutic Effect On Seizures? Acta Neurol Scand 2008; 118(4): 240-4.

120

Ottman R, Rosenberger L, Bagić A, Kamberakis K, Ritzl EK, Wohlschlager AM, Shamim S, Sato S, Liew C, Gaillard WD, Wiggs E, Reeves-Tyer P, Baker EH, & Theodore WH. Altered Language Processing in Autosomal Dominant Partial Epilepsy with Auditory Features. Neurology 2008; 71(24):1973-80.

Lerner A, Bagić A, Hanakawa T, Boudreau EA, Pagan F, Mari Z, Bara-Jimenez W, Aksu M, Sato S, Murphy DL, Hallett M. Is the insula responsible for control and suppression of natural urges? Cereb Cortex 2009; 19(1): 218-23.

Bagić A, Bagic D, Zivkovic I. First Population Study Of General Public Awareness And Perception Of Epilepsy In Bosnia & Herzegovina (BH). Epilepsy Behav 2009; 14:154-161.

Liew CJ, Lim YM, Bonwetsch R, Shamim S, Sato S, Giovacchini G, Herscovitch H, Dustin I, Bagić A, Reeves-Tyler P & Theodore WH. 18F-FCWAY and 18F-FDG PET in MRI Negative Temporal Lobe Epilepsy. Epilepsia 2009;50(2):234-9.

Bagić A, Bagic D, Zivkovic I. First Population Study Of General Public Awareness And Perception Of Epilepsy In Croatia. Epilepsy & Behavior 2009;15(2):170-8.

Gena Ghearing, MD, Assistant Professor

Ghearing GR, Munger TM, Jaffe AS, Benarroch EE, Britton, JW. Clinical Cues for detecting ictal asystole. Clinical Autonomic Research. 2007; 17(4):221-6

Cornelius JR, Boes CJ, Ghearing GR, Leavitt JA, Kumar N. Visual symptoms in the Heidenhain variant of Creutzfeldt-Jakob disease; J Neuroimaging. 2008; 19(3): 1-5

Rick Hendrickson, PhD, Assistant Professor

Pramuka, M., Hendrickson, R., Zinski, A. & Van Cott, A. (2007). A psychosocial self-management program for epilepsy: A randomized pilot study in adults. Epilepsy & Behavior, 11(4), 533-545

Bohnen, N.I., Kaufer, D.I., Hendrickson, R, Ivanco, L.S., Lopresti, B., Davis, J.G., Constantine, G., Mathis, C.A., Moore, R.Y., & DeKosky, S.T. (2007). Cholinergic denervation is associated with higher ratings of depressive symptoms in Parkinson’s disease and Parkinsonian dementia. Journal of Neurology, Neurosurgery & Psychiatry, 78, 641-643.

Anne Van Cott, MD, Assistant Professor

White, DM and Van Cott, AC. Clozapine (Clozaril), Seizures, and EEG Abnormalities. Am.J. Electroneurodiagnositic Technol. 2007 Sep; 47: 190-197.

Pramuka, M, Hendrickson, R, Zinski, A and Van Cott, AC. A Psychosocial Self-Management Program for Epilepsy: A Randomized Pilot Study in Adults. Epilepsy Behav. 2007 Dec 11 (4):533-45, 2007.

Pugh, MJ, Van Cott, AC, Cramer, JA, Knoefel, JE, Amuan, ME, Tabares, JV, Ramsay, RE and Berlowitz, DR; Treatment in Geriatric Epilepsy Research (TIGER). Trends in Antiepileptic Drug Prescribing for Older Patients with New-Onset Epilepsy: 2000-2004. Neurology 2008 May 27; 70 22 Pt 2): 2171-2178.

Van Cott, AC and Pugh, MJ. Epilepsy and the Elderly. Annals of Long-Term Care: Clinical Care and Aging 2008; 16 [1]; 28-32.

Hope, O, Kressin, N, Bokhour, B, Zeber, J, Van Cott, A, Cramer, J, Amuran, M, Knoefel, J, Pugh, M. New-onset geriatric epilepsy care: race, setting of diagnosis and choice of antiepileptic drug. Epilepsia, in press

Pugh, M, Knoefel, J, Mortensen, E, Amuran, M, Berlowitz, D, Van Cott, AC. New-onset epilepsy risk factors in older veterans. Journal of the American Geriatrics Society 2009; Feb; 57(2):237-42.

121

Headache Division Kathy Gardner, MD, Assistant Professor

Landsverk M, Ruzzo E, Mefford H, Buysse K, Buchan J, Eichler E, Petty E, Peterson E, Knutzen D, Barnett K, Farlow M, Caress J, Parry G, Quan D, Gardner K, Hong M, Simmons Z, Bird T, Chance P. 1. Duplication within the SEPT9 gene associated with a founder effect in North American families with Hereditary Neuralgic Amyotrophy. Hum Mol Genet. 2009 Apr 1;18(7):1200-8. Epub 2009 Jan 12.

Robert Kaniecki, MD, Assistant Professor and Chief, Headache Division

Kaniecki R. Tension-type headache. Headache and Pain 2007;18:27-33

Kaniecki R. Neuromodulators for migraine prevention. Headache 2008;48: 586-600.

Kaniecki R. Basilar-type migraine. Curr Pain Headache Rep 2009;13:217-220.

Lipton R, Dodick D, Kaniecki R, et al. Consistency of migraine response to sumatriptan/naproxen sodium in a placebo-controlled crossover study. Cephalalgia 2009; 29:826-836.

Movement Disorders Division

Sarah Berman, MD, PhD, Assistant Professor

Berman SB, Pineda F, and Hardwick JM (2008) Mitochondrial fission and fusion dynamics: the long and short of it. Cell Death Differ, 15(7), 1147-52. PMCID: PMC2614113.

Berman SB, Chen Y, Qi, B, McCaffery JM, Rucker EB, Goebbels S, Nave K-A, Arnold BA, Jonas EA, Pineda FJ, and Hardwick JM (2009) Bcl-xL increases mitochondrial fission, fusion and biomass in neurons. J. Cell Biol. 184(5) 707-719. PMCID: PMC2686401.

VanLaar VS and Berman SB. Mitochondrial dynamics in Parkinson’s disease (2009) Exp. Neurol. 218(2):247-56.NIHMSID: NIHMS135183

Edward A. Burton, MD, DPhil, Assistant Professor

Niranjan, A., Fellows, W., Stauffer, W., Burton EA, Hong, C.-S., Lunsford, L. D., Kondziolka, D., Glorioso, J. C., Gobbel, G. Brain radiation enhances survival of transplanted neural progenitors. J Neurosurg. 2007 Aug;107(2):383-91.

Bai Q, Garver JA, Hukriede NA, Burton EA. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 2007;35(19):6501-16.

Bai, Q., Wei, X., and Burton, E. A. (2009). Expression of a 12kb promoter fragment derived from the zebrafish enolase-2 gene in the zebrafish visual system. Neurosci Lett. 449(3), 252-7

J. Timothy Greenamyre, MD, PhD, Professor and Chief, Movement Disorders

Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, Matsuno-Yagi A, Miller GW, Greenamyre JT (2007) Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem 100:1469-1479.

Panov A, Dikalov S, Shalbuyeva N, Hemendinger R, Greenamyre JT, Rosenfeld J (2007) Species- and tissue-specific relationships between mitochondrial permeability transition and generation of ROS in brain and liver mitochondria of rats and mice. Am J Physiol Cell Physiol 292:C708-718.

122

Greenamyre JT (2007) Huntington's disease: getting closer. Am J Psychiatry 164:1318.

Greenamyre JT (2007) Huntington's disease--making connections. N Engl J Med 356:518-520.

Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, Papa SM (2007) Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 323:318-326.

Betarbet R, Greenamyre JT (2007) Parkinson's disease: animal models. Handb Clin Neurol 83:265-287.

Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28:2783-2792.

Mastroberardino PG, Orr AL, Hu X, Na HM, Greenamyre JT (2008) A FRET-based method to study protein thiol oxidation in histological preparations. Free Radic Biol Med 45:971-981.

Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, Yagi T (2008) Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One 3:e1433.

Greene JG, Greenamyre JT, Dingledine R (2008) Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience 152:198-207.

Dorsey ER, Beck CA, Adams M, Chadwick G, de Blieck EA, McCallum C, Briner L, Deuel L, Clarke A, Stewart R, Shoulson I (2008) Communicating clinical trial results to research participants. Arch Neurol 65:1590-1595.

Huntington Study Group TREND-HD Investigators (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582-1589.

Mastroberardino PG, Hoffman EK, Horowitz MP, Betarbet R, Taylor G, Cheng D, Na HM, Gutekunst CA, Gearing M, Trojanowski JQ, Anderson M, Chu CT, Peng J, Greenamyre JT (2009) A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis 34:417-431.

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I (2009) Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 73:385-392.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis 34:279-290.

Cannon JR, Greenamyre JT (2009) NeuN is not a reliable marker of dopamine neurons in rat substantia nigra. Neurosci Lett 464:14-17.

Bayir H, Kapralov AA, Jiang J, Huang Z, Tyurina YY, Tyurin VA, Zhao Q, Belikova NA, Vlasova, II, Maeda A, Zhu J, Na HM, Mastroberardino PG, Sparvero LJ, Amoscato AA, Chu CT, Greenamyre JT, Kagan VE (2009) Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J Biol Chem 284:15951-15969.

Tapias V, Cannon JR, Greenamyre JT (2009) Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res. In press.

Drolet RE, Cannon JR, Montero L, Greenamyre JT (2009) Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis. In press.

123

David Hinkle, MD, PhD, Assistant Professor

Mullett SJ, Hamilton RL, and Hinkle DA. DJ-1 immunoreactivity in human brain astrocytes is dependent on infarct presence and infarct age. Neuropathology 29:125-131, 2009.

Mullett SJ and Hinkle DA. DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone. Neurobiology of Disease 33:28-36, 2009.

Eric Hoffman, PhD, Research Assistant Professor

Matthews AG, Hoffman E.K., Zezza N, Stiffler S, Hill SY. The role of the GABRA2 polymorphism in multiplex alcohol dependence families with minimal comorbidity: within-family association and linkage analyses. Journal of Studies on Alcohol and Drugs. 2007 Sep;68(5):625-33.

Hill, S.Y., Hoffman E.K., Zezza N, Thalamuthu A, Weeks DE, Mathews AG, Mukhopadhyay I. Dopaminergic mutations: Within family association and linkage in multiplex alcohol dependence families. American Journal of Medical Genetics B (Neuropsychiatric Genetics)147B(4):517-526, 2008.

Thiels, E, Hoffman, E.K., Gorin, MB. A reliable behavioral assay for the assessment of sustained photophobia in mice. Current Eye Research. May;33(5):483-491 2008.

Mastroberadino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylo,G., Cheng, D., Na, H.M. Gutekunst, M., Trojanoski, J.Q., Anderson, M., Chu, C.T., Peng, J., Greenamyre, J.T. A novel transferring/TFR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease. Neurobiology of Disease. June;34(3):417-432. 2009.

Samay Jain, MD, Assistant Professor

Jain S., Waters C., Controversies with Dopamine Agonists: somnolence, valvulopathy and repetitive behaviors. Current Drug Therapy, 2007;2(1):17-20.

Vaughan C, Samy H, Jain S. Selective saccadic palsy after cardiac surgery. Neurology 2008 78(21):1746.

Mestre T, Jain S, Ferreira J. A multimodal approach to physical therapy in Parkinson disease: optimizing strategies. Movement Disorders. In press.

Robert Y. Moore, MD, PhD, Professor

Moore RY. Suprachiasmatic nucleus in sleep-wake. Sleep Med. 2007;8 Suppl 3:27- 33.

Bohnen NI, Kuwabara H, Constantine GM, Mathis CA, Moore RY. Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett.2007 13;424:185-9.

Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol. 2007;254:84-90.

Bohnen NI, Kaufer DI, Hendrickson R, Constantine GM, Mathis CA, Moore RY. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78:641-3.

Germain A, Nofzinger EA, Meltzer CC, Wood A, Kupfer DJ, Moore RY, Buysse DJ. Diurnal variation in regional brain glucose metabolism in depression. Biol Psychiatry. 2007;62:438-45.

Bohnen NI, Studenski SA, Constantine GM, Moore RY. Diagnostic performance ofclinical motor and non-motor tests of Parkinson disease: a matched case-controlstudy. Eur J Neurol. 2008;15:685-91.

Hall AM, Moore RY, Lopez OL, Kuller L, Becker JT. Basal forebrain atrophy is a presymptomatic marker for Alzheimer's disease. Alzheimers Dement. 2008;4:271-9.

124

Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett.2008;447:12-6.

Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function inParkinson's disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29(3):381-90.

Kondziolka D, Ong JG, Lee JY, Moore RY, Flickinger JC, Lunsford LD. GammaKnife thalamotomy for essential tremor. J Neurosurg. 2008;108:111-7.Erratum in: J Neurosurg. 2008;108:635.

Neuroimmunology/Multiple Sclerosis Rock Heyman, MD, Assistant Professor and Division Chief

O’Leary Margie, Lammers S, Mageras A, Boyd M, Constantino R, Heyman R . Relationship Between Domestic Violence and Multiple Sclerosis. Int J MS Care 2008; 10:27‐32

O’Leary, M, Heyman R, Erickson, J, and Chancellor, M. Premature Ejaculation in MS: A Review, June 2007, posted on the Consortium of MS Centers Website

Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis in children: Comparison of presenting features after long term follow-up. Developmental Medicine and Child Neurology, 2009; 51(6):480-486

Neuromuscular Diseases Division

David Lacomis, MD, Professor and Chief, Neuromuscular Diseases

Zivkovic SA, Lacomis D. Painful sensory neuropathy associated with hereditary spherocytosis. Ann Hematol 2007;86:535-536.

Zivkovic SA, Asherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand 2007;115:432-436.

Yeaney G, Linesch D, Lacomis D. Neuromuscular pathology case. [Cylindrical spirals myopathy] J Clin Neuromusc Dis 2007;8-234-236.

Lacomis D, Zivkovic SA. Approach to vasculitic neuropathies. J. Clin Neuromusc Dis 2007;9:265-276.

Ranganathan S, Georgina CBN, Henry S, Lutka F, Sathanoori R, Lacomis D, Bowser R. Comparative proteomic profiling of cerebrospinal fluid between living and postmortem ALS and control subjects. Amyotrophic Lateral Sclerosis 2007;8:373-379.

Wang H, Larrieviere KS, Keller KE, Ware KA, Burns TM, Conaway MA, Lacomis D, Pattee GL, Phillips LH, Solenski NJ, Zivkovic SA, Bennett JP. R(+) pramipexole as a mitochondrially focused neuroprotectant: Initial phase II studies in ALS. Amyotrophic Lateral Sclerosis 2007;9:50-58.

Lu A, Yeaney GA, Lacomis D. Neuromuscular pathology case. J Clin Neuromusc Dis 2007,9:361-363.

Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008;38:1206-1210.

Lacomis D. Neuromuscular pathology case (IBM in an HIV patient). J Clin Neuromusc Dis 2008;10:79-82.

Stevens MA, Yeaney GA, Lacomis D. 42-year-old man with ventilatory failure, progressive weakness and discoid lupus. (Case of the Month) Brain Pathol 2009;19:153-156.

125

López de Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extra-nodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum, in press.

Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR 2009, in press.

Saša Živković, MD, Associate Professor

Živković SA, Lacomis D. Painful sensory neuropathy associated with hereditary spherocytosis. Ann Hematol 2007; 86:535-536.

Živković SA, Asherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand 2007:115:432-436.

Živković, Medsger TA Jr. Myasthenia gravis and scleroderma: two cases and a review of the literature. Clin Neurol Neurosurg. 2007; 109:388-391.

Živković S. Neuroimaging and neurologic complications after organ transplantation. J Neuroimaging. 2007; 17:110-123.

Lacomis D, Živković SA. Approach to vasculitic neuropathies. J Clin Neuromuscul Dis 2007; 9(1):265-276

Wang H, Larrieviere KS, Keller KE, Ware K, Burns TM, Conaway M, Lacomis D, Pattee GL, Phillips LH, Solenski NJ, Živković SA, Bennett JP. R(+)-Pramipexole as a mitochondrially focused neuroprotectant: Initial phase II studies in ALS. Amyotroph Lateral Scler 2008; 9(1):50-58.

Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry C, Brown RH, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ, The Northeast ALS and the National VA ALS Research Consortium. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009; 10(2):99-106.

Živković SA, Jumaa M, Barisic N, McCurry KR. Neurologic complications following lung transplantation. J Neurol Sci 2009; 280(1-2):90-93.

Živković S, Delios A, Lacomis D, Lentzsch S. Small fiber neuropathy associated with multiple myeloma and IgA monoclonal gammopathy. Ann Hematol 2009, in press.

Neurooncology Program

Frank Lieberman, MD, Associate Professor

Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC Jr, Pollack IF. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007 Dec 19;5:67.

Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD,Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 1;13(23):7133-8.

126

Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, Aikin A, Whitcomb P, Renbarger J, Lieberman FS, Berg SL, Blaney SM. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul;62(2):355-61.

Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP,DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD; North American Brain Tumor Consortium. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug;10(4):631-42.

Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr;10(2):162-70. Epub 2008 Mar 4. PubMed PMID: 18356283; PubMed Central PMCID: PMC2613818.

Marsh GM, Buchanich JM, Youk AO, Cunningham MA, Lieberman FS, Kennedy KJ, Lacey SE, Hancock RP, Esmen NA. Long-term health experience of jet engine manufacturing workers: II. Total and cause-specific mortality excluding central nervous system neoplasms. J Occup Environ Med. 2008 Oct;50(10):1117-29. PubMed PMID: 18849757.

Marsh GM, Buchanich JM, Youk AO, Cunningham MA, Lieberman FS, Kennedy KJ, Lacey SE, Hancock RP, Esmen NA. Long-term health experience of jet engine manufacturing workers: I. Mortality from central nervous system neoplasms. J Occup Environ Med. 2008 Oct;50(10):1099-116. PubMed PMID: 18849756.

Park DM, Yeaney GA, Hamilton RL, Mabold J, Urban N, Appleman L, Flickinger J, Lieberman F, Mintz A. Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme. Neuro Oncol. 2009 Jan 12.

Buchanich JM, Youk AO, Marsh GM, Bornemann Z, Lacey SE, Kennedy KJ, Hancock RP, Esmen NA, Lieberman FS. Methodological issues in a retrospective cancer incidence study. Am J Epidemiol. 2009 Jul 1;170(1):112-9. Epub 2009 May 4.

Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L,Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan;91(2):183-9.

Kano H, Niranjan A, Khan A, Flickinger JC, Kondziolka D, Lieberman F, Lunsford LD. Does radiosurgery have a role in the management of oligodendrogliomas? J Neurosurg. 2009 Mar;110(3):564-71. PubMed PMID: 18950268.

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2009 Jun 28.

127

Research Division

Guodong Cao, PhD, Research Assistant Professor

Zhang F, Wang S, Cao G, Gao Y, Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis. 25(1):45-53, 2007.

Ji X, Luo Y, Ling F, Stetler RA, Lan J, Cao G, Chen J. Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia: a mechanism for neuroprotection. Front Biosci. 12:1737-47, 2007.

Luo Y, Ji X, Ling F, Li W, Zhang F, Cao G, Chen J. Impaired DNA repair via the base-excision repair pathway after focal ischemic brain injury: a protein phosphorylation-dependent mechanism revered by hypothermic neuroprotection. Front Biosci. 12:1852-62, 2007.

Yin W, Cao G, Johnnides MJ, Signore AP, Hickey RW, and Chen J. Hypoxic preconditioning protects against hypoxic/ischemic brain injury via PI3K/Akt activation and suppression of pro-inflammatory responses. Stroke. 38(3):1017-24, 2007.

Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin Promotes Neuronal Replacement via Revascularization and Neurogenesis after Neonatal Hypoxia/Ischemia in Rats. Stroke. 38(10):2795-803, 2007

Cao G, Xing J, Xiao X, Cao G, Liou AKF, GaoY, Yin X-M, Graham SH, Chen J: Critical role of calpain in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci. 27(35):9278-93, 2007.

Wei Y, Signore A, Iwai M, Cao G, Gao Y, Chen J. Rapidly Increased Neuronal Mitochondrial Biogenesis Following Hypoxic-Ischemic Brain Injury. Stroke. 39(11):3057-63, 2008.

Stetler RA, Cao G, Wang Z, Zhang F, Gao Y, Chen J. HSP27 protects against neuronal ischemia via attenuation of signaling pathways upstream of mitochondrial dysfunction. J Neurosci. 2008, 28(49): 13038-13055.

Vosler P, Sun D, Wang S, Gao Y, Kintner DB, Signore AP, Cao G, Chen J. Calcium Dysregulation Induces Apoptosis-inducing Factor Release: Cross-talk Between PARP-1- and Calpain- Signaling Pathways. Experimental Neurology. 2009 May 7. [Epub ahead of print].

Gao Y, Cao G, Stetler RA, Vosler P, Shen H, Zhang W, Chen J. Limiting hypoxic/ischemic brain injury by targeting the Apaf-1 signaling pathway. J Neuro Res (in press).

Iwai M, Xing J, Stetler RA, Gao Y, Cao G. Delayed administration of erythropoietin protects against ischemic injury by reducing white matter injury and enhancing neurogenesis. Stroke. (In press)

Jun Chen, MD, Professor

Zhang F, Wang S, and Chen J. Increased phosphorylation of signal transducers and activators of transcription 5 in hippocampal CA1 after global cerebral ischemia in rats. Neurobiology of Disease 2007 Jan;25(1):45-53.

Yin W, Signore AP, Iwai, M, Cao G, Gao Y, Johnnides MJ, Hickey RW, and Chen J. Preconditioning Suppresses Inflammation in Neonatal Hypoxic Ischemia via Akt Activation. Stroke 2007, 38:1017-1024.

Ji X, Luo Y, Lin F, Stetler RA, Lan J, Cao G, and Chen J. Mild hypothermia diminishes oxidative DNA damage and pro-death signaling events after cerebral ischemia: a mechanism for neuroprotection. Frontiers in Bioscience 2007, 12:1737-47.

128

Luo Y, Ji X, Lin F, Li W, Zhang F, Cao G, and Chen J. Impaired DNA repair via the base-excision pathway after focal ischemic brain injury: a protein phosphorylation-dependent mechanism reversed by hypothermic neuroprotection. Frontiers in Bioscience 2007, 12:1852-62.

Zhang F, Wang S, Signore A, and Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke 2007, 38: 2329-36.

Iwai M, Cao G, Yin W, Stetler RA, Liu J, and Chen J. Erythropoietin promotes neuronal replacement via tissue protection, angiogenesis and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007, 38: 2795-2803.

Cao G, Xing J, Xiao X, Liou AFK, Yin XM, RSB Clark, Graham SH, Chen J. Critical role of calpain I in activating the apoptosis-inducing factor signaling pathway in ischemic neuronal injury. Journal of Neuroscience 2007, 27(35): 9278-9293.

Li W, Wu S, Hickey RW, Ross ME, Chen J, and Graham SH. Neuronal Cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture. Neurochem Res. 2008, 33: 490-99.

Adhami F, Dan Y, Yin W, Schloemer A, Burns KA, Liao G, Degen JL, Chen J, Kuan C. A Critical Role of Plasminogen Activators in Neonatal Hypoxic-Ischemic Brain Injury. Am. J. Pathol. 2008, 172: 1704-16

Wang S, Xing Z, Vosler P, Yin H, Signore A, Stetler RA, Gao Y, and Chen J. NAD replenishment confers marked neuroprotection against oxygen-glucose deprivation: role of enhanced DNA repair. Stroke 2008, 49:2587-2593.

Yin W, Signore A, Gao Y, and Chen J. Rapidly increased mitochondrial biogenesis after hypoxic-ischemic brain injury. Stroke 2008, 39: 3057-3063.

Zhang F and Chen J. Leptin protects hippocampal CA1 neurons against ischemic injury. J Neurochem. 2008 107: 578-587.

Stetler RA, Cao G, Gao Y, Zhang F, Wang S, Weng Z, Vosler P, Zhang L, Signore A, Graham S, and Chen J. Hsp27 protects against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling. J Neurosci 2008, 28: 13038-13055.

Shue EH, Carson-Walter EB, Liu Y, Winans BN, Ali ZS, Chen J, and Walter KA. Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. BMC Neuroscience 2008, 9:29-36.

Paula Clemens, MD, Associate Professor and Chief of Service, VAMC

Mayhew JE, Florence JM, Henricson EK, Leshner RT, McCarter, RJ, Escolar DM, the CINRG Investigators. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2007 Jan;35:36-42

Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, Fertig N, Oury T, Vandersteen D, Clemens P, Camacho CJ, Weinberg A, Ascherman DP. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun 2007 Sep-Nov;29(2-3):174-86

Reay DP, Bilbao R, Koppanati BM, Cai L, O’Day TL, Jiang Z, Zheng H, Watchko JF, Clemens PR. Full-length dystrophin gene transfer to the mdx mouse in utero. Gene Therapy 2008 Apr;15(7):531-6. doi: 10.1038/sj.gt.3303113

Eghtesad S, Morel PA, Clemens PR. The Companions: Regulatory T Cells and Gene Therapy. Immunology. 2009;127:1-7

129

Koppanati BM, Li J, Xiao X, Clemens PR. Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: Treatment implications for muscle disorders. Gene Ther 2009 (In press)

Steven Graham, MD, PhD, Professor and Vice Chair for Research and Chief, Research Division

Hickey RW, Adelson PD, Johnnides MJ, Davis DS, Yu Z, Rose ME, Chang YF, Graham SH. Cyclooxygenase-2 Activity Following Traumatic Brain Injury in the Developing Rat. Pediatr Res. 2007 (e pub ahead of print).

Cao G., Xing J., Xiao X., Liou A. K., Gao Y., Yin X. M., Clark R. S., Graham SH. and Chen J. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 27, 9278-9293, 2007.

Li W, Wu S, Hickey RW, Rose ME, Chen J, Graham SH. Neuronal Cyclooxygenase-2 Activity and Prostaglandins PGE2, PGD2, and PGF2alpha Exacerbate Hypoxic Neuronal Injury in Neuron-enriched Primary Culture. Neurochem Res 33:490-499, 2008.

Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan ML, Chu CT, Kochanek PM, Dixon CE, Jenkins LW, Graham SH, Watkins SC, Clark RS. Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteinyl ethyl ester. J Cereb Blood Flow Metab 28: 540-550, 2008

Tehranian R, Rose ME, Vagni V, Pickrell AM, Griffith RP, Liu H, Clark RS, Dixon CE, Kochanek PM, Graham SH. Disruption of Bax Protein Prevents Neuronal Cell Death but Produces Cognitive Impairment in Mice following Traumatic Brain Injury. J Neurotrauma 25:755-767, 2008.

Ahmad M., Rose ME, Vagni V, Griffith R; Dixon CE, Kochanek P, Hickey R, Graham SH. Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice. J Neurochem Res. 86: 3605-12, 2008.

Mu Y, Klamerus MM, Miller TM, Rohan LC, Graham SH, Poloyac S. Intravenous Formulation of HET0016 for Inhibition of Rat Brain 20-Hydroxyeicosatetraenoic Acid (20-HETE) Formation. Drug Metab Dispos 36, 2324-30, 2008.

Stetler RA, Cao G, Gao Y, Zhang F, Wang S, Weng Z, Vosler P, Zhang L, Signore A, Graham SH, Chen J. Hsp27 protects against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling. J Neurosci 28:13038-13055, 2008.

Ahmad M, Zhang Y, Liu H, Rose M, Graham SH. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res 2009 (in press).

Vosler PS, Graham SH, Wechsler LR, Chen J. Mitochondrial targets for stroke: Focusing basic science research toward development of clinically translatable therapeutics. Stroke 2009 (in press).

Teresa Hastings, PhD, Associate Professor

Venneti, S., Lopresti, B.J., Wang, G., Slagel, S.L., Mason, N.S., Mathis, C.A., Fischer, M.L., Larsen, N.J., Mortimer, A.D., Hastings, T.G., Smith, A.D., Zigmond, M.J., Suhara, T., Higuchi, M. and Wiley, C.A. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: Implications for PET imaging of microglial activation. J. Neurochem. 102: 2118-2131, 2007.

Weng, Z.,Signore, A.P., Gao, Y., Wang, S., Zhang, F., Hastings, T., Yin, X.M., and Chen, J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J Biol Chem. 282:34479-91, 2007.

130

Chen,L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W., Hastings, T.G., Kang, U.J., and Zhuang, X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28:425-33, 2008.

Van Laar, V.S., Dukes, A.A., Cascio, M. and Hastings, T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: Implications for Parkinson disease. Neuro. Biol. Dis. 29: 477-489, 2008.

Dukes, A.A.,Van Laar, V.S., Cascio, M. and Hastings, T.G. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J. Neurochem. 106: 333-346, 2008.

Van Laar, V.S., Mishizen, J.A., Cascio, M. and Hastings, T.G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiology of Disease 34: 487-500, 2009.

Devinney, MJ, Malaiyandi, LM, Vergun, O, Defranco, DB, Hastings, TG, and Dineley, KE. A comparison of Zn2+- and Ca2+-triggered depolarization of liver mitochondria reveals no evidence of Zn2+-induced permeability transition. Cell Calcium 45:447-55, 2009.

Milos Ikonomovic, MD, Associate Professor

Ikonomovic MD, Abrahamson EE, Isanski BA, Wuu J, Mufson EJ, DeKosky ST (2007) Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch Neurol 64(9):1312-1317.

DeKosky ST, Abrahamson EE, Paljug WR, Wisniewski S, Clark RSB, Ikonomovic MD (2007) Association of increased cortical soluble Aβ42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 64(4):541-544.

Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of Presinilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27(23):6174-6184.

Perez SE, Dar S, Ikonomovic MD, DeKosky ST, Mufson EJ (2007) Cholinergic forebrain degeneration in APPswe/PS1ΔE9 transgenic mouse. Neurobiol Disease 28(1):3-15.

Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST, Ginsberg SD, Mufson EJ (2007) Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer’s disease. Arch Neurol 64(12):1771-1776.

Ikonomovic MD, Mathis CA, Price JC, Hamilton RL, Abrahamson EE, Paljug WR, Debnath ML, Hope CE, Isanski BA, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Klunk WE, DeKosky ST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(6):1630-1645.

Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 56(12):1065-1073.

Iwakiri M, Mizukami K, Ikonomovic MD, Ishikawa M, Abrahamson EE, Dekosky ST, Asada T (2008) An immunohistochemical study of GABA receptor gamma subunits in Alzheimer's disease hippocampus: Relationship to neurofibrillary tangle progression. Neuropathology 2008 Nov 19 (Epub ahead of print).

Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST (2009) Cortical α7 nicotinic acetylcholine receptor and β-amyloid levels in early Alzheimer disease. Arch Neurol 66(5):646-651.

131

Cohen AD, Ikonomovic MD, Abrahamson EE, Paljug WR, DeKosky ST, Lefterov IM, Koldamova RP, Shao L, Debnath ML, Mason NS, Mathis CA, Klunk WE (2009). Anti-amyloid effects of small molecule Aβ-binding Agents in PS1/APP mice. Letters in Drug Design & Discovery (In Press).

Ikonomovic MD (2009) Heart and brain tissue banks for research on co-occurring cardiovascular and neurological/psychiatric disorders. Cardiovascular Psychiatry and Neurology, Vol. 2009, Article ID 427840.

Abrahamson EE, Ikonomovic MD, Dixon CE and DeKosky ST (2009) Simvastatin therapy prevents brain trauma-induced elevations in β-amyloid peptide levels. Annals of Neurology (In Press).

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, Perry A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC (2009) PiB-PET detection of cerebral Aβ may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch Neurol (In Press).

Ruth Perez, PhD, Assistant Professor

Lin E, Cavanaugh JE, Leak RK, Perez RG¶, and Zigmond MJ¶ (¶contributed equally) (2008) Rapid activation of ERK by 6-OHDA promotes dopaminergic cell survival. J Neurosci Res. 86:108-17.

Sodhi CP, Perez RG, Gottardi-Littell NR (2008) Phosphorylation of β-amyloid precursor protein (APP) cytoplasmic tail facilitates amyloidogenic processing during apoptosis. Brain Research 1198C:204-212.

Alerte TNM, Akinfolarin AA, Friedrich EE, Mader SA, Hong C-S, Perez RG. (2008) α-Synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: Lessons from viral transduction of knockout mice. Neuroscience Letters 435:24-29. Wang J, Lou H, Pedersen CJ, Smith AD and Perez RG (2009) 14-3-3ζ contributes to tyrosine hydroxylase activity in MN9D cells: Localization of dopamine regulatory proteins to mitochondria. J. Biol. Chem. 284 (21):14011-14019

Amanda Smith, PhD, Research Assistant Professor

Venneti S, Lopresti, BJ, Wang,G, Slagel, SL, N. Scott Mason NS, Chester A. Mathis, CA, Michelle L. Fischer, ML, Larsen, NJ, Mortimer, AD, Teresa G. Hastings, TG, Smith, AD, Zigmond, MJ, Suhara, T, Higuchi, M and Wiley, CA (2007) The high-affinity Peripheral Benzodiazepine Receptor ligand [11C]-DAA1106 results/enables in improved PET imaging of microglia compared to [11C]-PK11195 in rodent models of neuroinflammation. J. Neurochem. 102:2118- 2131.

Lindgren N, Leak RK, Smith AD* and Zigmond MJ* (2008) Activation of ERK1/2 by GDNF and its relations to neuroprotection in a mouse model of Parkinson’s disease. J Neurosci Res 86:2039-49 [* denotes equal contribution]

Pienaar IS, Kellaway LA, Russell VA, Smith AD, Zigmond MJ, Stein DJ and Daniels WMU (2008) Early life stress exaggerates the toxic effects of 6-OHDA in adult rats: Implications for neurodegenerative disease. Stress. 11:448-456 Wang J, Lou H, Pedersen CJ, Smith AD and Perez RG (2009) 14-3-3ζ contributes to tyrosine hydroxylase activity in MN9D cells: Localization of dopamine regulatory proteins to mitochondria. J. Biol. Chem. 284 (21):14011-14019

Olga Vergun, PhD, Research Assistant Professor

Vergun O. (2007) Studies elucidating the mechanisms of calcium induced mitochondrial depol-arization in individual isolated brain mitochondria. Biochemistry (Moscow) Supplemental Series A. 1(1):138-144.

132

Michael Zigmond, PhD, Professor

Venneti S, Lopresti BJ, Wang G, Slagel SL, Mason NS, Mathis CA, Fischer ML, Larsen NJ, Mortimer AD, Hastings TG, Smith AD, Zigmond MJ, Suhara T, Higuchi M, Wiley, CA. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and ®-PK11195 in rat models of neuroinflammation: Implications for PET imaging of microglial activation. J Neurochem, 102:2118-31, 2007.

Lin E, Cavanaugh JE, Leak, RK, Perez RG, Zigmond MJ. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res, 86: 108-117, 2007.

Lindgren N, Leak RK, Carlson KM, Smith AD, Zigmond MJ. Activation of the extracellular signal-regulated kinases 1 and 2 by glial cell line-derived neurotrophic factor and its relation to neuroprotection in a mouse model of Parkinson's disease. J. Neurosci Res, 86:2039-49, 2008.

Pienaar IS, Kellaway LA, Russell VA, Smith AD, Stein DJ, Zigmond MJ, Daniels WM. Material separation exaggerates the toxic effects of 6-hydroxydopamine in rats: implications for neurodegenerative disorders. Stress, 11: 448-56, 2008.

Leak RK, Zigmond MJ, Liou AKF. Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism. J Neurochem, 106: 860-874, 2008.

Liou AKF, Leak RK, Li L, Zigmond MJ. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiology of Disease, 32116-124, 2008.

Vascular Neurology

Max Hammer, MD, Assistant Professor

Tayal AH, Gupta R, Yonas H, Jovin T, Uchino K, Hammer M, Wechsler L, Gebel JM. Quantitative Perihematomal Blood Flow in Spontaneous Intracerebral Hemorrhage Predicts In-Hospital Functional Outcome. Stroke. 2007 Feb;38(2):319-24

Vora NA, Gupta R, Thomas AJ, Horowitz MB, Tayal AH, Hammer MD, Uchino K, Wechsler LR, Jovin TG. Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. Am J Neuroradiol. 2007 Aug;28(7):1391-4.

Bhatt A, Vora NA, Thomas AJ, Majid A, Kassab M, Hammer MD, Uchino K, Wechsler L, Jovin TG, Gupta R. Lower pretreatment cerebral blood volume affects hemorrhagic risks after intra-arterial revascularization in acute stroke. Neurosurgery. 2008 Nov;63(5):874-8

Hammer MD, Wechsler LR. Neuroimaging of ischemia and infarction. Seminars in Neurology, Rohit Bakshi, M.D., F.A.A.N., Guest Editor. Semin Neurol. 2008 Sep;28(4):446-52.

Tudor Jovin, MD, Assistant Professor

Nemoto EM., Yonas Y., Pindzola RR., Kuwabara H., Sashin D., Chang Y., Jovin TG. PET OEF reactivity for hemodynamic compromise in occlusive vascular disease. J Neuroimaging 2007 Jan 17 (1) 54-60

Thomas A., Gupta R., Tayal A., Horowitz M., Jovin T** Stenting and angioplasty of the symptomatic chronically occluded carotid artery report of two cases. American Journal of Neuroradiol 2007 Jan 28(1):168-71

Jovin TG., Gupta R., Horowitz MB., Grahovac SZ, Jungreis C., Wechsler LR., Gebel J., Yonas H. Pretreatment cerebral ipsilateral regional cortical blood flow influences vessel recanalization in intraarterial thrombolysis for MCA occlusion. Am Journal of Neuroradiol. 2007 Jan 28(1):164-7

133

Gupta R., Jovin TG. Endovascular management of acute ischemic stroke : advances in patient and treatment selection . Expert rev Neurotherap. 2007 Feb :7(2):143-53

Jovin TG, Gupta R., Horowitz MB Management of symptomatic intracranial atherosclerotic disease. Curr Cardiology Reports. 2007 Mar 9(1):32-40

Vora NA, Germanwala AV, Thomas AJ, Horowitz MB, Jovin TG**. Endovascular management of traumatic ophthalmic artery aneurysm. J of trauma 2007 Jul 63(1):192-4

Vora NA., Gupta R., Thomas AJ., Horowitz MB., Tayal AH., Hammer MD., Uchino K., Wechsler LR., Jovin TG.** Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke AJNR American Journal of Neuroradiology 2007 Aug;28(7):1391-4.

Levy R., Mehta R., Gupta R., Hanel RA., Chamchuk AJ, Fiorella D., Woo HH, Albuquerque FC, Jovin TG, Horowitz MB, Hopkins LN. Self expanding stents for recanalization for acute cerebrovascular occlusion. American Journal of Neurorad 2007 May 28(5):816-22 Erratum in AJNR 2007 Sep 28 (8) 1624

Skidmore ER, Rodgers JC, Chandler LS, Jovin TG, Holm MB. A precise method for linking neuroanatomy to function after stroke: a pilot study. Topics in Stroke Rehab 2007 Sep- Oct 14(5)12-7

Qureshi AL, Abou-Chebl A, Jovin TG., Qualification requirements for performing neurointerventional procedures. A report of the practice guidelines committee of the American Society of Neuroimaging and the Society of Vascular and Interventional Neurology. Journal of Neuroimaging 2007 Nov 20 ( Epub ahead of print)

Gupta R, Vora N., Thomas A , Crammond D, Roth R., Jovin T., Horowitz M. Symptomatic cerebral air embolism during neuro-angiographic procedures incidence and problem avoidance. Neurocritical Care 2007:7(3)241-6

Gupta R., Crago EA, Gallek M., Horowitz M., Hoffman L., Jovin T., Yonas H. Reduced ipsilateral hemispheric cerebral blood flow at admission is predictive of vasospasm with infarction after aneurismal subarachnoid hemorrhage. Neurocritical Care 2007 Oct

Tomycz ND, Holm MB, Horowitz MB., Wechsler LR., Raina K., Gupta R., Jovin TG**. Extensive brainstem ischemia on neuroimaging does not preclude meaningful recovery from locked in syndrome two cases of endovascularly managed basilar thrombosis J Neuroimaging 2008 Jan 18(1):15-7

Vora N, Thomas A, Germanwala A, Jovin T., Horowitz M. Retrieval of a displaced detachable coil and intracranial stent with an L5 Merci Retriever during endovascular embolization of an intracranial aneurysm. J Neuroimaging 2008 Jan 18(1) 81-4

Germanwala AV, Vora NA, Thomas AJ, Jovin T., Gologorsky Y, Horowitz MB. Ethylenvinyl alcohol copolymer (Onyx 18) used in endovascular treatment of vein of Galen malformation Child Nerv System 2008 Jan:24(1):135-8

Barbato JE, Dillavou E, Horowitz MB, Jovin TG, Kana E., David S., Makaroun MS. A randomized trial of carotid artery stenting with and without cerebral protection. J Vasc Surg 2008 Apr 47(4):760-5

Thomas AJ., Germanwala AV, Vora N., Prevedello DM, Jovin T, Kassam A, Horowitz M. Dual origin extracranial vertebral artery: case report and embryology. J Neuroimaging 2008 Apr 18(2) 173-6 ( Epub 2007 Nov 6)

Jankowitz BT, Vora N., Jovin T, Horowitz M. Treatment of pediatric intracranial vascular malformation using Onyx 18. J Neurosurg Padiatr 2008 Sep 2(3) 171-6

Jankowitz BT, Vora N., Jovin T., Horowitz M Ear necrosis resulting from endovascular Onyx 18 embolization of a dural arteriovenous fistula fed by the posterior auricular artery. J Neuroimaging. 2008 Oct 31

134

Bhatt A, Vora NA, Thomas AJ, Majid A, Kassab M., Hammer MD, Uchino K., Wechsler LR, Jovin TG, Gupta R. Lower pretreatment cerebral blood volume affects hemorrhagic risks after intraarterial revascularization in acute stroke . Neurosurgery 2008 Nov; 63(5):874-8discussion 878-9

Kim SR, Vora N, Jovin TG, Gupta R , Thomas A, Kassam A MD, Lee K, Gologorsky Y, Jankowitz B, Panapitiya N, Aleu A, Horowitz MB. Anatomic Results and Complications of Stent-Assisted Coil Embolization of Intracranial Aneurysms. Interventional Neuroradiology 2008 14: 3, 267

Jovin TG, Demchuk A, Gupta R . Pathophysiology of acute ischemic stroke. Neurology Continuum, December 2008 14:6, 28-45

Kathia P, Levine J, Jovin T Intravenous thrombolytic therapy for acute ischemic stroke . Neurology Continuum, December 2008 14:6, 46-60

Complications of ischemic stroke: Prevention and Management Barett K., Khatri P, Jovin T, Neurology Continuum, December 2008 14:6, 61-79

Vora N, Thomas AJ, Horowitz MB, Jovin T Retrograde back coiling technique for ruptured aneurysm of a double origin posterior fossa cerebellar artery. J Neuroimaging 2009 Jan 19(1);65-7 Epub 2008 Sep 13

Lin R., Vora N., Zaidi S., Aleu A., Jankowitz B., Thomas A., Gupta R., Horowitz M., Kim S., Reddy V., Hammer M., Uchino K., Wechsler LR, Jovin T** Mechanical approaches combined with intraarterial pharmacological therapy are associated with higher recanalization rates than either intervention alone in revascularization of acute carotid terminus occlusion. Stroke 2009 Jun;40(6):2092-7

Ken Uchino, MD, Assistant Professor

Saqqur M, Molina CA, Salam A, Siddiqui M, Ribo M, Uchino K, Calleja S, Garami Z, Khan K, Akhtar N, O'Rourke F, Shuaib A, Demchuk AM, Alexandrov AV; CLOTBUST Investigators. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke. 2007;38(1):69-74.

Tayal AH, Gupta R, Yonas H, Jovin T, Uchino K, Hammer M, Wechsler L, Gebel JM. Quantitative Perihematomal Blood Flow in Spontaneous Intracerebral Hemorrhage Predicts In-Hospital Functional Outcome. Stroke. 2007;38: 319 – 324.

Saqqur M, Uchino K, Demchuk AM, Molina CM, Garami Z, Akhtar N, Calleja S, Shuaib A, Orouk FO, Salam A, Alexandrov AV. Site of Arterial Occlusion Identified By Transcranial Doppler (TCD) Predicts the Response to Intravenous Thrombolysis for Stroke. Stroke, 2007;38(3):948-54.

Vora NA, Gupta R, Thomas AJ, Horowitz MB, Tayal AH, Hammer MD, Uchino K, Wechsler LR, Jovin TG. Factors Predicting Hemorrhagic Complications after Multimodal Reperfusion Therapy for Acute Ischemic Stroke. AJNR. 2007;28:1391-1394.

Mehta N, Uchino K, Fakhran S, Sattar MA, Branstetter BF, Au K, Navratil JS, Paul B, Lee M, Gallagher KM, Manzi S, Ahearn J, and Kao AH. Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke. 2008;39:3236-3241

Lawrence Wechsler, MD, Professor and Vice Chair for Clinical Affairs and Chief, Vascular Neurology

Tayal AH, Gupta R, Yonas H, Jovin TG, Uchino K, Hammer MD, Wechsler LR, Gebel JM. Quantitative Perihematomal Blood Flow in Spontaneous Intracerebral Hemorrhage Predicts In-Hospital Functional Outcome. Stroke 2007. 38: 319-324.

Jovin TG, Gupta R, Horowitz MB, Grahovac SZ, Jungreis CA, Wechsler L, Gebel JM, Yonas H. Pretreatment ipsilateral regional cortical blood flow influences vessel recanalization in intra-arterial thrombolysis for MCA occlusion. AJNR 2007; 28:164-167.

135

Khatri P, Wechsler LR, Broderick JP. Intracranial hemorrhage associated with revascularization therapies. Stroke 2007;38:431-440.

Feldmann E, Wilterdink JL, Kosinski A, Lynn M, Chimowitz MI, Sarafin J, Smith HH, H Nichols F, Rogg J, Cloft HJ, Wechsler L, Saver J, Levine SR, Tegeler C, Adams R, Sloan M; The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) Trial Investigators. The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) trial. Neurology 2007; 68:2099-2106.

Vora NA, Gupta R, Thomas AJ, Horowitz MB, Tayal AH, Hammer MD, Uchino K, Wechsler LR, Jovin TG. Factors Predicting Hemorrhagic Complications after Multimodal Reperfusion Therapy for Acute Ischemic Stroke. AJNR 2007; 28: 1391-1394.

Wechsler, L. PFO and Stroke-What Are the Data?. Cardiolgy in Review 2008; 16: 53-57.

Tomycz ND, Holm MB, Horowitz MB, Wechsler LR, Raina K, Gupta R, Jovin TG. Extensive brainstem ischemia on neuroimaging does not preclude meaningful recovery from locked-in syndrome: two cases of endovascularly managed basilar thrombosis. J Neuroimaging 2008;18:15-17.

Kakuda w, Lansberg MG, Thijs VN, Kemp SM, Bammer R, Wechsler LR, Moseley ME, Parks MP, Albers GW. Optimal definition for PWI / DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab 2008: 28:1272.

Bhatt A, Vora NA, Thomas AJ, Majid A, Kassab M, Hammer MD, Uchino K, Wechsler L, Jovin TG, Gupta R. Lower pretreatment cerebral blood volume affects hemorrhagic risks after intra-arterial revascularization in acute stroke. Neurosurgery 2008;63: 874-878.

Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, Albers GW, Thijs V, DEFUSE investigators. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology 2008;249:614-623.

Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, Schlaug G, Bammer R, Marks MP, Albers GW. Relationships Between Infarct Growth, Clinical Outcome, and Early Recanalization in Diffusion and Perfusion Imaging for Understanding Stroke Evolution (DEFUSE). Stroke 2008;39:2257-2263.

Lansberg MG, Thijs VN, Bammer R, Olivot JM, Marks MP, Wechsler LR, Kemp S, Albers GW. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke 2008;39:2491-2496.

Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, Bammer R, Marks MP, Albers GW. Optimal Tmax threshold for predicting penumbral tissue in acute stoke. Stoke 2009;40:469-475.

STEPS Participants (LR Wechsler, corresponding author). Stem cell therapies as an emerging paradigm in stroke (STEPS). Bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009;40:510-515.

Olivot JM, Mlynash M, Thijs VN, Purushotham A, Kemp S, Lansberg MG, Wechsler L, Bammer R, Marks MP, Albers GW. Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE- Insights from RADAR. Stroke 2009, 40:1692-1697.

Lin R, Vora N, Zaidi S, Aleu A, Jankowitz B, Thomas A, Gupta R, Horowitz M, Kim S, Reddy V, Hammer M, Uchino K, Wechlser LR, Jovin T. Mechanical approaches combined with intra-arterial pharmacological therpay are associated with higher recanalization rates than either intervention aloine in revascularization of acute carotid terminus occlusion. Stroke 2009;40:2092-2097.

136